{ "meta": { "total_records": 590, "timestamp": "2026-06-02T18:33:21Z" }, "data": [ { "category": "Human", "referral_name": "Tecovirimat SIGA", "international_non_proprietary_name_inn_common_name": "tecovirimat", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Tecovirimat SIGA", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000287477", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "24/07/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/03/2026", "european_commission_decision_date": "29/05/2026", "first_published_date": "25/07/2025", "last_updated_date": "02/06/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tecovirimat-siga" }, { "category": "Human", "referral_name": "Levamisole-containing medicinal products", "international_non_proprietary_name_inn_common_name": "levamisole", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Decaris ;Levamisol Arena", "class": "Anthelmintic products", "reference_number": "EMA/REF/0000293746", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "04/09/2025", "prac_recommendation_date": "12/02/2026", "cmdh_position_date": "26/03/2026", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "05/09/2025", "last_updated_date": "13/05/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/levamisole-containing-medicinal-products" }, { "category": "Human", "referral_name": "Tavneos", "international_non_proprietary_name_inn_common_name": "avacopan", "current_status": "Under evaluation", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Tavneos", "associated_names_non_centrally_authorised_medicines": "", "class": "Antineoplastic and immunomodulating agents", "reference_number": "EMA/REF/0000325221", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "29/01/2026", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "30/01/2026", "last_updated_date": "31/03/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tavneos" }, { "category": "Human", "referral_name": "Ipidacrine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "ipidacrine", "current_status": "Under evaluation", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000271842", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "22/05/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "23/05/2025", "last_updated_date": "30/03/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ipidacrine-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Quarter-based selective dry cow therapy", "international_non_proprietary_name_inn_common_name": "", "current_status": "CVMP opinion", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000285673", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "16/07/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/03/2026", "european_commission_decision_date": "", "first_published_date": "18/07/2025", "last_updated_date": "24/03/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/quarter-based-selective-dry-cow-therapy" }, { "category": "Human", "referral_name": "Melatomed and associated names", "international_non_proprietary_name_inn_common_name": "melatonin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000303296", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "16/10/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/12/2025", "european_commission_decision_date": "18/02/2026", "first_published_date": "12/12/2025", "last_updated_date": "17/03/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/melatomed-associated-names" }, { "category": "Human", "referral_name": "Oxbryta", "international_non_proprietary_name_inn_common_name": "voxelotor", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Oxbryta", "associated_names_non_centrally_authorised_medicines": "", "class": "Haemoglobin S (HbS) polymerization inhibitor", "reference_number": "EMEA/H/A-20/1538/C/004869/0014", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/10/2025", "european_commission_decision_date": "09/12/2025", "first_published_date": "30/07/2024", "last_updated_date": "16/01/2026", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/oxbryta" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing amoxicillin", "international_non_proprietary_name_inn_common_name": "amoxicillin", "current_status": "Under evaluation", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000290626", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "06/11/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "06/11/2025", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-amoxicillin" }, { "category": "Human", "referral_name": "Sodium oxybate-containing syrup and oral solution for alcohol dependence", "international_non_proprietary_name_inn_common_name": "sodium oxybate", "current_status": "Under evaluation", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000278933", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "19/06/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "20/06/2025", "last_updated_date": "28/10/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sodium-oxybate-containing-syrup-oral-solution-alcohol-dependence" }, { "category": "Human", "referral_name": "Azithromycin-containing medicinal products for systemic use", "international_non_proprietary_name_inn_common_name": "azithromycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Macrolides", "reference_number": "EMEA/H/A-31/1532", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "09/11/2023", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/05/2025", "european_commission_decision_date": "08/09/2025", "first_published_date": "10/11/2023", "last_updated_date": "21/10/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/azithromycin-containing-medicinal-products-systemic-use" }, { "category": "Human", "referral_name": "Ixchiq", "international_non_proprietary_name_inn_common_name": "Chikungunya vaccine (live)", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Ixchiq", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1540", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "08/05/2025", "prac_recommendation_date": "10/07/2025", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2025", "european_commission_decision_date": "12/09/2025", "first_published_date": "07/05/2025", "last_updated_date": "19/09/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ixchiq" }, { "category": "Human", "referral_name": "Finasteride- and dutasteride-containing medicinal products", "international_non_proprietary_name_inn_common_name": "finasteride;dutasteride", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "genito-urinary system and sex hormones; dermatologicals", "reference_number": "EMEA/H/A-31/1539", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "03/10/2024", "prac_recommendation_date": "", "cmdh_position_date": "19/06/2025", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "22/08/2025", "first_published_date": "04/10/2024", "last_updated_date": "19/09/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/finasteride-dutasteride-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing albendazole as a single active substance presented as oral suspension in sheep", "international_non_proprietary_name_inn_common_name": "albendazole", "current_status": "Procedure started", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/REF/0000271819", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "11/06/2025", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "13/06/2025", "last_updated_date": "24/07/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-albendazole-single-active-substance-presented-oral-suspension-sheep" }, { "category": "Human", "referral_name": "Mysimba", "international_non_proprietary_name_inn_common_name": "naltrexone;bupropion", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Mysimba", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1530/C/3687/0065", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/03/2025", "european_commission_decision_date": "22/05/2025", "first_published_date": "15/09/2023", "last_updated_date": "03/06/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/mysimba" }, { "category": "Human", "referral_name": "Metamizole-containing medicinal products", "international_non_proprietary_name_inn_common_name": "metamizole", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-107i/1537", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "13/06/2024", "prac_recommendation_date": "05/09/2024", "cmdh_position_date": "18/09/2024", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "22/11/2024", "first_published_date": "14/06/2024", "last_updated_date": "29/01/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products-0" }, { "category": "Human", "referral_name": "Ocaliva", "international_non_proprietary_name_inn_common_name": "obeticholic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Ocaliva", "associated_names_non_centrally_authorised_medicines": "", "class": "Bile acids and derivatives", "reference_number": "EMEA/H/A-20/1531/C/004093/0045", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2024", "european_commission_decision_date": "30/08/2024", "first_published_date": "13/10/2023", "last_updated_date": "07/01/2025", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ocaliva" }, { "category": "Human", "referral_name": "Lorazepam Macure 4 mg/ml, solution for injection", "international_non_proprietary_name_inn_common_name": "lorazepam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-13/1536", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "22/02/2024", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2024", "european_commission_decision_date": "29/08/2024", "first_published_date": "28/06/2024", "last_updated_date": "08/10/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lorazepam-macure-4-mg-ml-solution-injection" }, { "category": "Human", "referral_name": "Havrix", "international_non_proprietary_name_inn_common_name": "hepatitis A virus (inactivated, adsorbed)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Havrix and associated names", "class": "", "reference_number": "EMEA/H/A-30/1527", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2024", "european_commission_decision_date": "26/08/2024", "first_published_date": "15/09/2023", "last_updated_date": "04/09/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/havrix" }, { "category": "Human", "referral_name": "Hydroxyprogesterone caproate-containing medicinal products", "international_non_proprietary_name_inn_common_name": "hydroxyprogesterone caproate", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Lentogest ;Progesterone Retard Pharlon ;Proluton Depot", "class": "progestogens", "reference_number": "EMEA-H-A-31-1528", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "12/05/2023", "prac_recommendation_date": "16/05/2024", "cmdh_position_date": "26/06/2024", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "12/05/2023", "last_updated_date": "05/07/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyprogesterone-caproate-containing-medicinal-products" }, { "category": "Human", "referral_name": "Micrazym and associated names", "international_non_proprietary_name_inn_common_name": "porcine pancreas enzymes", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1535", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/03/2024", "european_commission_decision_date": "16/05/2024", "first_published_date": "22/03/2024", "last_updated_date": "11/06/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/micrazym-associated-names" }, { "category": "Human", "referral_name": "Synapse", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1529", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/03/2024", "european_commission_decision_date": "24/05/2024", "first_published_date": "21/07/2023", "last_updated_date": "05/06/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/synapse" }, { "category": "Human", "referral_name": "Ibuprofen NVT", "international_non_proprietary_name_inn_common_name": "ibuprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1533", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/02/2024", "european_commission_decision_date": "10/05/2024", "first_published_date": "23/02/2024", "last_updated_date": "05/06/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-nvt" }, { "category": "Veterinary", "referral_name": "Kexxtone 32.4 g continuous-release intraruminal device for cattle", "international_non_proprietary_name_inn_common_name": "monensin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "Kexxtone", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/150", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "14/03/2024", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/04/2024", "european_commission_decision_date": "15/05/2024", "first_published_date": "04/06/2024", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/kexxtone-324-g-continuous-release-intraruminal-device-cattle" }, { "category": "Veterinary", "referral_name": "Procaine benzylpenicillin", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/145", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "16/02/2022", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/09/2023", "european_commission_decision_date": "11/12/2023", "first_published_date": "23/02/2022", "last_updated_date": "29/05/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/procaine-benzylpenicillin" }, { "category": "Human", "referral_name": "Pseudoephedrine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "pseudoephedrine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Aerinaze", "associated_names_non_centrally_authorised_medicines": "", "class": "Nasal decongestants for systemic use", "reference_number": "EMEA/H/A-31/1526", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "09/02/2023", "prac_recommendation_date": "30/11/2023", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/01/2024", "european_commission_decision_date": "27/03/2024", "first_published_date": "10/02/2023", "last_updated_date": "04/04/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pseudoephedrine-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing N-methyl pyrrolidone as an excipient", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "Vectra 3D;Melovem", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/146", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/12/2022", "european_commission_decision_date": "28/03/2023", "first_published_date": "18/05/2022", "last_updated_date": "22/03/2024", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-n-methyl-pyrrolidone-excipient" }, { "category": "Human", "referral_name": "Topiramate", "international_non_proprietary_name_inn_common_name": "topiramate", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1520", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "01/09/2022", "prac_recommendation_date": "31/08/2023", "cmdh_position_date": "10/11/2023", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "02/09/2022", "last_updated_date": "23/11/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/topiramate" }, { "category": "Human", "referral_name": "Adakveo", "international_non_proprietary_name_inn_common_name": "crizanlizumab", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Adakveo", "associated_names_non_centrally_authorised_medicines": "", "class": "Other haematological agents", "reference_number": "EMEA/H/A-20/1525/C/4874/0013", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "26/01/2023", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/05/2023", "european_commission_decision_date": "03/08/2023", "first_published_date": "27/01/2023", "last_updated_date": "29/08/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/adakveo" }, { "category": "Human", "referral_name": "Quinolone- and fluoroquinolone-containing medicinal products", "international_non_proprietary_name_inn_common_name": "nalidixic acid;pipemidic acid;cinoxacin;enoxacin;pefloxacin;lomefloxacin;ciprofloxacin;levofloxacin;ofloxacin;moxifloxacin;norfloxacin;prulifloxacin;rufloxacin;flumequin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Quinsair", "associated_names_non_centrally_authorised_medicines": "", "class": "Quinolones and fluoroquinolones", "reference_number": "EMEA/H/A-31/1452", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "09/02/2017", "prac_recommendation_date": "04/10/2018", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2018", "european_commission_decision_date": "11/03/2019", "first_published_date": "10/02/2017", "last_updated_date": "08/06/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products" }, { "category": "Human", "referral_name": "Janus kinase inhibitors (JAKi)", "international_non_proprietary_name_inn_common_name": "tofacitinib;abrocitinib;baricitinib;upadacitinib;filgotinib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Xeljanz;Cibinqo;Olumiant;Rinvoq;Jyseleca;Xeljanz", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "10/02/2022", "prac_recommendation_date": "12/01/2023", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/01/2023", "european_commission_decision_date": "10/03/2023", "first_published_date": "11/02/2022", "last_updated_date": "22/05/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki" }, { "category": "Veterinary", "referral_name": "Catophos 100 mg/ml+0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names", "international_non_proprietary_name_inn_common_name": "butafosfan;cyanocobalamin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/147", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/02/2023", "european_commission_decision_date": "03/04/2023", "first_published_date": "25/04/2023", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/catophos-100-mg-ml005-mg-ml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names" }, { "category": "Veterinary", "referral_name": "Vey Tosal 100 mg/ml + 0.05 mg/ml solution for injection for horses, cattle, dogs and cats and associated names", "international_non_proprietary_name_inn_common_name": "butafosfan;cyanocobalamin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/148", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/02/2023", "european_commission_decision_date": "03/04/2023", "first_published_date": "25/04/2023", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/vey-tosal-100-mg-ml-005-mg-ml-solution-injection-horses-cattle-dogs-and-cats-and-associated-names" }, { "category": "Human", "referral_name": "Pholcodine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "pholcodine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Cough and cold preparations", "reference_number": "EMEA/H/A-107i/1521", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Revocation", "procedure_start_date": "01/09/2022", "prac_recommendation_date": "01/12/2022", "cmdh_position_date": "14/12/2022", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "06/03/2023", "first_published_date": "02/09/2022", "last_updated_date": "29/03/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine-containing-medicinal-products" }, { "category": "Human", "referral_name": "Gelisia and associated names", "international_non_proprietary_name_inn_common_name": "timolol maleate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Genoptol ;Gelisia ;Timolol sifi 1 mg/g gel oftalmico", "class": "", "reference_number": "EMEA/H/A-29(4)/1522", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2022", "european_commission_decision_date": "27/02/2023", "first_published_date": "16/12/2022", "last_updated_date": "16/03/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gelisia-and-associated-names" }, { "category": "Human", "referral_name": "Rambis and associated names", "international_non_proprietary_name_inn_common_name": "ramipril;bisoprolol fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Ralbior", "class": "", "reference_number": "EMEA/H/A-29(4)/1519", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2022", "european_commission_decision_date": "15/02/2023", "first_published_date": "16/12/2022", "last_updated_date": "08/03/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rambis-and-associated-names" }, { "category": "Human", "referral_name": "Amfepramone-containing medicinal products", "international_non_proprietary_name_inn_common_name": "amfepramone", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Regenon ;Tenuate Retard ;Amfepramon-Hormosan ;Regenon Retard", "class": "", "reference_number": "EMEA/H/A-31/1501", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Revocation", "procedure_start_date": "11/02/2021", "prac_recommendation_date": "27/10/2022", "cmdh_position_date": "10/11/2022", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "13/01/2023", "first_published_date": "12/02/2021", "last_updated_date": "20/01/2023", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/amfepramone-containing-medicinal-products" }, { "category": "Human", "referral_name": "Synchron", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1515", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2022", "european_commission_decision_date": "28/11/2022", "first_published_date": "28/01/2022", "last_updated_date": "16/12/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/synchron" }, { "category": "Human", "referral_name": "Nomegestrol and chlormadinone", "international_non_proprietary_name_inn_common_name": "nomegestrol;chlormadinone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Zoely", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1510", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "30/09/2021", "prac_recommendation_date": "07/07/2022", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "01/09/2022", "european_commission_decision_date": "28/11/2022", "first_published_date": "01/10/2021", "last_updated_date": "14/12/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nomegestrol-chlormadinone" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing toltrazuril to be administered orally to chickens", "international_non_proprietary_name_inn_common_name": "toltrazuril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/144", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/07/2022", "european_commission_decision_date": "09/11/2022", "first_published_date": "14/12/2022", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-toltrazuril-be-administered-orally-chickens" }, { "category": "Human", "referral_name": "Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome", "international_non_proprietary_name_inn_common_name": "terlipressin", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "vasopressin and analogues", "reference_number": "EMEA/H/A-31/1514", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "13/01/2022", "prac_recommendation_date": "29/09/2022", "cmdh_position_date": "10/11/2022", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "21/02/2022", "last_updated_date": "22/11/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/terlipressin-containing-medicinal-products-indicated-treatment-hepatorenal-syndrome" }, { "category": "Human", "referral_name": "Rubraca", "international_non_proprietary_name_inn_common_name": "rucaparib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Rubraca", "associated_names_non_centrally_authorised_medicines": "", "class": "Other antineoplastic agents", "reference_number": "EMEA/H/A-20/1518/C/4272/0033", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "22/04/2022", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2022", "european_commission_decision_date": "21/09/2022", "first_published_date": "22/04/2022", "last_updated_date": "17/10/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rubraca" }, { "category": "Human", "referral_name": "Daruph and Anafezyn", "international_non_proprietary_name_inn_common_name": "dasatinib (anhydrous)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1516", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2022", "european_commission_decision_date": "18/07/2022", "first_published_date": "20/05/2022", "last_updated_date": "09/08/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/daruph-and-anafezyn" }, { "category": "Human", "referral_name": "Zynteglo", "international_non_proprietary_name_inn_common_name": "betibeglogene autotemcel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Zynteglo", "associated_names_non_centrally_authorised_medicines": "", "class": "Haematological agents", "reference_number": "EMEA/H/A-20/1504/C/003691/0023", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CAT-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/03/2021", "prac_recommendation_date": "09/07/2021", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/07/2021", "european_commission_decision_date": "16/09/2021", "first_published_date": "12/03/2021", "last_updated_date": "08/07/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zynteglo" }, { "category": "Human", "referral_name": "Nasolam and associated names", "international_non_proprietary_name_inn_common_name": "midazolam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Hypnotics and sedatives (benzodiazepine derivatives)", "reference_number": "EMEA/H/A-29(4)/1511", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/01/2022", "european_commission_decision_date": "01/04/2022", "first_published_date": "28/01/2022", "last_updated_date": "29/04/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nasolam-and-associated-names" }, { "category": "Human", "referral_name": "Lidocain/Prilocain Idetec and associated names", "international_non_proprietary_name_inn_common_name": "lidocaine;prilocaine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Lidocaïne / Prilocaïne 5% Focus, Crème", "class": "", "reference_number": "EMEA/H/A-29(4)/1506", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/10/2021", "european_commission_decision_date": "", "first_published_date": "15/10/2021", "last_updated_date": "21/04/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lidocain-prilocain-idetec-associated-names" }, { "category": "Human", "referral_name": "Etifoxine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "etifoxine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Stresam", "class": "Non-benzodiazepine anxiolytic", "reference_number": "EMEA/H/A-31/1509", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/06/2021", "european_commission_decision_date": "24/03/2022", "first_published_date": "25/06/2021", "last_updated_date": "21/04/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/etifoxine-containing-medicinal-products" }, { "category": "Human", "referral_name": "Hydroxyethyl starch (HES) containing medicinal products", "international_non_proprietary_name_inn_common_name": "hydroxyethyl starch", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-107i/1457", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "26/10/2017", "prac_recommendation_date": "12/01/2018", "cmdh_position_date": "26/10/2017", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "17/07/2018", "first_published_date": "27/10/2017", "last_updated_date": "11/02/2022", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-hes-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Injectable veterinary medicinal products containing vitamin A for use in food producing species", "international_non_proprietary_name_inn_common_name": "vitamin A (retinol and its esters)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/141", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/05/2021", "european_commission_decision_date": "18/08/2021", "first_published_date": "27/09/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/injectable-veterinary-medicinal-products-containing-vitamin-use-food-producing-species" }, { "category": "Veterinary", "referral_name": "Ronaxan and its associated names", "international_non_proprietary_name_inn_common_name": "doxycycline", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/135", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/06/2021", "european_commission_decision_date": "30/08/2021", "first_published_date": "27/09/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/ronaxan-and-its-associated-names" }, { "category": "Human", "referral_name": "Intravenous iron-containing medicinal products", "international_non_proprietary_name_inn_common_name": "ferric carboxymaltose;iron dextran;sodium ferric gluconate;iron isomaltoside;iron sucrose", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1322", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2013", "european_commission_decision_date": "13/09/2013", "first_published_date": "28/06/2013", "last_updated_date": "28/07/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-iron-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Modified live porcine respiratory and reproductive syndrome (PRRS) virus vaccines", "international_non_proprietary_name_inn_common_name": "porcine respiratory and reproductive syndrome virus vaccine (live)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA-V-A-142", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/04/2021", "european_commission_decision_date": "13/07/2021", "first_published_date": "28/07/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/modified-live-porcine-respiratory-and-reproductive-syndrome-prrs-virus-vaccines" }, { "category": "Human", "referral_name": "Ifosfamide solutions", "international_non_proprietary_name_inn_common_name": "ifosfamide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Ifosfamide Eg ;Ifo-Cell ;Ifo-Cell N ;Ifo-Cell N 2000", "class": "alkylating agent", "reference_number": "EMEA/H/A-31/1495", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "12/03/2020", "prac_recommendation_date": "11/03/2021", "cmdh_position_date": "21/04/2021", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "21/06/2021", "first_published_date": "12/03/2020", "last_updated_date": "19/07/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ifosfamide-solutions" }, { "category": "Human", "referral_name": "Varilrix", "international_non_proprietary_name_inn_common_name": "live attenuated varicella virus (OKA strain)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1499", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/02/2021", "european_commission_decision_date": "21/04/2021", "first_published_date": "26/06/2020", "last_updated_date": "09/06/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/varilrix" }, { "category": "Veterinary", "referral_name": "Adjusol trimethoprim sulfa liquide and its associated names", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/134", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/12/2020", "european_commission_decision_date": "25/02/2021", "first_published_date": "19/03/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/adjusol-trimethoprim-sulfa-liquide-and-its-associated-names" }, { "category": "Human", "referral_name": "Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group", "international_non_proprietary_name_inn_common_name": "valsartan;candesartan;irbesartan;losartan;olmesartan", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Karvezide;Karvea;Irbesartan/Hydrochlorothiazide Teva;Irbesartan Zentiva (previously Irbesartan Winthrop);Irbesartan Teva;Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop);Ifirmasta (previously Irbesartan Krka);Ifirmacombi;Aprovel;Neparvis;Exforge;Exforge HCT;Entresto;Dafiro HCT;Dafiro;Copalia HCT;Copalia;Amlodipine / Valsartan Mylan;CoAprovel", "associated_names_non_centrally_authorised_medicines": "", "class": "angiotensin-II-receptor antagonist", "reference_number": "EMEA/H/A-31/1471", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/11/2020", "european_commission_decision_date": "19/02/2021", "first_published_date": "17/07/2018", "last_updated_date": "19/03/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group" }, { "category": "Veterinary", "referral_name": "Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names, including its generic/hybrid products", "international_non_proprietary_name_inn_common_name": "albendazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA-V-A-140", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "05/11/2020", "european_commission_decision_date": "18/01/2021", "first_published_date": "22/02/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/valbazen-100-mg-ml-total-spectrum-wormer-oral-suspension-and-associated-names-including-its-generic-hybrid-products" }, { "category": "Human", "referral_name": "Ranitidine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "ranitidine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1491", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/09/2020", "european_commission_decision_date": "24/11/2020", "first_published_date": "26/06/2020", "last_updated_date": "17/02/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Tiamulin hydrogen fumarate presented as premix for medicated feeding stuff and oral powder for in-feed use to be administered to pigs", "international_non_proprietary_name_inn_common_name": "tiamulin hydrogen fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/137", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/09/2020", "european_commission_decision_date": "09/12/2020", "first_published_date": "05/02/2021", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/tiamulin-hydrogen-fumarate-presented-premix-medicated-feeding-stuff-oral-powder-feed-use-be-administered-pigs" }, { "category": "Human", "referral_name": "Ulipristal acetate 5mg medicinal products", "international_non_proprietary_name_inn_common_name": "ulipristal acetate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Esmya;Ulipristal Acetate Gedeon Richter", "associated_names_non_centrally_authorised_medicines": "", "class": "Progesterone receptor modulators", "reference_number": "EMEA/H/A-31/1496", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "", "procedure_start_date": "12/03/2020", "prac_recommendation_date": "04/09/2020", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/11/2020", "european_commission_decision_date": "11/01/2021", "first_published_date": "13/03/2020", "last_updated_date": "03/02/2021", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ulipristal-acetate-5mg-medicinal-products" }, { "category": "Human", "referral_name": "Picato", "international_non_proprietary_name_inn_common_name": "ingenol mebutate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Picato", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1489/C/002275/0030", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "05/09/2019", "prac_recommendation_date": "17/04/2020", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/04/2020", "european_commission_decision_date": "06/07/2020", "first_published_date": "06/09/2019", "last_updated_date": "16/11/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/picato" }, { "category": "Veterinary", "referral_name": "Betamox LA 150 mg/ml suspension for injection and associated names, and generics products thereof", "international_non_proprietary_name_inn_common_name": "amoxicillin trihydrate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Stresnil", "class": "", "reference_number": "EMEA/V/A/132", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2020", "european_commission_decision_date": "12/10/2020", "first_published_date": "12/11/2020", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/betamox-la-150-mg-ml-suspension-injection-and-associated-names-and-generics-products-thereof" }, { "category": "Veterinary", "referral_name": "Stresnil 40 mg/ml solution for injection for pigs and associated names, and generic products thereof", "international_non_proprietary_name_inn_common_name": "azaperone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Stresnil", "class": "", "reference_number": "EMEA/V/A/138", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2020", "european_commission_decision_date": "12/10/2020", "first_published_date": "30/10/2020", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/stresnil-40-mg-ml-solution-injection-pigs-associated-names-generic-products-thereof" }, { "category": "Human", "referral_name": "Ibuprofen Kabi 400 mg Infusionslösung and associated names", "international_non_proprietary_name_inn_common_name": "ibuprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Ibuprofen Fresenius Kabi 400 mg oplossing voor infusie ;Ibuprofen Fresenius Kabi 400 mg solution pour perfusion ;Ibuprofen Kabi ;Ibuprofen Kabi 400 mg oldatos infúzió ;Ibuprofen Kabi 400 mg soluţie perfuzabilă ;Ibuprofen Kabi 400 mg ;Ibuprofen Kabi 400 mg raztopina za infundiranje ;Ibuprofeno Kabi 400 mg solución para perfusion ;Ibuprofen Kabi 400 mg Solution for Infusion", "class": "", "reference_number": "EMEA/H/A-29(4)/1498", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/07/2020", "european_commission_decision_date": "15/10/2020", "first_published_date": "24/07/2020", "last_updated_date": "26/10/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-kabi-400-mg-infusionslosung-and-associated-names" }, { "category": "Human", "referral_name": "Panexcell", "international_non_proprietary_name_inn_common_name": "atazanavir;atazanavir sulfate;amoxicillin trihydrate;iron sucrose;amoxicillin;azithromycin dihydrate;carbocisteine;trimethoprim", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1494", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/02/2020", "european_commission_decision_date": "24/09/2020", "first_published_date": "28/02/2020", "last_updated_date": "22/10/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/panexcell" }, { "category": "Human", "referral_name": "Yondelis", "international_non_proprietary_name_inn_common_name": "trabectedin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Yondelis", "associated_names_non_centrally_authorised_medicines": "", "class": "Antineoplastic agents", "reference_number": "EMEA/H/A-20/1493/C/0773/0060", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2020", "european_commission_decision_date": "24/09/2020", "first_published_date": "28/02/2020", "last_updated_date": "09/10/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/yondelis" }, { "category": "Veterinary", "referral_name": "Dinolytic 12.5 mg/ml and 5 mg/ml solutions for injection and associated names, and generic products thereof", "international_non_proprietary_name_inn_common_name": "dinoprost", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA-V-A-136", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/06/2020", "european_commission_decision_date": "16/09/2020", "first_published_date": "06/10/2020", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/dinolytic-125-mg-ml-5-mg-ml-solutions-injection-associated-names-generic-products-thereof" }, { "category": "Human", "referral_name": "Budesonide SUN", "international_non_proprietary_name_inn_common_name": "budesonide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1492", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2020", "european_commission_decision_date": "19/08/2020", "first_published_date": "27/03/2020", "last_updated_date": "16/09/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/budesonide-sun" }, { "category": "Human", "referral_name": "Leuprorelin-containing depot medicinal products", "international_non_proprietary_name_inn_common_name": "leuprorelin", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Daronda ;Depo-Eligard ;Eligard ;Eligard Depot ;Eligard Mensua ;Eligard Semestral ;Eligard Trimestral ;Elityran 1 Month Depot (Dps) ;Elityran 3 Month Depot (Dps) ;Enanton Depot Dual ;Enanton Depot Set ;Enantone ;Enantone L.P ;Enantone Lp ;Enantone Monats-Depot ;Ginecrin Depot ;Klebrocid 3-Monats-Depot ;Klebrocid Depot Zweikammerspritze ;Leptoprol ;Lerin ;Leugon ;Leuprex 3 ;Leuprol ;Leuprolin Ratiopharm ;Leuprone 1-Monatsdepot ;Leuprone 3-Monatsdepot ;Leuprorelin 1-Month Depot Gp-Pharm ;Leuprorelin Hexal ;Leuprorelin Sandoz ;Leuprorelina Gp-Pharm ;Leupro-Sandoz 1-Monats-Depot ;Leupro-Sandoz 3-Monats-Depot ;Leuprorelina Trimestral Sandoz ;Leuprostin ;Leuproreline Sandoz ;Lucrin ;Lucrin Depot ;Lucrin Pds Depot ;Lucrin Pds Depot 1 Maand ;Lucrin Pds Depot 3 Maanden ;Lucrin Pds Depot 6 Maanden ;Lupron Depo ;Lutrate 1 Month Depot ;Lutrate 3 Month Depot ;Lutrate Depo ;Lutrate Depot ;Lutrate Depot Trimestral ;Politrate ;Politrate Depot ;Procren Depot ;Procren Depot Pds ;Procrin Mensual ;Procrin Semestral ;Procrin Trimestral ;Prostap 3 Dcs ;Prostap 6 Dcs ;Prostap Sr Dcs ;Prostaplant ;Sixantone ;Trenantone ;Trenantone-Gyn ;Zeulide ;Елигард ;Лутрат Депо", "class": "", "reference_number": "EMEA/H/A-31/1486", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "14/05/2020", "cmdh_position_date": "25/06/2020", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "14/06/2019", "last_updated_date": "31/07/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/leuprorelin-containing-depot-medicinal-products" }, { "category": "Human", "referral_name": "Fluorouracil and fluorouracil related substances (capecitabine, tegafur and flucytosine) containing medicinal products", "international_non_proprietary_name_inn_common_name": "capecitabine;fluorouracil;tegafur;flucytosine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Xeloda;Teysuno;Capecitabine Accord;Capecitabine Medac;Capecitabine Teva;Ecansya (previously Capecitabine Krka)", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1481", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Variation", "procedure_start_date": "15/03/2019", "prac_recommendation_date": "12/03/2020", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/04/2020", "european_commission_decision_date": "07/07/2020", "first_published_date": "15/03/2019", "last_updated_date": "23/07/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products" }, { "category": "Human", "referral_name": "Carbamazepin Tillomed", "international_non_proprietary_name_inn_common_name": "carbamazepin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Carbamazepin Tillomed ;Carbamazepina Tillomed ;Karbamazepin Tillomed ;Karbamazepina Tillomed", "class": "", "reference_number": "EMEA/H/A-29(4)/1497", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/04/2020", "european_commission_decision_date": "25/06/2020", "first_published_date": "30/04/2020", "last_updated_date": "21/07/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/carbamazepin-tillomed" }, { "category": "Human", "referral_name": "Fosfomycin-containing medicinal products", "international_non_proprietary_name_inn_common_name": "fosfomycin calcium;fosfomycin disodium;fosfomycin sodium;fosfomycin trometamol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Afastural ;Berny Adulti ;Danifos Adulti ;Fomicyt ;Fosfocin ;Fosfocina ;Fosfocine ;Fosfopharm ;Fosfuro ;Fosmol ;Fostrofemge ;Gynofostrome ;Infectofos ;Infeur Adulti ;Interfos ;Monural ;Monuril ;Monurol ;Rapidnorm ;Solufos ;Symural ;Uridoz ;Urifos ;Urinex ;Urofast ;Uromaste ;Uroseptic", "class": "Antibiotics", "reference_number": "EMEA/H/A-31/1476", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/03/2020", "european_commission_decision_date": "09/06/2020", "first_published_date": "14/12/2018", "last_updated_date": "06/07/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fosfomycin-containing-medicinal-products" }, { "category": "Human", "referral_name": "Methocarbamol / paracetamol-containing medicinal products", "international_non_proprietary_name_inn_common_name": "methocarbamol;paracetamol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Robaxisal compuesto", "class": "Analgesic", "reference_number": "EMEA/H/A-31/1484", "non_prac_decision_making_model": "CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/03/2020", "european_commission_decision_date": "09/06/2020", "first_published_date": "29/05/2019", "last_updated_date": "17/06/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methocarbamol-paracetamol-containing-medicinal-products" }, { "category": "Human", "referral_name": "Cyproterone-containing medicinal products", "international_non_proprietary_name_inn_common_name": "cyproterone", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "antiandrogens", "reference_number": "EMEA/H/A-31/1488", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "11/07/2019", "prac_recommendation_date": "13/02/2020", "cmdh_position_date": "25/03/2020", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "12/07/2019", "last_updated_date": "20/05/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing tylosin base (as a single active substance) presented as solutions for injection for intramuscular use in pigs", "international_non_proprietary_name_inn_common_name": "tylosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/V/A/131", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "05/12/2019", "european_commission_decision_date": "17/04/2020", "first_published_date": "13/05/2020", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-base-single-active-substance-presented-solutions-injection-intramuscular-use-pigs" }, { "category": "Veterinary", "referral_name": "Ketabel 100 mg/ml solution for injection and associated names", "international_non_proprietary_name_inn_common_name": "ketamine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/133", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "05/12/2019", "european_commission_decision_date": "04/03/2020", "first_published_date": "16/04/2020", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/ketabel-100-mg-ml-solution-injection-and-associated-names" }, { "category": "Human", "referral_name": "Estradiol-containing (0.01% w/w) medicinal products for topical use", "international_non_proprietary_name_inn_common_name": "estradiol", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Linoladiol ;Linoladiol N ;Linoladiol Estradiol ;Estradiol Wolff ;Montadiol", "class": "Hormonal", "reference_number": "EMEA/H/A-31/1482", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/04/2019", "prac_recommendation_date": "16/01/2020", "cmdh_position_date": "30/01/2020", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "12/07/2019", "last_updated_date": "08/04/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/estradiol-containing-001-w-w-medicinal-products-topical-use" }, { "category": "Human", "referral_name": "Xeljanz", "international_non_proprietary_name_inn_common_name": "tofacitinib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Xeljanz", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1485", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "16/05/2019", "prac_recommendation_date": "31/10/2019", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/11/2019", "european_commission_decision_date": "31/01/2020", "first_published_date": "17/05/2019", "last_updated_date": "06/03/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz" }, { "category": "Human", "referral_name": "Lemtrada", "international_non_proprietary_name_inn_common_name": "alemtuzumab", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Lemtrada", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1483/C/3718/0028", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/04/2019", "prac_recommendation_date": "31/10/2019", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/11/2019", "european_commission_decision_date": "16/01/2020", "first_published_date": "12/04/2019", "last_updated_date": "04/02/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada" }, { "category": "Human", "referral_name": "Flurbiprofen Geiser", "international_non_proprietary_name_inn_common_name": "flurbiprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Flurbiprofen Sejmet ;Mentocaína Spray ;Flurbiprofeno Geiser", "class": "", "reference_number": "EMEA/H/A-29(4)/1487", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/10/2019", "european_commission_decision_date": "16/12/2019", "first_published_date": "18/10/2019", "last_updated_date": "20/01/2020", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/flurbiprofen-geiser" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing paromomycin to be administered parenterally to pigs", "international_non_proprietary_name_inn_common_name": "paromycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/129", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/07/2019", "european_commission_decision_date": "11/10/2019", "first_published_date": "20/11/2019", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-paromomycin-be-administered-parenterally-pigs" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep", "international_non_proprietary_name_inn_common_name": "tylosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/130", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/06/2019", "european_commission_decision_date": "20/09/2019", "first_published_date": "19/11/2019", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-presented-solution-injection-be-administered-sheep" }, { "category": "Human", "referral_name": "Methotrexate containing medicinal products", "international_non_proprietary_name_inn_common_name": "methotrexate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Nordimet;Jylamvo", "associated_names_non_centrally_authorised_medicines": "Jylamvo ;Nordimet ;Ledertrexate ;Maxtrex ;Metex ;Metoject", "class": "", "reference_number": "EMEA/H/A-31/1463", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "12/04/2018", "prac_recommendation_date": "11/07/2019", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/08/2019", "european_commission_decision_date": "21/10/2019", "first_published_date": "13/04/2018", "last_updated_date": "31/10/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methotrexate-containing-medicinal-products" }, { "category": "Human", "referral_name": "Bacterial lysates-containing medicinal products indicated for respiratory conditions", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1465", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2019", "european_commission_decision_date": "09/09/2019", "first_published_date": "29/06/2018", "last_updated_date": "16/09/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bacterial-lysates-containing-medicinal-products-indicated-respiratory-conditions" }, { "category": "Human", "referral_name": "Lartruvo", "international_non_proprietary_name_inn_common_name": "olaratumab", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Lartruvo", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1479/C/4216/015", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "31/01/2019", "european_commission_decision_date": "19/07/2019", "first_published_date": "01/02/2019", "last_updated_date": "22/08/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lartruvo" }, { "category": "Human", "referral_name": "Basiron AC and associated names", "international_non_proprietary_name_inn_common_name": "benzoyl peroxide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/H/A-13/1475", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/03/2019", "european_commission_decision_date": "04/07/2019", "first_published_date": "29/03/2019", "last_updated_date": "19/07/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/basiron-ac-associated-names" }, { "category": "Veterinary", "referral_name": "Closantel", "international_non_proprietary_name_inn_common_name": "closantel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/126", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/02/2019", "european_commission_decision_date": "20/05/2019", "first_published_date": "27/06/2019", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/closantel" }, { "category": "Human", "referral_name": "Fenspiride containing medicinal products", "international_non_proprietary_name_inn_common_name": "fenspiride", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Drugs for obstructive airway diseases", "reference_number": "EMEA/H/A-107i/1480", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "14/02/2019", "prac_recommendation_date": "17/05/2019", "cmdh_position_date": "29/05/2019", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "15/02/2019", "last_updated_date": "26/06/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fenspiride-containing-medicinal-products" }, { "category": "Human", "referral_name": "Septanest and associated names", "international_non_proprietary_name_inn_common_name": "articaine (hydrochloride);adrenaline (tartrate)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "local anaesthetic", "reference_number": "EMEA/H/A-30/1461", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2018", "european_commission_decision_date": "28/03/2019", "first_published_date": "29/06/2018", "last_updated_date": "19/06/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/septanest-associated-names" }, { "category": "Human", "referral_name": "Omega-3 acid ethyl esters - containing medicinal products for oral in use in secondary prevention after myocardial infarction", "international_non_proprietary_name_inn_common_name": "omega-3 fatty acid ethyl esters", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1464", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2018", "european_commission_decision_date": "06/06/2019", "first_published_date": "23/03/2018", "last_updated_date": "13/06/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/omega-3-acid-ethyl-esters-containing-medicinal-products-oral-use-secondary-prevention-after-myocardial-infarction" }, { "category": "Human", "referral_name": "Syner-Kinase and associated names", "international_non_proprietary_name_inn_common_name": "urokinase", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA-H-A-29(4)-1472", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/02/2019", "european_commission_decision_date": "16/05/2019", "first_published_date": "01/03/2019", "last_updated_date": "03/06/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/syner-kinase-associated-names" }, { "category": "Human", "referral_name": "Metamizole containing medicinal products", "international_non_proprietary_name_inn_common_name": "metamizole", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1469", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2018", "european_commission_decision_date": "20/03/2019", "first_published_date": "01/06/2018", "last_updated_date": "28/03/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/metamizole-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Fortekor", "international_non_proprietary_name_inn_common_name": "benazepril hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/055", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/11/2011", "european_commission_decision_date": "06/02/2012", "first_published_date": "24/02/2012", "last_updated_date": "11/03/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/fortekor" }, { "category": "Human", "referral_name": "Diotop capsules", "international_non_proprietary_name_inn_common_name": "diclofenac;omeprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1474", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2018", "european_commission_decision_date": "31/01/2019", "first_published_date": "16/11/2018", "last_updated_date": "15/02/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diotop-capsules" }, { "category": "Human", "referral_name": "Diclofenac Sodium Spray Gel 4%", "international_non_proprietary_name_inn_common_name": "diclofenac sodium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1467", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2018", "european_commission_decision_date": "18/01/2019", "first_published_date": "29/01/2019", "last_updated_date": "14/02/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-sodium-spray-gel-4" }, { "category": "Human", "referral_name": "Perlinring and associated names", "international_non_proprietary_name_inn_common_name": "etonogestrel;ethinylestradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1473", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2018", "european_commission_decision_date": "18/12/2018", "first_published_date": "19/10/2018", "last_updated_date": "21/01/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/perlinring-and-associated-names" }, { "category": "Human", "referral_name": "Paclitaxel Hetero and associated names", "international_non_proprietary_name_inn_common_name": "paclitaxel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29(4)/1466", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2018", "european_commission_decision_date": "11/01/2019", "first_published_date": "19/10/2018", "last_updated_date": "21/01/2019", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/paclitaxel-hetero-associated-names" }, { "category": "Human", "referral_name": "Xofigo", "international_non_proprietary_name_inn_common_name": "radium Ra223 dichloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Xofigo", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1459/C/002653/0028", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "30/11/2017", "prac_recommendation_date": "12/07/2018", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/07/2018", "european_commission_decision_date": "28/09/2018", "first_published_date": "01/12/2017", "last_updated_date": "11/10/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/xofigo" }, { "category": "Human", "referral_name": "Esmya", "international_non_proprietary_name_inn_common_name": "ulipristal acetate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Esmya", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1460/C/2041/0043", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "30/11/2017", "prac_recommendation_date": "17/05/2018", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "31/05/2018", "european_commission_decision_date": "26/07/2018", "first_published_date": "01/12/2017", "last_updated_date": "08/08/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/esmya" }, { "category": "Human", "referral_name": "Scandonest and associated names", "international_non_proprietary_name_inn_common_name": "mepivacaine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Biocaine ;Scandicaine", "class": "Anaesthetic", "reference_number": "EMEA/H/A-30/1455", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "31/05/2018", "european_commission_decision_date": "02/08/2018", "first_published_date": "15/09/2017", "last_updated_date": "07/08/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/scandonest-associated-names" }, { "category": "Human", "referral_name": "Zinbryta", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Zinbryta", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1462/C/003862/0018", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "02/03/2018", "prac_recommendation_date": "17/05/2018", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "27/03/2018", "first_published_date": "02/03/2018", "last_updated_date": "11/07/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta" }, { "category": "Veterinary", "referral_name": "Seresto and its associated name Foresto", "international_non_proprietary_name_inn_common_name": "imidacloprid;flumethrin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/125", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/02/2018", "european_commission_decision_date": "25/05/2018", "first_published_date": "10/07/2018", "last_updated_date": "10/07/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/seresto-its-associated-name-foresto" }, { "category": "Human", "referral_name": "Maci", "international_non_proprietary_name_inn_common_name": "matrix applied characterised autologous cultured chondrocytes", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Maci", "associated_names_non_centrally_authorised_medicines": "", "class": "Advanced therapies", "reference_number": "EMEA/H/A20/1409/C/002522/0004", "non_prac_decision_making_model": "CAT-CHMP-EC", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/09/2014", "european_commission_decision_date": "19/11/2014", "first_published_date": "26/09/2014", "last_updated_date": "05/07/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/maci" }, { "category": "Human", "referral_name": "Retinoid-containing medicinal products", "international_non_proprietary_name_inn_common_name": "acitretin;adapalene;alitretinoin;bexarotene;isotretinoin;tretinoin;tazarotene", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Targretin;Panretin", "associated_names_non_centrally_authorised_medicines": "", "class": "dermatological agents", "reference_number": "EMEA/H/A-31/1446", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/07/2016", "prac_recommendation_date": "08/02/2018", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/03/2018", "european_commission_decision_date": "21/06/2018", "first_published_date": "08/07/2016", "last_updated_date": "02/07/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containing-medicinal-products" }, { "category": "Veterinary", "referral_name": "Girolan and its associated name Apralan", "international_non_proprietary_name_inn_common_name": "apramycin sulfate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA-V-A-122", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "15/06/2018", "last_updated_date": "15/06/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/girolan-its-associated-name-apralan" }, { "category": "Human", "referral_name": "Valproate and related substances", "international_non_proprietary_name_inn_common_name": "sodium valproate;valproate magnesium;valproate semisodium;valproic acid;valpromide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Absenor ;Convival Chrono ;Convulex ;Delepsine ;Depakin ;Depakine ;Depakote ;Depamag ;Depamide ;Deprakine ;Diplexil ;Dipromal ;Epilim ;Episenta ;Epival ;Ergenyl ;Espa-Valept ;Hexaquin ;Kentlim ;Leptilan ;Micropakine L.P. ;Orfiril ;Petilin ;Valepil ;Valhel PR ;Valpal ;Valpro and Valprolek", "class": "", "reference_number": "EMEA/H/A-31/1454", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "09/03/2017", "prac_recommendation_date": "08/02/2018", "cmdh_position_date": "21/03/2018", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "31/05/2018", "first_published_date": "10/03/2017", "last_updated_date": "07/06/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances-0" }, { "category": "Human", "referral_name": "Flupirtine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "flupirtine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Analgesics", "reference_number": "EMEA/H/A-31/1458", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Revocation", "procedure_start_date": "26/10/2017", "prac_recommendation_date": "08/02/2018", "cmdh_position_date": "21/03/2018", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "27/10/2017", "last_updated_date": "04/05/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/flupirtine-containing-medicinal-products" }, { "category": "Human", "referral_name": "Paracetamol modified-release", "international_non_proprietary_name_inn_common_name": "paracetamol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Alvedon", "class": "analgesics/antipyretics", "reference_number": "EMEA/H/A-31/1445", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "07/07/2016", "prac_recommendation_date": "01/09/2017", "cmdh_position_date": "13/12/2017", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "19/02/2018", "first_published_date": "08/07/2016", "last_updated_date": "01/03/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/paracetamol-modified-release" }, { "category": "Human", "referral_name": "Hydroxyethyl starch solutions for infusion", "international_non_proprietary_name_inn_common_name": "hydroxyethyl starch", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1348", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "29/11/2012", "prac_recommendation_date": "10/10/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2013", "european_commission_decision_date": "19/12/2013", "first_published_date": "30/11/2012", "last_updated_date": "12/01/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-solutions-infusion" }, { "category": "Human", "referral_name": "Alcover and associated names", "international_non_proprietary_name_inn_common_name": "sodium oxybate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "n/a", "class": "-", "reference_number": "EMEA/H/A-29(4)/1451", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/01/2017", "european_commission_decision_date": "18/12/2017", "first_published_date": "23/06/2017", "last_updated_date": "12/01/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/alcover-associated-names" }, { "category": "Human", "referral_name": "Zinbryta", "international_non_proprietary_name_inn_common_name": "daclizumab", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Zinbryta", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-20/1456/C/003862/0010", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "09/06/2017", "prac_recommendation_date": "26/10/2017", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/11/2017", "european_commission_decision_date": "08/01/2018", "first_published_date": "09/06/2017", "last_updated_date": "12/01/2018", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zinbryta-0" }, { "category": "Human", "referral_name": "Factor VIII", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Iblias;Elocta;Kovaltry;Nuwiq;Obizur;NovoEight;Voncento;ReFacto AF;Kogenate Bayer;Helixate NexGen;Advate", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1448", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/07/2016", "prac_recommendation_date": "01/09/2017", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/09/2017", "european_commission_decision_date": "10/10/2017", "first_published_date": "08/07/2016", "last_updated_date": "05/12/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/factor-viii" }, { "category": "Human", "referral_name": "Gadolinium-containing contrast agents", "international_non_proprietary_name_inn_common_name": "gadobenic acid;gadobutrol;gadodiamide;gadopentetic acid;gadoteric acid;gadoteridol;gadoversetamide;gadoxetic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Optimark", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1437", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Suspension", "procedure_start_date": "17/03/2016", "prac_recommendation_date": "06/07/2017", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/07/2017", "european_commission_decision_date": "23/11/2017", "first_published_date": "18/03/2016", "last_updated_date": "04/12/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents" }, { "category": "Human", "referral_name": "Vancomycin-containing medicines", "international_non_proprietary_name_inn_common_name": "vancomycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1440", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/05/2017", "european_commission_decision_date": "21/09/2017", "first_published_date": "01/04/2016", "last_updated_date": "17/11/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vancomycin-containing-medicines" }, { "category": "Veterinary", "referral_name": "Lincocin and its associated names", "international_non_proprietary_name_inn_common_name": "lincomycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/123", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/07/2017", "european_commission_decision_date": "05/10/2017", "first_published_date": "14/11/2017", "last_updated_date": "14/11/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/lincocin-its-associated-names" }, { "category": "Veterinary", "referral_name": "Zanil and associated names, and generic products thereof", "international_non_proprietary_name_inn_common_name": "oxyclozanide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/124", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/07/2017", "european_commission_decision_date": "28/09/2017", "first_published_date": "25/10/2017", "last_updated_date": "25/10/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/zanil-associated-names-generic-products-thereof" }, { "category": "Veterinary", "referral_name": "Moxidectin-containing veterinary medicines used in cattle, sheep and horses", "international_non_proprietary_name_inn_common_name": "moxidectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/116", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/05/2017", "european_commission_decision_date": "", "first_published_date": "24/10/2017", "last_updated_date": "24/10/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/moxidectin-containing-veterinary-medicines-used-cattle-sheep-horses" }, { "category": "Human", "referral_name": "Symbioflor 2", "international_non_proprietary_name_inn_common_name": "escherichia coli bacteria (cells and autolysate)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Symbioflor E. Coli ;Symbioflor® 2 ;Symbioflor Escherichia", "class": "Other immunostimulants, Antidiarrheal microorganisms", "reference_number": "EMEA/H/A-31/1441", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "22/06/2017", "first_published_date": "01/04/2016", "last_updated_date": "07/09/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/symbioflor-2" }, { "category": "Human", "referral_name": "Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions", "international_non_proprietary_name_inn_common_name": "methylprednisolone", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1449", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "01/12/2016", "prac_recommendation_date": "06/07/2017", "cmdh_position_date": "31/07/2017", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "02/12/2016", "last_updated_date": "04/09/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/medicinal-products-containing-lactose-bovine-origin-iv-im-use-acute-allergic-reactions" }, { "category": "Human", "referral_name": "Paracetamol/Ibuprofen 500 mg/150 mg film-coated tablets", "international_non_proprietary_name_inn_common_name": "paracetamol;ibuprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Paracomb", "class": "", "reference_number": "EMEA/H/A-29(4)/1447", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/05/2017", "european_commission_decision_date": "07/08/2017", "first_published_date": "19/05/2017", "last_updated_date": "18/08/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/paracetamol-ibuprofen-500-mg-150-mg-film-coated-tablets" }, { "category": "Veterinary", "referral_name": "Zinc oxide", "international_non_proprietary_name_inn_common_name": "zinc oxide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/118", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/03/2017", "european_commission_decision_date": "26/06/2017", "first_published_date": "14/08/2017", "last_updated_date": "14/08/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/zinc-oxide" }, { "category": "Veterinary", "referral_name": "Denagard 45%", "international_non_proprietary_name_inn_common_name": "tiamulin hydrogen fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/114", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/04/2017", "european_commission_decision_date": "14/07/2017", "first_published_date": "11/08/2017", "last_updated_date": "11/08/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/denagard-45" }, { "category": "Veterinary", "referral_name": "Methylprednisolone injection for cattle", "international_non_proprietary_name_inn_common_name": "methylprednisolone hydrogen succinate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/119", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/03/2017", "european_commission_decision_date": "20/06/2017", "first_published_date": "04/08/2017", "last_updated_date": "04/08/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/methylprednisolone-injection-cattle" }, { "category": "Veterinary", "referral_name": "Tylosin injection for mastitis", "international_non_proprietary_name_inn_common_name": "tylosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA-V-A-121", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/03/2017", "european_commission_decision_date": "10/07/2017", "first_published_date": "31/07/2017", "last_updated_date": "31/07/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/tylosin-injection-mastitis" }, { "category": "Human", "referral_name": "Cardioxane", "international_non_proprietary_name_inn_common_name": "dexrazoxane", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-13/1453", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2017", "european_commission_decision_date": "19/07/2017", "first_published_date": "19/05/2017", "last_updated_date": "26/07/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cardioxane" }, { "category": "Human", "referral_name": "Vepesid", "international_non_proprietary_name_inn_common_name": "etoposide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1425", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2017", "european_commission_decision_date": "26/06/2017", "first_published_date": "21/04/2017", "last_updated_date": "14/07/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vepesid" }, { "category": "Human", "referral_name": "Etopophos", "international_non_proprietary_name_inn_common_name": "etoposide phosphate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1417", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2017", "european_commission_decision_date": "26/06/2017", "first_published_date": "21/04/2017", "last_updated_date": "14/07/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/etopophos" }, { "category": "Human", "referral_name": "Micro Therapeutic Research", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1450", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/03/2017", "european_commission_decision_date": "23/06/2017", "first_published_date": "16/12/2016", "last_updated_date": "10/07/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/micro-therapeutic-research" }, { "category": "Human", "referral_name": "Saroten and associated names", "international_non_proprietary_name_inn_common_name": "amitriptyline", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Saroten Retard ;Redomex ;Redomex Diffucaps ;Saroten Tabs ;Saroten retard Tabs ;Saroten 2ml ;Sarotex ;Sarotex Retard ;Sarotex Retard 25 ;Sarotex Retard 50", "class": "antidepressant", "reference_number": "EMEA/H/A-30/1430", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/02/2017", "european_commission_decision_date": "08/05/2017", "first_published_date": "24/02/2017", "last_updated_date": "06/06/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/saroten-associated-names" }, { "category": "Human", "referral_name": "Haldol Decanoate and associated names", "international_non_proprietary_name_inn_common_name": "haloperidol decanoate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Haldol Decanoat ;Haldol Decanoas ;Serenase Dekanoat ;Serenase Depot ;Haldol - Janssen Decanoat Depot ;Haldol Decanoato ;Haldol Depot", "class": "", "reference_number": "EMEA/H/A-30/1405", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/02/2017", "european_commission_decision_date": "28/04/2017", "first_published_date": "24/02/2017", "last_updated_date": "11/05/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/haldol-decanoate-associated-names" }, { "category": "Human", "referral_name": "SGLT2 inhibitors (previously canagliflozin)", "international_non_proprietary_name_inn_common_name": "canagliflozin;empagliflozin;dapagliflozin;metformin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Xigduo;Ebymect;Edistride;Synjardy;Forxiga;Jardiance;Vokanamet;Invokana", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1442", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "15/04/2016", "prac_recommendation_date": "09/02/2017", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/02/2017", "european_commission_decision_date": "04/05/2017", "first_published_date": "15/04/2016", "last_updated_date": "08/05/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors-previously-canagliflozin" }, { "category": "Human", "referral_name": "Haldol and associated names", "international_non_proprietary_name_inn_common_name": "haloperidol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Aloperidin ;Haldol-Janssen ;Serenase", "class": "", "reference_number": "EMEA/H/A-30/1393", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/02/2017", "european_commission_decision_date": "28/04/2017", "first_published_date": "24/02/2017", "last_updated_date": "05/05/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/haldol-associated-names" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to cattle and pigs", "international_non_proprietary_name_inn_common_name": "gentamicin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/117", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/11/2016", "european_commission_decision_date": "27/02/2017", "first_published_date": "21/04/2017", "last_updated_date": "21/04/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-gentamicin-presented-solutions-injection-be-administered-cattle-pigs" }, { "category": "Human", "referral_name": "Dienogest/ethinylestradiol-containing medicinal products indicated in acne", "international_non_proprietary_name_inn_common_name": "dienogest;ethinyl estradiol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1435", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/01/2017", "european_commission_decision_date": "22/03/2017", "first_published_date": "26/02/2016", "last_updated_date": "24/03/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dienogest-ethinylestradiol-containing-medicinal-products-indicated-acne" }, { "category": "Human", "referral_name": "Lovenox and associated names", "international_non_proprietary_name_inn_common_name": "enoxaparin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1429", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2016", "european_commission_decision_date": "09/03/2017", "first_published_date": "16/12/2016", "last_updated_date": "22/03/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lovenox-associated-names" }, { "category": "Human", "referral_name": "Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)", "international_non_proprietary_name_inn_common_name": "daclatasvir;dasabuvir;sofosbuvir;ledipasvir;simeprevir;ombitasvir;paritaprevir;ritonavir", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Sovaldi;Olysio;Viekirax;Harvoni;Exviera;Daklinza", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1438", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "17/03/2016", "prac_recommendation_date": "01/12/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2016", "european_commission_decision_date": "23/02/2017", "first_published_date": "18/03/2016", "last_updated_date": "09/03/2017", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/direct-acting-antivirals-indicated-treatment-hepatitis-c-interferon-free" }, { "category": "Human", "referral_name": "Metformin and metformin-containing medicines", "international_non_proprietary_name_inn_common_name": "metformin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Xigduo;Vipdomet;Velmetia;Synjardy;Ristfor;Komboglyze;Jentadueto;Janumet;Icandra (previously Vildagliptin / metformin hydrochloride Novartis);Glubrava;Eucreas;Efficib;Ebymect;Competact", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1432", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/10/2016", "european_commission_decision_date": "12/12/2016", "first_published_date": "29/01/2016", "last_updated_date": "21/12/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/metformin-metformin-containing-medicines" }, { "category": "Human", "referral_name": "Pharmaceutics International Inc.", "international_non_proprietary_name_inn_common_name": "sodium phenylbutyrate;progesterone;dutasteride;colecalciferol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Ammonaps", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1444", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2016", "european_commission_decision_date": "05/12/2016", "first_published_date": "24/06/2016", "last_updated_date": "14/12/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pharmaceutics-international-inc" }, { "category": "Human", "referral_name": "Clenil and associated names", "international_non_proprietary_name_inn_common_name": "beclometasone dipropionate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Becloneb ;Beclospin and Sanasthmax", "class": "", "reference_number": "EMEA/H/A-30/1418", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2016", "european_commission_decision_date": "11/11/2016", "first_published_date": "16/09/2016", "last_updated_date": "18/11/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/clenil-associated-names" }, { "category": "Human", "referral_name": "Semler", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1443", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2016", "european_commission_decision_date": "22/09/2016", "first_published_date": "29/04/2016", "last_updated_date": "17/11/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/semler" }, { "category": "Human", "referral_name": "Durogesic and associated names", "international_non_proprietary_name_inn_common_name": "fentanyl", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1413", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2016", "european_commission_decision_date": "22/09/2016", "first_published_date": "22/07/2016", "last_updated_date": "19/10/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/durogesic-associated-names" }, { "category": "Human", "referral_name": "Diclofenac epolamine 50 mg tablets", "international_non_proprietary_name_inn_common_name": "diclofenac", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1434", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/02/2016", "european_commission_decision_date": "22/09/2016", "first_published_date": "22/07/2016", "last_updated_date": "10/10/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-epolamine-50-mg-tablets" }, { "category": "Human", "referral_name": "Alkem", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1436", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2016", "european_commission_decision_date": "08/09/2016", "first_published_date": "01/04/2016", "last_updated_date": "07/10/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/alkem" }, { "category": "Human", "referral_name": "Zydelig", "international_non_proprietary_name_inn_common_name": "idelalisib", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Zydelig", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1439/C/3843/0023", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "17/03/2016", "prac_recommendation_date": "07/07/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2016", "european_commission_decision_date": "15/09/2016", "first_published_date": "18/03/2016", "last_updated_date": "03/10/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zydelig" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and, or poultry", "international_non_proprietary_name_inn_common_name": "lincomycin;spectinomycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/110", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2016", "european_commission_decision_date": "22/08/2016", "first_published_date": "16/09/2016", "last_updated_date": "16/09/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-combination-lincomycin-spectinomycin-be-administered-orally-pigs-or-poultry" }, { "category": "Veterinary", "referral_name": "Altrenogest", "international_non_proprietary_name_inn_common_name": "altrenogest", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/095", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2016", "european_commission_decision_date": "29/07/2016", "first_published_date": "08/09/2016", "last_updated_date": "08/09/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/altrenogest" }, { "category": "Human", "referral_name": "Levonelle 1500 microgram tablets and associated names", "international_non_proprietary_name_inn_common_name": "levonorgestrel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-13/1427", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/05/2016", "european_commission_decision_date": "01/08/2016", "first_published_date": "27/05/2016", "last_updated_date": "09/08/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/levonelle-1500-microgram-tablets-associated-names" }, { "category": "Veterinary", "referral_name": "Colistin combinations", "international_non_proprietary_name_inn_common_name": "colistin sulfate;oxytetracycline hydrochloride;trimethoprim;enrofloxacin;amoxicillin trihydrate;spiramycin adipate;ampicillin trihydrate;erythromycin estolate;scopolamine;sulfaguanidine;neomycin sulfate;sulfadimethoxine;sulfamethoxypyridazine;doxycycline hyclate;sulfadimidine sodium;chlortetracycline hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/111", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2016", "european_commission_decision_date": "14/07/2016", "first_published_date": "05/08/2016", "last_updated_date": "05/08/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin-combinations" }, { "category": "Veterinary", "referral_name": "Benzathine benzylpenicillin intended for administration to food-producing species", "international_non_proprietary_name_inn_common_name": "benzathine benzylpenicillin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/20/002", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/01/2003", "european_commission_decision_date": "22/04/2003", "first_published_date": "13/08/2014", "last_updated_date": "26/07/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/benzathine-benzylpenicillin-intended-administration-food-producing-species" }, { "category": "Veterinary", "referral_name": "CattleMarker IBR Inactivated", "international_non_proprietary_name_inn_common_name": "infectious bovine rhinotracheitis vaccine (inactivated)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/115", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/03/2016", "european_commission_decision_date": "10/06/2016", "first_published_date": "19/07/2016", "last_updated_date": "19/07/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cattlemarker-ibr-inactivated" }, { "category": "Human", "referral_name": "Inhaled corticosteroids containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease", "international_non_proprietary_name_inn_common_name": "beclometasone;budesonide;flunisolide;fluticasone propionate;fluticasone furoate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1415", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Variation", "procedure_start_date": "07/05/2015", "prac_recommendation_date": "17/03/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/04/2016", "european_commission_decision_date": "29/06/2016", "first_published_date": "08/05/2015", "last_updated_date": "15/07/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive-pulmonary-disease" }, { "category": "Human", "referral_name": "Novantrone and associated names", "international_non_proprietary_name_inn_common_name": "mitoxantrone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Elsep ;Ralenova", "class": "Antineoplastic agent", "reference_number": "EMEA/H/A-30/1399", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/04/2016", "european_commission_decision_date": "24/06/2016", "first_published_date": "29/04/2016", "last_updated_date": "05/07/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/novantrone-associated-names" }, { "category": "Human", "referral_name": "Cymevene", "international_non_proprietary_name_inn_common_name": "ganciclovir", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cymevan ;Citovirax", "class": "Antiviral", "reference_number": "EMEA/H/A-30/1406", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/02/2016", "european_commission_decision_date": "28/04/2016", "first_published_date": "26/02/2016", "last_updated_date": "21/06/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cymevene" }, { "category": "Veterinary", "referral_name": "Closamectin Pour-on Solution and associated names", "international_non_proprietary_name_inn_common_name": "ivermectin;closantel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/113", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/10/2015", "european_commission_decision_date": "22/03/2016", "first_published_date": "31/05/2016", "last_updated_date": "31/05/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/closamectin-pour-solution-associated-names" }, { "category": "Human", "referral_name": "Amoxil", "international_non_proprietary_name_inn_common_name": "amoxicillin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-30/1372", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2015", "european_commission_decision_date": "20/08/2015", "first_published_date": "26/06/2015", "last_updated_date": "19/05/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/amoxil" }, { "category": "Human", "referral_name": "SGLT2 inhibitors", "international_non_proprietary_name_inn_common_name": "canagliflozin;dapagliflozin;empagliflozin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Edistride;Ebymect;Xigduo;Vokanamet;Synjardy;Jardiance;Invokana;Forxiga", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1419", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/06/2015", "prac_recommendation_date": "11/02/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/02/2016", "european_commission_decision_date": "28/04/2016", "first_published_date": "12/06/2015", "last_updated_date": "18/05/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors" }, { "category": "Human", "referral_name": "Tysabri", "international_non_proprietary_name_inn_common_name": "natalizumab", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Tysabri", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-20/1416/C/000603/0083", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/05/2015", "prac_recommendation_date": "11/02/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/02/2016", "european_commission_decision_date": "25/04/2016", "first_published_date": "08/05/2015", "last_updated_date": "12/05/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tysabri" }, { "category": "Human", "referral_name": "Tobramycin VVB and associated names", "international_non_proprietary_name_inn_common_name": "tobramycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1428", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/01/2015", "european_commission_decision_date": "04/04/2016", "first_published_date": "29/01/2016", "last_updated_date": "04/05/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tobramycin-vvb-associated-names" }, { "category": "Human", "referral_name": "Fusafungine containing medicinal products for oromucosal and nasal use", "international_non_proprietary_name_inn_common_name": "fusafungine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1420", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Revocation", "procedure_start_date": "10/09/2015", "prac_recommendation_date": "11/02/2016", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "31/03/2016", "european_commission_decision_date": "", "first_published_date": "11/09/2015", "last_updated_date": "14/04/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fusafungine-containing-medicinal-products-oromucosal-nasal-use" }, { "category": "Human", "referral_name": "Ambroxol and bromhexine-containing medicines", "international_non_proprietary_name_inn_common_name": "ambroxol;bromhexine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1397", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "10/04/2014", "prac_recommendation_date": "10/09/2015", "cmdh_position_date": "18/11/2015", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "14/01/2016", "first_published_date": "11/04/2014", "last_updated_date": "05/02/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ambroxol-bromhexine-containing-medicines" }, { "category": "Veterinary", "referral_name": "Solamocta 697 mg/g powder for use in drinking water for chickens, ducks and turkeys", "international_non_proprietary_name_inn_common_name": "amoxicillin trihydrate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/112", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "04/11/2015", "european_commission_decision_date": "07/01/2016", "first_published_date": "05/02/2016", "last_updated_date": "05/02/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/solamocta-697-mg-g-powder-use-drinking-water-chickens-ducks-turkeys" }, { "category": "Human", "referral_name": "Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard", "international_non_proprietary_name_inn_common_name": "bivalent human papillomavirus vaccine (types 16, 18);quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18);9-valent human papillomavirus vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Silgard;Gardasil 9;Gardasil;Cervarix", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1421", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "No further action", "procedure_start_date": "09/07/2015", "prac_recommendation_date": "06/11/2015", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2015", "european_commission_decision_date": "12/01/2016", "first_published_date": "13/07/2015", "last_updated_date": "20/01/2016", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard" }, { "category": "Human", "referral_name": "Inductos", "international_non_proprietary_name_inn_common_name": "dibotermin alfa", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Inductos", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-20/1422/C/0408/0082", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/10/2015", "european_commission_decision_date": "20/11/2015", "first_published_date": "24/07/2015", "last_updated_date": "07/12/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/inductos" }, { "category": "Veterinary", "referral_name": "Gutal", "international_non_proprietary_name_inn_common_name": "zinc oxide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/108", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/05/2015", "european_commission_decision_date": "22/10/2015", "first_published_date": "26/11/2015", "last_updated_date": "26/11/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/gutal" }, { "category": "Veterinary", "referral_name": "Coglapix suspension for injection for pigs", "international_non_proprietary_name_inn_common_name": "inactivated porcine actinobacillosis vaccine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/109", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "03/06/2015", "european_commission_decision_date": "28/08/2015", "first_published_date": "02/10/2015", "last_updated_date": "02/10/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/coglapix-suspension-injection-pigs" }, { "category": "Human", "referral_name": "Adrenaline auto-injectors", "international_non_proprietary_name_inn_common_name": "adrenaline (epinephrine)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1398", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2015", "european_commission_decision_date": "14/08/2015", "first_published_date": "25/04/2014", "last_updated_date": "26/08/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/adrenaline-auto-injectors" }, { "category": "Human", "referral_name": "GVK Biosciences", "international_non_proprietary_name_inn_common_name": "esomeprazole magnesium;candesartan cilexetil;nebivolol;desloratadine;donepezil;repaglinide;candesartan;esomeprazole;alendronic acid;ropinirole;cefpodoxime;quetiapine;trimetazidine;bosentan;tramadol;paracetamol;escitalopram;trimetazidine hydrochloride;entacapone;valsartan;hydrochlorothiazide;donepezil hydrochloride;ropinirole hydrochloride;clopidogrel hydrochloride;escitalopram oxalate;metformin hydrochloride;trimetazidine dihydrochloride;rizatriptan benzoate;metformin;fluconazole;eletriptan;rizatriptan;ebastine;ibuprofen;desmopressin;aciclovir;levetiracetam;irbesartan;venlafaxine;ciprofloxacin;cefpodoxime proxetil;tacrolimus;fexofenadine hydrochloride;phenoxymethylpenicillin;amlodipine besilate;metoclopramide;clopidogrel;levodopa;carbidopa;entacapone;atorvastatin;telmisartan;clindamycin hydrochloride;metoclopramide hydrochloride;clonazepam;clobazam;dexamethasone;thiamine hydrochloride;tramadol hydrochloride;pioglitazone;dipyridamole;fexofenadine;amlodipine;pantoprazole;hydrocortisone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1408", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/05/2015", "european_commission_decision_date": "16/07/2015", "first_published_date": "26/09/2014", "last_updated_date": "04/08/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gvk-biosciences" }, { "category": "Human", "referral_name": "Myoson and associated names", "international_non_proprietary_name_inn_common_name": "tolperisone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1411 EMEA/H/A-29/1412", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/04/2015", "european_commission_decision_date": "", "first_published_date": "28/07/2015", "last_updated_date": "28/07/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/myoson-associated-names" }, { "category": "Human", "referral_name": "Merisone and associated names", "international_non_proprietary_name_inn_common_name": "tolperisone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1411", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/04/2015", "european_commission_decision_date": "25/06/2015", "first_published_date": "24/04/2015", "last_updated_date": "28/07/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/merisone-associated-names" }, { "category": "Human", "referral_name": "Ibuprofen- and dexibuprofen-containing medicines", "international_non_proprietary_name_inn_common_name": "ibuprofen;dexibuprofen", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1401", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "13/06/2014", "prac_recommendation_date": "10/04/2015", "cmdh_position_date": "20/05/2015", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "13/06/2014", "last_updated_date": "14/07/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ibuprofen-dexibuprofen-containing-medicines" }, { "category": "Human", "referral_name": "Ikorel and Dancor", "international_non_proprietary_name_inn_common_name": "nicorandil", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "cardiovascular", "reference_number": "EMEA/H/A-30/1380", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/03/2015", "european_commission_decision_date": "05/06/2015", "first_published_date": "27/03/2015", "last_updated_date": "30/06/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ikorel-dancor" }, { "category": "Human", "referral_name": "Hydroxyzine", "international_non_proprietary_name_inn_common_name": "hydroxyzine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Atarax", "class": "", "reference_number": "EMEA/H/A-31/1400", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "08/05/2014", "prac_recommendation_date": "12/02/2015", "cmdh_position_date": "25/03/2015", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "08/05/2014", "last_updated_date": "08/06/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyzine" }, { "category": "Human", "referral_name": "Codeine-containing medicinal products for the treatment of cough or cold in paediatric patients", "international_non_proprietary_name_inn_common_name": "", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1394", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "10/04/2014", "prac_recommendation_date": "12/03/2015", "cmdh_position_date": "22/04/2015", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "11/04/2014", "last_updated_date": "18/05/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/codeine-containing-medicinal-products-treatment-cough-or-cold-paediatric-patients" }, { "category": "Veterinary", "referral_name": "Colistin oral", "international_non_proprietary_name_inn_common_name": "colistin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Polymyxins", "reference_number": "EMEA/V/A/106", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/12/2014", "european_commission_decision_date": "16/03/2015", "first_published_date": "13/04/2015", "last_updated_date": "13/04/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin-oral" }, { "category": "Veterinary", "referral_name": "Gentamicin", "international_non_proprietary_name_inn_common_name": "gentamicin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Aminoglycosides", "reference_number": "EMEA/V/A/104", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/11/2014", "european_commission_decision_date": "11/02/2015", "first_published_date": "10/04/2015", "last_updated_date": "", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/gentamicin" }, { "category": "Human", "referral_name": "Plendil and associated names", "international_non_proprietary_name_inn_common_name": "felodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1385", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2014", "european_commission_decision_date": "16/12/2014", "first_published_date": "24/10/2014", "last_updated_date": "30/03/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/plendil-associated-names" }, { "category": "Human", "referral_name": "Iclusig", "international_non_proprietary_name_inn_common_name": "ponatinib", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Iclusig", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/C/2695/A20/0003", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "05/12/2013", "prac_recommendation_date": "09/10/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2014", "european_commission_decision_date": "15/01/2015", "first_published_date": "06/12/2013", "last_updated_date": "02/03/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/iclusig" }, { "category": "Human", "referral_name": "Corlentor and Procoralan", "international_non_proprietary_name_inn_common_name": "ivabradine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Corlentor and Procoralan", "class": "", "reference_number": "EMEA/H/A20/1404/C/000598/0031 EMEA/H/A20/1404/C/000597/0032", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "08/05/2014", "prac_recommendation_date": "06/11/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/11/2014", "european_commission_decision_date": "15/01/2015", "first_published_date": "08/05/2014", "last_updated_date": "16/02/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/corlentor-procoralan" }, { "category": "Veterinary", "referral_name": "Suanovil 20 / Captalin associated names and generic products thereof", "international_non_proprietary_name_inn_common_name": "spiramycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/086", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/09/2014", "european_commission_decision_date": "11/12/2014", "first_published_date": "03/02/2015", "last_updated_date": "03/02/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suanovil-20-captalin-associated-names-generic-products-thereof" }, { "category": "Human", "referral_name": "Nasonex", "international_non_proprietary_name_inn_common_name": "mometasone furoate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1374", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/11/2014", "european_commission_decision_date": "19/01/2015", "first_published_date": "21/11/2014", "last_updated_date": "03/02/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nasonex" }, { "category": "Human", "referral_name": "Seasonique and associated names", "international_non_proprietary_name_inn_common_name": "levonorgestrel;ethinylestradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/139", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/11/2014", "european_commission_decision_date": "12/01/2015", "first_published_date": "27/06/2014", "last_updated_date": "29/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/seasonique-associated-names" }, { "category": "Human", "referral_name": "Valproate and related substances", "international_non_proprietary_name_inn_common_name": "sodium valproate;valproic acid;valproate semisodium;valpromide", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Absenor ;Convival Chrono ;Convulex ;Convulsofin Tabletten ;Delepsine ;Depakine ;Deprakine ;Diplexil ;Dipromal ;Epilim ;Episenta ;Epival ;Ergenyl ;Espa-Valept ;Hexaquin ;Leptilan ;Micropakine L.P. ;Orfiril ;Orlept ;Petilin ;Valberg ;Valepil and Valhel", "class": "", "reference_number": "EMEA/H/A-31/1387", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "10/10/2013", "prac_recommendation_date": "09/10/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2014", "european_commission_decision_date": "", "first_published_date": "11/10/2013", "last_updated_date": "29/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valproate-related-substances" }, { "category": "Human", "referral_name": "Oxynal Targin and associated names", "international_non_proprietary_name_inn_common_name": "oxycodone hydrochloride;naloxone hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-13/1402", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2014", "european_commission_decision_date": "22/12/2014", "first_published_date": "24/10/2014", "last_updated_date": "27/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/oxynal-targin-associated-names" }, { "category": "Human", "referral_name": "EMLA cream and associated names", "international_non_proprietary_name_inn_common_name": "lidocaine;prilocaine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1388", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/09/2014", "european_commission_decision_date": "28/11/2014", "first_published_date": "26/09/2014", "last_updated_date": "15/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/emla-cream-associated-names" }, { "category": "Veterinary", "referral_name": "Resflor solution injectable and associated names", "international_non_proprietary_name_inn_common_name": "florfenicol;flunixin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/101", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/10/2014", "european_commission_decision_date": "05/12/2014", "first_published_date": "09/01/2015", "last_updated_date": "09/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/resflor-solution-injectable-associated-names" }, { "category": "Human", "referral_name": "Testosterone-containing medicines", "international_non_proprietary_name_inn_common_name": "testosterone", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1396", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "10/04/2014", "prac_recommendation_date": "09/10/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2014", "european_commission_decision_date": "", "first_published_date": "11/04/2014", "last_updated_date": "08/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/testosterone-containing-medicines" }, { "category": "Human", "referral_name": "Polymyxin-containing medicines", "international_non_proprietary_name_inn_common_name": "colistimethate sodium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Colobreathe", "associated_names_non_centrally_authorised_medicines": "Colobreathe", "class": "antibiotics", "reference_number": "EMEA/H/A-31/1383", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2014", "european_commission_decision_date": "16/12/2014", "first_published_date": "24/10/2014", "last_updated_date": "05/01/2015", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/polymyxin-containing-medicines" }, { "category": "Veterinary", "referral_name": "Baytril injectable and generics", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/097", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/04/2014", "european_commission_decision_date": "01/09/2014", "first_published_date": "10/12/2014", "last_updated_date": "10/12/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-injectable-generics" }, { "category": "Veterinary", "referral_name": "Baytril injectable", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/091", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/04/2014", "european_commission_decision_date": "01/09/2014", "first_published_date": "10/12/2014", "last_updated_date": "10/12/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-injectable" }, { "category": "Human", "referral_name": "Bromocriptine-containing medicines indicated in the prevention or suppression of physiological lactation post-partum", "international_non_proprietary_name_inn_common_name": "bromocriptine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1379", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "05/09/2013", "prac_recommendation_date": "10/07/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/08/2014", "european_commission_decision_date": "30/10/2014", "first_published_date": "06/09/2013", "last_updated_date": "08/12/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bromocriptine-containing-medicines-indicated-prevention-or-suppression-physiological-lactation-post-partum" }, { "category": "Human", "referral_name": "Emergency contraceptives", "international_non_proprietary_name_inn_common_name": "levonorgestrel;ulipristal acetate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Norlevo ;Levonelle/Postinor and Levodonna ;ellaOne", "class": "", "reference_number": "EMEA/H/A-31/1391", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2014", "european_commission_decision_date": "30/09/2014", "first_published_date": "24/07/2014", "last_updated_date": "24/10/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/emergency-contraceptives" }, { "category": "Human", "referral_name": "Renin-angiotensin-system (RAS)-acting agents", "international_non_proprietary_name_inn_common_name": "captopril;imidapril;zofenopril;candesartan;delapril;telmisartan;aliskiren;moexipril;enalapril;valsartan;fosinopril;irbesartan;perindopril;quinapril;ramipril;eprosartan;olmesartan;trandolapril;losartan;azilsartan;lisinopril;spirapril;benazepril;cilazapril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Tolucombi;Telmisartan Teva;Telmisartan Teva Pharma;Tolura;Onduarp;Twynsta;Actelsar HCT;Kinzalkomb;MicardisPlus;PritorPlus;Copalia HCT;Dafiro HCT;Exforge HCT;Rasilamlo;Rasilez;Rasilez HCT;Rasitrio;Edarbi;Ipreziv;Aprovel;Ifirmasta (previously Irbesartan Krka);Irbesartan Teva;Irbesartan Zentiva (previously Irbesartan Winthrop);Karvea;Sabervel;CoAprovel;Ifirmacombi;Irbesartan/Hydrochlorothiazide Teva;Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop);Karvezide;Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG);Micardis;Pritor;Telmisartan Actavis", "associated_names_non_centrally_authorised_medicines": "", "class": "angiotensin-receptor blockers (ARBs), angiotensin-converting-enzyme inhibitors (ACEIs), direct renin inhibitors (aliskiren)", "reference_number": "EMEA/H/A-31/1370", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "16/05/2013", "prac_recommendation_date": "10/04/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/05/2014", "european_commission_decision_date": "04/09/2014", "first_published_date": "17/05/2013", "last_updated_date": "08/10/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents" }, { "category": "Human", "referral_name": "Diacerein-containing medicines for oral administration", "international_non_proprietary_name_inn_common_name": "diacerein", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Zondar", "class": "-", "reference_number": "EMEA/H/A-31/1349", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "29/11/2012", "prac_recommendation_date": "06/03/2014", "cmdh_position_date": "23/07/2014", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "04/09/2014", "first_published_date": "30/11/2012", "last_updated_date": "19/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diacerein-containing-medicines-oral-administration" }, { "category": "Human", "referral_name": "Protelos and Osseor", "international_non_proprietary_name_inn_common_name": "strontium ranelate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A20/1371/C/00560-561/0039-0034", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "16/05/2013", "prac_recommendation_date": "09/01/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/02/2014", "european_commission_decision_date": "15/04/2014", "first_published_date": "17/05/2013", "last_updated_date": "18/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/protelos-osseor" }, { "category": "Human", "referral_name": "Linoladiol N and Linoladiol HN", "international_non_proprietary_name_inn_common_name": "estradiol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "hormonal", "reference_number": "EMEA/H/A-31/1336", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2014", "european_commission_decision_date": "19/08/2014", "first_published_date": "20/12/2013", "last_updated_date": "11/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/linoladiol-n-linoladiol-hn" }, { "category": "Human", "referral_name": "Domperidone-containing medicines", "international_non_proprietary_name_inn_common_name": "domperidone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1365", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "07/03/2013", "prac_recommendation_date": "06/06/2014", "cmdh_position_date": "24/04/2014", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "01/09/2014", "first_published_date": "08/03/2013", "last_updated_date": "11/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/domperidone-containing-medicines" }, { "category": "Human", "referral_name": "Seroquel / Seroquel XR and associated names", "international_non_proprietary_name_inn_common_name": "quetiapine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1362", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/05/2014", "european_commission_decision_date": "06/08/2014", "first_published_date": "23/05/2014", "last_updated_date": "09/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-seroquel-xr-associated-names" }, { "category": "Veterinary", "referral_name": "Veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs", "international_non_proprietary_name_inn_common_name": "tylosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/100", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/05/2014", "european_commission_decision_date": "31/07/2014", "first_published_date": "05/09/2014", "last_updated_date": "05/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicinal-products-containing-tylosin-be-administered-orally-feed-or-drinking-water-pigs" }, { "category": "Veterinary", "referral_name": "Linco-Spectin 100 and associated names", "international_non_proprietary_name_inn_common_name": "lincomycin;spectinomycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/088", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/04/2014", "european_commission_decision_date": "11/07/2014", "first_published_date": "04/09/2014", "last_updated_date": "04/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/linco-spectin-100-associated-names" }, { "category": "Human", "referral_name": "Dexamed and associated names", "international_non_proprietary_name_inn_common_name": "dexamfetamine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1375", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/05/2014", "european_commission_decision_date": "06/08/2014", "first_published_date": "23/05/2014", "last_updated_date": "02/09/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dexamed-associated-names" }, { "category": "Veterinary", "referral_name": "Fiprex", "international_non_proprietary_name_inn_common_name": "fipronil", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/099", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/04/2014", "european_commission_decision_date": "14/07/2014", "first_published_date": "14/08/2014", "last_updated_date": "14/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/fiprex" }, { "category": "Veterinary", "referral_name": "Vasotop P", "international_non_proprietary_name_inn_common_name": "ramipril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/051", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/12/2009", "european_commission_decision_date": "27/04/2010", "first_published_date": "14/08/2014", "last_updated_date": "14/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/vasotop-p" }, { "category": "Veterinary", "referral_name": "Dectomax injectable solution and its associated names", "international_non_proprietary_name_inn_common_name": "doramectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/12/2004", "european_commission_decision_date": "29/03/2005", "first_published_date": "13/08/2014", "last_updated_date": "13/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/dectomax-injectable-solution-its-associated-names" }, { "category": "Veterinary", "referral_name": "Porcimectin Injection and its associated names", "international_non_proprietary_name_inn_common_name": "ivermectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/003", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/06/2002", "european_commission_decision_date": "12/09/2002", "first_published_date": "13/08/2014", "last_updated_date": "13/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcimectin-injection-its-associated-names" }, { "category": "Veterinary", "referral_name": "Bovimectin Injection and its associated names", "international_non_proprietary_name_inn_common_name": "ivermectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/002", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/06/2002", "european_commission_decision_date": "19/09/2002", "first_published_date": "13/08/2014", "last_updated_date": "13/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/bovimectin-injection-its-associated-names" }, { "category": "Veterinary", "referral_name": "Cobactan DC and its associated names", "international_non_proprietary_name_inn_common_name": "cefquinome", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/014", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/07/2006", "european_commission_decision_date": "13/10/2006", "first_published_date": "12/08/2014", "last_updated_date": "12/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cobactan-dc-its-associated-names" }, { "category": "Veterinary", "referral_name": "Micotil 300 and its associated names", "international_non_proprietary_name_inn_common_name": "tilmicosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/11/2005", "european_commission_decision_date": "23/06/2006", "first_published_date": "12/08/2014", "last_updated_date": "12/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/micotil-300-its-associated-names" }, { "category": "Veterinary", "referral_name": "Cobactan IV 4.5% powder and solvent for solution for injection and its associated names", "international_non_proprietary_name_inn_common_name": "cefquinome", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/012", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/05/2006", "european_commission_decision_date": "21/08/2006", "first_published_date": "12/08/2014", "last_updated_date": "12/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cobactan-iv-45-powder-solvent-solution-injection-its-associated-names" }, { "category": "Veterinary", "referral_name": "Eprinex pour-on and its associated names", "international_non_proprietary_name_inn_common_name": "eprinomectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/02/2004", "european_commission_decision_date": "11/08/2004", "first_published_date": "11/08/2014", "last_updated_date": "11/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/eprinex-pour-its-associated-names" }, { "category": "Veterinary", "referral_name": "Orbax", "international_non_proprietary_name_inn_common_name": "orbifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/004", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/01/2003", "european_commission_decision_date": "16/04/2003", "first_published_date": "11/08/2014", "last_updated_date": "11/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/orbax" }, { "category": "Human", "referral_name": "Caustinerf arsenical and Yranicid arsenical", "international_non_proprietary_name_inn_common_name": "ephedrine hydrochloride;lidocaine;arsenous anhydride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Dental pulp devitalising", "reference_number": "EMEA/H/A-31/1382", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2014", "european_commission_decision_date": "11/07/2014", "first_published_date": "25/04/2014", "last_updated_date": "06/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/caustinerf-arsenical-yranicid-arsenical" }, { "category": "Veterinary", "referral_name": "Avinew", "international_non_proprietary_name_inn_common_name": "Newcastle disease virus, VG/GA strain, live", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/001", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/09/2001", "european_commission_decision_date": "04/02/2002", "first_published_date": "05/08/2014", "last_updated_date": "05/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/avinew" }, { "category": "Veterinary", "referral_name": "Bayovac IBR Marker Vivum", "international_non_proprietary_name_inn_common_name": "bovine Herpes virus type 1 (BHV-1), strain Difivac (IBR-Marker virus, gE-negative), modified live (attenuated) virus", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/023b/001", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2000", "european_commission_decision_date": "10/07/2000", "first_published_date": "05/08/2014", "last_updated_date": "05/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/bayovac-ibr-marker-vivum" }, { "category": "Human", "referral_name": "Methadone medicinal products for oral use containing povidone", "international_non_proprietary_name_inn_common_name": "methadone", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-107i/1395", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "10/04/2014", "prac_recommendation_date": "10/07/2014", "cmdh_position_date": "23/07/2014", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "11/04/2014", "last_updated_date": "04/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methadone-medicinal-products-oral-use-containing-povidone" }, { "category": "Human", "referral_name": "Zolpidem-containing medicines", "international_non_proprietary_name_inn_common_name": "zolpidem", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1377", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/07/2013", "prac_recommendation_date": "06/03/2014", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2014", "european_commission_decision_date": "23/06/2014", "first_published_date": "12/07/2013", "last_updated_date": "04/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zolpidem-containing-medicines" }, { "category": "Human", "referral_name": "Crestor and associated names", "international_non_proprietary_name_inn_common_name": "rosuvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29-PAE/1378", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/06/2014", "european_commission_decision_date": "", "first_published_date": "01/08/2014", "last_updated_date": "01/08/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/crestor-associated-names" }, { "category": "Human", "referral_name": "Sandostatin LAR and associated names", "international_non_proprietary_name_inn_common_name": "ocreotide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/001355", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2014", "european_commission_decision_date": "26/06/2014", "first_published_date": "27/06/2014", "last_updated_date": "27/06/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sandostatin-lar-associated-names" }, { "category": "Human", "referral_name": "Sandostatin and associated names", "international_non_proprietary_name_inn_common_name": "ocreotide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/001354", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2014", "european_commission_decision_date": "26/06/2014", "first_published_date": "27/06/2014", "last_updated_date": "27/06/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sandostatin-associated-names" }, { "category": "Human", "referral_name": "Nanotop and associated names", "international_non_proprietary_name_inn_common_name": "human albumin, denatured", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1386", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2013", "european_commission_decision_date": "28/02/2014", "first_published_date": "20/12/2013", "last_updated_date": "16/06/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nanotop-associated-names" }, { "category": "Human", "referral_name": "Ketoconazole-containing medicines", "international_non_proprietary_name_inn_common_name": "ketoconazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Nizoral ;Fungoral", "class": "Antifungal", "reference_number": "EMEA/H/A-31/1314", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/07/2013", "european_commission_decision_date": "11/10/2013", "first_published_date": "26/07/2013", "last_updated_date": "13/06/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ketoconazole-containing-medicines" }, { "category": "Veterinary", "referral_name": "Long-acting formulations for injection containing barium selenate for all food producing species", "international_non_proprietary_name_inn_common_name": "barium selenate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/077", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/11/2013", "european_commission_decision_date": "28/03/2014", "first_published_date": "27/05/2014", "last_updated_date": "27/05/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/long-acting-formulations-injection-containing-barium-selenate-all-food-producing-species" }, { "category": "Human", "referral_name": "Methysergide-containing medicines", "international_non_proprietary_name_inn_common_name": "methysergide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Deseril ;Desernil", "class": "Ergot alkaloids", "reference_number": "EMEA/H/A-31/1335", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/02/2014", "european_commission_decision_date": "28/04/2014", "first_published_date": "21/02/2014", "last_updated_date": "27/05/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methysergide-containing-medicines" }, { "category": "Human", "referral_name": "Rocephin", "international_non_proprietary_name_inn_common_name": "rabbit", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1302", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/01/2014", "european_commission_decision_date": "21/03/2014", "first_published_date": "24/01/2014", "last_updated_date": "19/05/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rocephin" }, { "category": "Veterinary", "referral_name": "Norbonex 5 mg/ml pour-on solution for beef and dairy cattle", "international_non_proprietary_name_inn_common_name": "eprinomectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/098", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/01/2014", "european_commission_decision_date": "21/03/2014", "first_published_date": "14/05/2014", "last_updated_date": "14/05/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/norbonex-5-mg-ml-pour-solution-beef-dairy-cattle" }, { "category": "Veterinary", "referral_name": "Veterinary medicines containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/089", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/11/2013", "european_commission_decision_date": "28/02/2014", "first_published_date": "10/04/2014", "last_updated_date": "10/04/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/veterinary-medicines-containing-enrofloxacin-be-administered-drinking-water-chickens-or-turkeys" }, { "category": "Human", "referral_name": "Kogenate Bayer and Helixate NexGen", "international_non_proprietary_name_inn_common_name": "octocog alfa", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/C/275/A20/150, EMEA/H/C/276/A20/143", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "07/03/2013", "prac_recommendation_date": "05/12/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2013", "european_commission_decision_date": "20/02/2014", "first_published_date": "08/03/2013", "last_updated_date": "09/04/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/kogenate-bayer-helixate-nexgen" }, { "category": "Human", "referral_name": "Tibolona Aristo and Tibocina and associated names", "international_non_proprietary_name_inn_common_name": "tibolone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Tibolon Aristo ;Tibolinia", "class": "", "reference_number": "EMEA/H/A-29/1389 and EMEA/H/A-29/1390", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2013", "european_commission_decision_date": "05/03/2014", "first_published_date": "20/12/2013", "last_updated_date": "08/04/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tibolona-aristo-tibocina-associated-names" }, { "category": "Human", "referral_name": "Valebo and associated names", "international_non_proprietary_name_inn_common_name": "alendronic acid;alfacalcidol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Tevabone ;Teboneva", "class": "", "reference_number": "EMEA/H/A-29/1364", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2013", "european_commission_decision_date": "10/03/2014", "first_published_date": "20/12/2013", "last_updated_date": "31/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valebo-associated-names" }, { "category": "Human", "referral_name": "Valtrex", "international_non_proprietary_name_inn_common_name": "valaciclovir", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Zelitrex ;Talavir ;Valaciclovir Allen ;Valherpes", "class": "", "reference_number": "EMEA/H/A-30/1004", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/04/2010", "european_commission_decision_date": "13/07/2010", "first_published_date": "23/04/2010", "last_updated_date": "25/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valtrex" }, { "category": "Human", "referral_name": "Substances related to nicotinic acid", "international_non_proprietary_name_inn_common_name": "acipimox", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Olbetam", "class": "Lipid-lowering agents", "reference_number": "EMEA/H/A-31/1366", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Variation", "procedure_start_date": "07/03/2013", "prac_recommendation_date": "07/11/2013", "cmdh_position_date": "18/12/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "20/02/2014", "first_published_date": "08/03/2013", "last_updated_date": "13/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/substances-related-nicotinic-acid" }, { "category": "Human", "referral_name": "Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines", "international_non_proprietary_name_inn_common_name": "monovalent and multivalent measles, mumps, rubella and varicella vaccines (live)", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Amunovax ;Priorix ;Priorix Tetra ;Provarivax ;R.O.R. Vax ;Rouvax ;Trivivac ;Varilrix ;Varivax", "class": "Vaccines", "reference_number": "EMEA/H/A-31/1333", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2012", "european_commission_decision_date": "27/06/2013", "first_published_date": "14/12/2012", "last_updated_date": "12/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/monovalent-multivalent-measles-mumps-rubella-or-varicella-vaccines" }, { "category": "Human", "referral_name": "Intravenous nicardipine medicines", "international_non_proprietary_name_inn_common_name": "nicardipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cardene IV ;Loxen ;Nicardipine Aguettant ;Nicardipine Arrow ;Rydene ;Vasonase", "class": "Antihypertensive", "reference_number": "EMEA/H/A-31/1339", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/10/2013", "european_commission_decision_date": "20/12/2013", "first_published_date": "25/10/2013", "last_updated_date": "12/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/intravenous-nicardipine-medicines" }, { "category": "Human", "referral_name": "Hydroxyethyl starch solutions for infusion", "international_non_proprietary_name_inn_common_name": "hydroxyethyl starch", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-107i/1376", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "11/07/2013", "prac_recommendation_date": "10/10/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2013", "european_commission_decision_date": "19/12/2013", "first_published_date": "12/07/2013", "last_updated_date": "06/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hydroxyethyl-starch-solutions-infusion-0" }, { "category": "Human", "referral_name": "Thiocolchicoside-containing medicines", "international_non_proprietary_name_inn_common_name": "thiocolchicoside", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Muscoril and Coltramyl", "class": "muscle relaxant", "reference_number": "EMA/H/A-31/1361", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2013", "european_commission_decision_date": "17/01/2014", "first_published_date": "22/11/2013", "last_updated_date": "06/03/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines" }, { "category": "Human", "referral_name": "Ergot derivatives", "international_non_proprietary_name_inn_common_name": "dihydroergocristine;dihydroergotamine;dihydroergotoxine;nicergoline;dihydroergocryptine;caffeine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Ergot derivatives", "reference_number": "EMEA/H/A-31/1325", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2013", "european_commission_decision_date": "27/09/2013", "first_published_date": "28/06/2013", "last_updated_date": "17/02/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ergot-derivatives" }, { "category": "Human", "referral_name": "Metoclopramide-containing medicines", "international_non_proprietary_name_inn_common_name": "metoclopramide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Maxolon ;Primperan", "class": "Anti-emetic", "reference_number": "EMEA/H/A-31/1321", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/10/2013", "european_commission_decision_date": "20/12/2013", "first_published_date": "26/07/2013", "last_updated_date": "06/02/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/metoclopramide-containing-medicines" }, { "category": "Human", "referral_name": "Combined hormonal contraceptives", "international_non_proprietary_name_inn_common_name": "desogestrel;gestodene;norgestimate;etonogestrel;drospirenone;dienogest;chlormadinone;nomegestrol;norelgestromin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1356", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally and nationally authorised products (mixed)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/02/2013", "prac_recommendation_date": "10/10/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/01/2014", "european_commission_decision_date": "", "first_published_date": "08/02/2013", "last_updated_date": "31/01/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/combined-hormonal-contraceptives" }, { "category": "Human", "referral_name": "Okrido", "international_non_proprietary_name_inn_common_name": "prednisolone sodium phosphate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1368", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2013", "european_commission_decision_date": "05/09/2013", "first_published_date": "28/06/2013", "last_updated_date": "03/01/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/okrido" }, { "category": "Human", "referral_name": "Targocid and associated names", "international_non_proprietary_name_inn_common_name": "teicoplanin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Targocid ;Teicomid", "class": "-", "reference_number": "EMEA/H/A-30/1301", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/05/2013", "european_commission_decision_date": "12/09/2013", "first_published_date": "31/05/2013", "last_updated_date": "03/01/2014", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/targocid-associated-names" }, { "category": "Human", "referral_name": "Sandimmun and associated names", "international_non_proprietary_name_inn_common_name": "ciclosporin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1300, EMEA/H/A-30/1320", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2013", "european_commission_decision_date": "31/10/2013", "first_published_date": "28/06/2013", "last_updated_date": "20/12/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sandimmun-associated-names" }, { "category": "Human", "referral_name": "Sandimmun Neoral and associated names", "international_non_proprietary_name_inn_common_name": "ciclosporin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1300, EMEA/H/A-30/1320", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2013", "european_commission_decision_date": "31/10/2013", "first_published_date": "28/06/2013", "last_updated_date": "20/12/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sandimmun-neoral-associated-names" }, { "category": "Human", "referral_name": "Didanosine", "international_non_proprietary_name_inn_common_name": "didanosine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1367", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/09/2013", "european_commission_decision_date": "20/11/2013", "first_published_date": "20/09/2013", "last_updated_date": "10/12/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/didanosine" }, { "category": "Human", "referral_name": "Methylphenidate Sandoz", "international_non_proprietary_name_inn_common_name": "methylphenidate hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1359", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/07/2013", "european_commission_decision_date": "09/10/2013", "first_published_date": "26/07/2013", "last_updated_date": "05/12/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate-sandoz" }, { "category": "Human", "referral_name": "Methylphenidate Hexal", "international_non_proprietary_name_inn_common_name": "methylphenidate hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1360", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/07/2013", "european_commission_decision_date": "09/10/2013", "first_published_date": "26/07/2013", "last_updated_date": "05/12/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate-hexal" }, { "category": "Human", "referral_name": "Diclofenac-containing medicines", "international_non_proprietary_name_inn_common_name": "diclofenac", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Non-steroidal anti-inflammatory drugs (NSAIDs)", "reference_number": "EMEA/H/A-31/1344", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "31/10/2012", "prac_recommendation_date": "13/06/2013", "cmdh_position_date": "26/06/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "25/09/2013", "first_published_date": "31/10/2012", "last_updated_date": "27/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diclofenac-containing-medicines" }, { "category": "Veterinary", "referral_name": "Dexadreson", "international_non_proprietary_name_inn_common_name": "dexamethasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/087", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/07/2013", "european_commission_decision_date": "18/10/2013", "first_published_date": "27/11/2013", "last_updated_date": "27/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/dexadreson" }, { "category": "Human", "referral_name": "Flupirtine-containing medicines", "international_non_proprietary_name_inn_common_name": "flupirtine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-107i/1363", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/03/2013", "prac_recommendation_date": "13/06/2013", "cmdh_position_date": "26/06/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "05/09/2013", "first_published_date": "08/03/2013", "last_updated_date": "21/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/flupirtine-containing-medicines" }, { "category": "Veterinary", "referral_name": "Micotil 300 Injectie", "international_non_proprietary_name_inn_common_name": "tilmicosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A-34/82", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/07/2013", "european_commission_decision_date": "18/10/2013", "first_published_date": "20/11/2013", "last_updated_date": "20/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/micotil-300-injectie" }, { "category": "Human", "referral_name": "Baxter dialysis solutions", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "dialysis solutions", "reference_number": "EMEA/H/A-31/1290", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/10/2011", "european_commission_decision_date": "16/12/2011", "first_published_date": "23/09/2011", "last_updated_date": "20/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/baxter-dialysis-solutions" }, { "category": "Human", "referral_name": "Ciclosporin IDL", "international_non_proprietary_name_inn_common_name": "ciclosporin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1105", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "22/07/2010", "first_published_date": "23/07/2009", "last_updated_date": "20/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ciclosporin-idl" }, { "category": "Human", "referral_name": "Tazocin", "international_non_proprietary_name_inn_common_name": "piperacillin;tazobactam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Tazobac ;Tazocel ;Tazonam", "class": "", "reference_number": "EMEA/H/A-30/001149", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/10/2010", "european_commission_decision_date": "21/02/2011", "first_published_date": "22/10/2010", "last_updated_date": "19/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tazocin" }, { "category": "Human", "referral_name": "Avalox", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1082", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2009", "european_commission_decision_date": "02/10/2009", "first_published_date": "25/06/2009", "last_updated_date": "19/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/avalox" }, { "category": "Human", "referral_name": "Vivaglobin", "international_non_proprietary_name_inn_common_name": "human normal immunoglobulin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-36/1296", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/02/2012", "european_commission_decision_date": "07/05/2012", "first_published_date": "17/02/2012", "last_updated_date": "18/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vivaglobin" }, { "category": "Human", "referral_name": "Octagam", "international_non_proprietary_name_inn_common_name": "human normal immunoglobulin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-107/001278", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/09/2010", "european_commission_decision_date": "04/10/2010", "first_published_date": "24/09/2010", "last_updated_date": "18/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/octagam-0" }, { "category": "Human", "referral_name": "Augmentin", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/97898/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/01/2009", "european_commission_decision_date": "19/10/2009", "first_published_date": "25/06/2009", "last_updated_date": "18/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/augmentin" }, { "category": "Human", "referral_name": "Short-acting beta-agonists", "international_non_proprietary_name_inn_common_name": "terbutaline;salbutamol;hexoprenaline;ritodrine;fenoterol;isoxsuprine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1347", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "27/11/2012", "prac_recommendation_date": "05/09/2013", "cmdh_position_date": "23/10/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "30/11/2012", "last_updated_date": "07/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/short-acting-beta-agonists" }, { "category": "Human", "referral_name": "Antifibrinolytic medicines", "international_non_proprietary_name_inn_common_name": "aprotinin;aminocaproic acid;tranexamic acid", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "B02A, Antihemorrhagics", "reference_number": "EMEA/H/A-31/1267", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/06/2012", "european_commission_decision_date": "", "first_published_date": "17/02/2012", "last_updated_date": "06/11/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/antifibrinolytic-medicines" }, { "category": "Veterinary", "referral_name": "Suifertil 4-mg/ml oral solution for pigs and associated names", "international_non_proprietary_name_inn_common_name": "altrenogest", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/094", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/07/2013", "european_commission_decision_date": "02/10/2013", "first_published_date": "30/10/2013", "last_updated_date": "30/10/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suifertil-4-mg-ml-oral-solution-pigs-associated-names" }, { "category": "Veterinary", "referral_name": "Cydectin TriclaMox", "international_non_proprietary_name_inn_common_name": "moxidectin;triclabendazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/096", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2013", "european_commission_decision_date": "25/09/2013", "first_published_date": "18/10/2013", "last_updated_date": "18/10/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cydectin-triclamox" }, { "category": "Veterinary", "referral_name": "Doramectin", "international_non_proprietary_name_inn_common_name": "doramectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/081", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/06/2013", "european_commission_decision_date": "06/09/2013", "first_published_date": "18/10/2013", "last_updated_date": "18/10/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/doramectin" }, { "category": "Veterinary", "referral_name": "Deltanil", "international_non_proprietary_name_inn_common_name": "deltamethrin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/093", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/09/2013", "european_commission_decision_date": "24/09/2013", "first_published_date": "11/10/2013", "last_updated_date": "11/10/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/deltanil" }, { "category": "Human", "referral_name": "Numeta G13%E and Numeta G16%E emulsion for infusion", "international_non_proprietary_name_inn_common_name": "", "current_status": "CMDh final position", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-107i/1373", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "13/06/2013", "prac_recommendation_date": "05/09/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/09/2013", "european_commission_decision_date": "", "first_published_date": "14/06/2013", "last_updated_date": "27/09/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/numeta-g13e-numeta-g16e-emulsion-infusion" }, { "category": "Veterinary", "referral_name": "Soludox", "international_non_proprietary_name_inn_common_name": "doxycycline hyclate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/090", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/06/2013", "european_commission_decision_date": "12/08/2013", "first_published_date": "24/09/2013", "last_updated_date": "24/09/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/soludox" }, { "category": "Veterinary", "referral_name": "Strenzen 500/125-mg/g powder", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/085", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/04/2013", "european_commission_decision_date": "12/08/2013", "first_published_date": "19/09/2013", "last_updated_date": "19/09/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/strenzen-500-125-mg-g-powder" }, { "category": "Human", "referral_name": "Cilostazol-containing medicines", "international_non_proprietary_name_inn_common_name": "cilostazol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Pletal ;Ekistol", "class": "antiplatelet agents", "reference_number": "EMEA/H/A-31/1306", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/03/2013", "european_commission_decision_date": "24/06/2013", "first_published_date": "22/03/2013", "last_updated_date": "11/09/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cilostazol-containing-medicines" }, { "category": "Human", "referral_name": "Cyproterone- and ethinylestradiol-containing medicines", "international_non_proprietary_name_inn_common_name": "cyproterone;ethinyl estradiol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Acnemine ;Acneson ;Chloe ;Clairette ;Cyprest ;Cyprodiol ;Diane 35 ;Dianette ;Feminil ;Minerva ;Zyrona", "class": "", "reference_number": "EMEA/H/A-107i/1357", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "07/02/2013", "prac_recommendation_date": "16/05/2013", "cmdh_position_date": "29/05/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "25/07/2013", "first_published_date": "08/02/2013", "last_updated_date": "05/08/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-ethinylestradiol-containing-medicines" }, { "category": "Human", "referral_name": "Codeine-containing medicines", "international_non_proprietary_name_inn_common_name": "codeine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1342", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Risk minimisation measures", "procedure_start_date": "03/10/2012", "prac_recommendation_date": "13/06/2013", "cmdh_position_date": "26/06/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "05/10/2012", "last_updated_date": "02/08/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/codeine-containing-medicines" }, { "category": "Human", "referral_name": "Furosemide Vitabalans", "international_non_proprietary_name_inn_common_name": "furosemide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1334", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/02/2013", "european_commission_decision_date": "14/05/2013", "first_published_date": "22/02/2013", "last_updated_date": "30/07/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/furosemide-vitabalans" }, { "category": "Human", "referral_name": "Simvastatin Vale", "international_non_proprietary_name_inn_common_name": "simvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Simvastatin Vale pharmaceuticals", "class": "Statin", "reference_number": "EMEA/H/A-29/1358", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/03/2013", "european_commission_decision_date": "27/05/2013", "first_published_date": "03/04/2013", "last_updated_date": "22/07/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/simvastatin-vale" }, { "category": "Human", "referral_name": "Calcitonin", "international_non_proprietary_name_inn_common_name": "calcitonin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1291", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2012", "european_commission_decision_date": "13/02/2013", "first_published_date": "20/07/2012", "last_updated_date": "19/07/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcitonin" }, { "category": "Human", "referral_name": "Tetrazepam-containing medicines", "international_non_proprietary_name_inn_common_name": "tetrazepam", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107i procedures", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Myolastan and generics", "class": "-", "reference_number": "EMEA/H/A107i/1352", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "10/01/2013", "prac_recommendation_date": "11/04/2013", "cmdh_position_date": "24/04/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "29/05/2013", "first_published_date": "11/01/2013", "last_updated_date": "18/07/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tetrazepam-containing-medicines" }, { "category": "Veterinary", "referral_name": "Florgane", "international_non_proprietary_name_inn_common_name": "florfenicol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/083", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/03/2013", "european_commission_decision_date": "23/05/2013", "first_published_date": "10/07/2013", "last_updated_date": "10/07/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/florgane" }, { "category": "Veterinary", "referral_name": "Nuflor Swine Once", "international_non_proprietary_name_inn_common_name": "florfenicol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/080", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/02/2013", "european_commission_decision_date": "16/05/2013", "first_published_date": "14/06/2013", "last_updated_date": "14/06/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/nuflor-swine-once" }, { "category": "Human", "referral_name": "Almitrine-containing medicines", "international_non_proprietary_name_inn_common_name": "almitrine", "current_status": "CMDh final position", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Vectarion ;Armanor", "class": "", "reference_number": "EMEA/H/A-31/1346", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CMDh", "authorisation_model": "Nationally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "29/11/2012", "prac_recommendation_date": "16/05/2013", "cmdh_position_date": "29/05/2013", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "", "first_published_date": "30/11/2012", "last_updated_date": "10/06/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/almitrine-containing-medicines" }, { "category": "Human", "referral_name": "Tredaptive, Pelzont and Trevaclyn", "international_non_proprietary_name_inn_common_name": "laropiprant;nicotinic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 20 procedures", "associated_names_centrally_authorised_medicines": "Tredaptive;Pelzont;Trevaclyn", "associated_names_non_centrally_authorised_medicines": "", "class": "cardiovascular", "reference_number": "EMEA/H/C/889/A20/37, EMEA/H/C/903/A20/38, EMEA/H/C/897/A20/38", "non_prac_decision_making_model": "", "prac_decision_making_model": "PRAC-CHMP-EC", "authorisation_model": "Centrally authorised product(s)", "prac_recommendation": "Suspension", "procedure_start_date": "20/12/2012", "prac_recommendation_date": "10/01/2013", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "22/03/2013", "first_published_date": "21/12/2012", "last_updated_date": "17/05/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tredaptive-pelzont-trevaclyn" }, { "category": "Human", "referral_name": "Kantos Master", "international_non_proprietary_name_inn_common_name": "beclometasone dipropionate;formoterol fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Kantos ;Formodual ;Foster ;Inuxair ;Innovair and associated names", "class": "-", "reference_number": "EMEA/H/A-13/1350", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/01/2013", "european_commission_decision_date": "10/04/2013", "first_published_date": "18/01/2013", "last_updated_date": "02/05/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/kantos-master" }, { "category": "Human", "referral_name": "Fibrates", "international_non_proprietary_name_inn_common_name": "bezafibrate;ciprofibrate;fenofibrate;gemfibrozil", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Bezalip ;Lipanor ;Lipanthyl ;Lopid", "class": "fibrates", "reference_number": "EMEA/H/A-31/001238", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/10/2010", "european_commission_decision_date": "28/02/2011", "first_published_date": "22/10/2010", "last_updated_date": "03/04/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fibrates" }, { "category": "Human", "referral_name": "Fibrinogen-containing solutions for sealant authorised for administration by spray application", "international_non_proprietary_name_inn_common_name": "fibrin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "Evicel", "associated_names_non_centrally_authorised_medicines": "Quixil", "class": "Fibrin sealants", "reference_number": "EMEA/H/A-31/1337", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2012", "european_commission_decision_date": "13/02/2013", "first_published_date": "16/11/2012", "last_updated_date": "02/04/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fibrinogen-containing-solutions-sealant-authorised-administration-spray-application-0" }, { "category": "Human", "referral_name": "Fibrinogen-containing solutions for sealant authorised for administration by spray application", "international_non_proprietary_name_inn_common_name": "fibrin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Tisseel ;Tissucol ;Artiss ;Beriplast P", "class": "Fibrin sealants", "reference_number": "EMEA/H/A-31/1337", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2012", "european_commission_decision_date": "15/03/2013", "first_published_date": "14/12/2012", "last_updated_date": "02/04/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fibrinogen-containing-solutions-sealant-authorised-administration-spray-application" }, { "category": "Human", "referral_name": "Tolperisone", "international_non_proprietary_name_inn_common_name": "tolperisone", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1311", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2012", "european_commission_decision_date": "21/01/2013", "first_published_date": "22/06/2012", "last_updated_date": "02/04/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tolperisone" }, { "category": "Veterinary", "referral_name": "Melosolute", "international_non_proprietary_name_inn_common_name": "meloxicam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/084", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/11/2012", "european_commission_decision_date": "12/02/2013", "first_published_date": "15/03/2013", "last_updated_date": "15/03/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/melosolute" }, { "category": "Human", "referral_name": "Medicines studied at Cetero Research facility", "international_non_proprietary_name_inn_common_name": "fenofibrate;cilazapril;leflunomide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cilazapril Teva ;Fenofibrato Pensa ;Fenofibrato Ranbaxy ;Leflunomide Actavis ;Leflunomide Apotex", "class": "-", "reference_number": "EMEA/H/A-31/001340", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2012", "european_commission_decision_date": "20/02/2013", "first_published_date": "14/12/2012", "last_updated_date": "12/03/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/medicines-studied-cetero-research-facility" }, { "category": "Human", "referral_name": "Loraxin", "international_non_proprietary_name_inn_common_name": "loratadine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1325", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2012", "european_commission_decision_date": "20/12/2012", "first_published_date": "22/06/2012", "last_updated_date": "28/02/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/loraxin" }, { "category": "Veterinary", "referral_name": "Hipralona Enro-S", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/079", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/09/2012", "european_commission_decision_date": "17/12/2012", "first_published_date": "04/02/2013", "last_updated_date": "04/02/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/hipralona-enro-s" }, { "category": "Human", "referral_name": "Zinacef", "international_non_proprietary_name_inn_common_name": "cefuroxime sodium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Curocef ;Curoxim ;Curoxim Monovial ;Curoxima ;Curoxime ;Zinnat ;Zinocep ;Zinocep Vena", "class": "Anti-infectives", "reference_number": "EMEA/H/A-30/1158", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2012", "european_commission_decision_date": "10/09/2012", "first_published_date": "25/05/2012", "last_updated_date": "29/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zinacef" }, { "category": "Human", "referral_name": "Zinnat", "international_non_proprietary_name_inn_common_name": "cefuroxime axetil", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cefuroxima Solasma ;Cefuroxima Allen ;Cefuroxima Duncan ;Elobact ;Nivador ;Oraxim ;Selan ;Tilexim ;Zinadol ;Zipos ;Zoref", "class": "Anti-infectives", "reference_number": "EMEA/H/A-30/1157", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2012", "european_commission_decision_date": "23/08/2012", "first_published_date": "25/05/2012", "last_updated_date": "29/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zinnat" }, { "category": "Human", "referral_name": "Mometasone Furoate Sandoz", "international_non_proprietary_name_inn_common_name": "mometasone furoate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Mometasone Sandoz ;Mometasone Sandoz 50 ;Mometasone Furoato Sandoz 50 ;Mommox ;Nasometi ;Fumomo 50", "class": "Glucocorticoids", "reference_number": "EMEA/H/A-29/1332", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2012", "european_commission_decision_date": "08/10/2012", "first_published_date": "20/07/2012", "last_updated_date": "24/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/mometasone-furoate-sandoz" }, { "category": "Veterinary", "referral_name": "Flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants producing milk for human consumption", "international_non_proprietary_name_inn_common_name": "clorsulon;closantel;nitroxinil;rafoxanide;triclabendazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/069", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/06/2012", "european_commission_decision_date": "19/11/2012", "first_published_date": "18/01/2013", "last_updated_date": "18/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/flukicides-which-no-maximum-residue-limit-has-been-established-milk-which-are-intended-use-ruminants-producing-milk-human-consumption" }, { "category": "Human", "referral_name": "Ethinylestradiol-Drospirenone 24+4", "international_non_proprietary_name_inn_common_name": "ethinyl estradiol;drospirenone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Yaz 24+4", "class": "", "reference_number": "EMEA/H/A-6(12)/1313", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/04/2012", "european_commission_decision_date": "06/07/2012", "first_published_date": "20/04/2012", "last_updated_date": "11/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ethinylestradiol-drospirenone-244" }, { "category": "Human", "referral_name": "Yaz 24+4", "international_non_proprietary_name_inn_common_name": "ethinylestradiol;drospirenone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Ethinylestradiol-Drospirenone 24+4", "class": "", "reference_number": "EMEA/H/A-6(12)/1312", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/04/2012", "european_commission_decision_date": "03/07/2012", "first_published_date": "20/04/2012", "last_updated_date": "11/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/yaz-244" }, { "category": "Human", "referral_name": "Mifepristone Linepharma", "international_non_proprietary_name_inn_common_name": "mifepristone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1331", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/06/2012", "european_commission_decision_date": "11/09/2012", "first_published_date": "22/06/2012", "last_updated_date": "03/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/mifepristone-linepharma" }, { "category": "Human", "referral_name": "Yvidually", "international_non_proprietary_name_inn_common_name": "ethinylestradiol;drospirenone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Flexyess", "class": "", "reference_number": "EMEA/H/A-29/1330", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/04/2012", "european_commission_decision_date": "28/09/2012", "first_published_date": "20/04/2012", "last_updated_date": "03/01/2013", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/yvidually" }, { "category": "Human", "referral_name": "Orlistat", "international_non_proprietary_name_inn_common_name": "orlistat", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-31/1318", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/02/2012", "european_commission_decision_date": "24/04/2012", "first_published_date": "16/02/2012", "last_updated_date": "21/12/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/orlistat" }, { "category": "Human", "referral_name": "Glimepirida Parke-Davis", "international_non_proprietary_name_inn_common_name": "glimepiride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Glimepiride Pfizer ;Glimepirid Pfizer ;Glimepiride tablets 2 mg ;Glimepiride tablets 3 mg ;Glimepiride tablets 4 mg", "class": "Sulfonamides, urea derivatives", "reference_number": "EMEA/H/A-29/1338", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2012", "european_commission_decision_date": "19/11/2012", "first_published_date": "20/07/2012", "last_updated_date": "06/12/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/glimepirida-parke-davis" }, { "category": "Veterinary", "referral_name": "Baytril 10% oral solution", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/067", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/06/2012", "european_commission_decision_date": "08/10/2012", "first_published_date": "20/11/2012", "last_updated_date": "20/11/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/baytril-10-oral-solution" }, { "category": "Human", "referral_name": "Iffeza", "international_non_proprietary_name_inn_common_name": "fluticasone propionate;formoterol fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Flutiform ;Flofera ;Flutiformo", "class": "", "reference_number": "EMEA/H/A-29/001327", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/04/2012", "european_commission_decision_date": "28/06/2012", "first_published_date": "20/04/2012", "last_updated_date": "25/10/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/iffeza" }, { "category": "Human", "referral_name": "Flutiform", "international_non_proprietary_name_inn_common_name": "fluticasone propionate;formoterol fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Iffeza ;Flofera ;Flutiformo", "class": "", "reference_number": "EMEA/H/A-29/001326", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/04/2012", "european_commission_decision_date": "28/06/2012", "first_published_date": "20/04/2012", "last_updated_date": "25/10/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/flutiform" }, { "category": "Veterinary", "referral_name": "Nuflor", "international_non_proprietary_name_inn_common_name": "florfenicol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/078", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/06/2012", "european_commission_decision_date": "17/09/2012", "first_published_date": "19/10/2012", "last_updated_date": "19/10/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/nuflor" }, { "category": "Human", "referral_name": "Trimetazidine", "international_non_proprietary_name_inn_common_name": "trimetazidine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Vastarel", "class": "", "reference_number": "EMEA/H/A-31/1305", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/06/2012", "european_commission_decision_date": "03/09/2012", "first_published_date": "22/06/2012", "last_updated_date": "17/10/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/trimetazidine" }, { "category": "Human", "referral_name": "Flolan", "international_non_proprietary_name_inn_common_name": "epoprostenol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Epoprostenol", "class": "", "reference_number": "EMEA/H/A-30/1299", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2012", "european_commission_decision_date": "08/08/2012", "first_published_date": "25/05/2012", "last_updated_date": "14/09/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/flolan" }, { "category": "Human", "referral_name": "Tavanic", "international_non_proprietary_name_inn_common_name": "levofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Levofloxacin", "class": "", "reference_number": "EMEA/H/A-30/1262", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2012", "european_commission_decision_date": "31/07/2012", "first_published_date": "25/05/2012", "last_updated_date": "12/09/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tavanic" }, { "category": "Veterinary", "referral_name": "Milaxyn Plus", "international_non_proprietary_name_inn_common_name": "praziquantel;pyrantel;febantel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/076", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/03/2012", "european_commission_decision_date": "18/06/2012", "first_published_date": "23/07/2012", "last_updated_date": "23/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/milaxyn-plus" }, { "category": "Human", "referral_name": "Valproat Ratiopharm Chrono", "international_non_proprietary_name_inn_common_name": "valproic acid;valproate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-6(12)/1147", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/05/2010", "european_commission_decision_date": "26/05/2010", "first_published_date": "23/07/2012", "last_updated_date": "23/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valproat-ratiopharm-chrono" }, { "category": "Human", "referral_name": "Preflucel", "international_non_proprietary_name_inn_common_name": "influenza vaccine, purified antigen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-36/1323", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2012", "european_commission_decision_date": "10/12/2012", "first_published_date": "20/07/2012", "last_updated_date": "20/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/preflucel" }, { "category": "Veterinary", "referral_name": "All pre-mixes for medicated feedingstuff containing 40 g, 100 g or 200 g tilmicosin per kg pre-mix and administered to rabbits", "international_non_proprietary_name_inn_common_name": "tilmicosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/071", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/03/2012", "european_commission_decision_date": "14/06/2012", "first_published_date": "19/07/2012", "last_updated_date": "19/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/all-pre-mixes-medicated-feedingstuff-containing-40-g-100-g-or-200-g-tilmicosin-kg-pre-mix-administered-rabbits" }, { "category": "Veterinary", "referral_name": "Prontax 5 mg/ml pour-on solution for cattle", "international_non_proprietary_name_inn_common_name": "doramectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/074", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/02/2012", "european_commission_decision_date": "25/05/2012", "first_published_date": "05/07/2012", "last_updated_date": "05/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/prontax-5-mg-ml-pour-solution-cattle" }, { "category": "Veterinary", "referral_name": "Prontax 10 mg/ml solution for injection for cattle, sheep and pigs", "international_non_proprietary_name_inn_common_name": "doramectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A-73", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/02/2012", "european_commission_decision_date": "25/05/2012", "first_published_date": "05/07/2012", "last_updated_date": "05/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/prontax-10-mg-ml-solution-injection-cattle-sheep-pigs" }, { "category": "Human", "referral_name": "Docetaxel Teva Generics", "international_non_proprietary_name_inn_common_name": "docetaxel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/001277", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/02/2011", "european_commission_decision_date": "07/07/2011", "first_published_date": "18/02/2011", "last_updated_date": "03/07/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/docetaxel-teva-generics" }, { "category": "Human", "referral_name": "Priorix", "international_non_proprietary_name_inn_common_name": "measles, mumps and rubella vaccine (live)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1283", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/03/2012", "european_commission_decision_date": "25/05/2012", "first_published_date": "16/03/2012", "last_updated_date": "19/06/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/priorix" }, { "category": "Human", "referral_name": "Buflomedil", "international_non_proprietary_name_inn_common_name": "buflomedil", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "vasoactive agent", "reference_number": "EMEA/H/A-107/1293", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/11/2011", "european_commission_decision_date": "13/02/2012", "first_published_date": "20/05/2011", "last_updated_date": "13/06/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/buflomedil" }, { "category": "Human", "referral_name": "Femara", "international_non_proprietary_name_inn_common_name": "letrozole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Femar ;Fémara ;Loxifan", "class": "", "reference_number": "EMEA/H/A-30/1264", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/03/2012", "european_commission_decision_date": "22/05/2012", "first_published_date": "16/03/2012", "last_updated_date": "12/06/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/femara" }, { "category": "Human", "referral_name": "Meprobamate", "international_non_proprietary_name_inn_common_name": "meprobamate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Equanil and other trade names", "class": "", "reference_number": "EMEA/H/A-107/1316", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/01/2012", "european_commission_decision_date": "30/03/2012", "first_published_date": "20/01/2011", "last_updated_date": "08/06/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/meprobamate" }, { "category": "Human", "referral_name": "Galantamine Stada", "international_non_proprietary_name_inn_common_name": "galantamine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Galantamina ;Galantamine Tiefenbacher ;Galantamina Ciclum ;Galatnax xl ;Galastad", "class": "", "reference_number": "EMEA/H/A-29/001268", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/09/2010", "european_commission_decision_date": "21/02/2011", "first_published_date": "24/09/2010", "last_updated_date": "08/06/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/galantamine-stada" }, { "category": "Human", "referral_name": "Somatropin", "international_non_proprietary_name_inn_common_name": "somatropin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Genotropin ;Humatrope ;Maxomat ;Norditropin ;Saizen ;Zomacton", "class": "", "reference_number": "EMEA/H/A-107/001287", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2011", "european_commission_decision_date": "27/02/2012", "first_published_date": "15/12/2011", "last_updated_date": "23/04/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/somatropin" }, { "category": "Human", "referral_name": "Nimesulide", "international_non_proprietary_name_inn_common_name": "nimesulide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/001261", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "20/01/2012", "first_published_date": "23/06/2011", "last_updated_date": "19/04/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-1" }, { "category": "Human", "referral_name": "Norditropin", "international_non_proprietary_name_inn_common_name": "somatropin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 13 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Norditropin FlexPro ;Norditropin NordiFlex ;Norditropin SimpleXx", "class": "", "reference_number": "EMEA/H/A-13/1304", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2011", "european_commission_decision_date": "06/03/2012", "first_published_date": "16/12/2011", "last_updated_date": "19/04/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/norditropin-0" }, { "category": "Human", "referral_name": "Terpenic derivatives", "international_non_proprietary_name_inn_common_name": "camphor;cineole;niaouli;wild thyme;terpineol;terpine;citral;menthol;essential oils of pine needle, eucalyptus and turpentine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Terpenic derivatives", "reference_number": "EMA/CHMP/763180/2011", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/11/2011", "european_commission_decision_date": "20/01/2012", "first_published_date": "23/09/2011", "last_updated_date": "13/04/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/terpenic-derivatives" }, { "category": "Human", "referral_name": "Lipitor", "international_non_proprietary_name_inn_common_name": "atorvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Atorvastatin ;Atorvastatina Nostrum ;Atorvastatina Parke-Davis ;Atorvastatina Pharmacia ;Cardyl ;Edovin ;Liprimar ;Orbeos ;Prevencor ;Sortis ;Tahor ;Texzor ;Torvast ;Totalip ;Xarator ;Zarator", "class": "", "reference_number": "EMEA/H/A-30/001154", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/09/2010", "european_commission_decision_date": "13/12/2010", "first_published_date": "24/09/2010", "last_updated_date": "10/04/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lipitor" }, { "category": "Human", "referral_name": "Norvasc", "international_non_proprietary_name_inn_common_name": "amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Amlodipine Pfizer ;Amlodipino ;Amlor ;Istin ;Monopina", "class": "", "reference_number": "EMEA/H/A-30/1288", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2011", "european_commission_decision_date": "07/10/2011", "first_published_date": "22/07/2011", "last_updated_date": "29/03/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/norvasc" }, { "category": "Human", "referral_name": "Pholcodine", "international_non_proprietary_name_inn_common_name": "pholcodine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1292", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2011", "european_commission_decision_date": "17/02/2012", "first_published_date": "18/11/2011", "last_updated_date": "28/03/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pholcodine" }, { "category": "Human", "referral_name": "Priligy", "international_non_proprietary_name_inn_common_name": "dapoxetine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1294", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/10/2011", "european_commission_decision_date": "20/01/2012", "first_published_date": "21/01/2011", "last_updated_date": "28/03/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/priligy" }, { "category": "Human", "referral_name": "Tienam", "international_non_proprietary_name_inn_common_name": "imipenem;cilastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Conet ;Imipem ;Primaxin ;Tenacid ;Zienam", "class": "", "reference_number": "EMEA/H/A-30/001187", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/12/2010", "european_commission_decision_date": "10/03/2011", "first_published_date": "17/12/2010", "last_updated_date": "20/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tienam" }, { "category": "Human", "referral_name": "Canazole", "international_non_proprietary_name_inn_common_name": "clotrimazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Canesten", "class": "", "reference_number": "EMEA/H/A-29/1286", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/03/2011", "european_commission_decision_date": "22/09/2011", "first_published_date": "18/03/2011", "last_updated_date": "09/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/canazole" }, { "category": "Human", "referral_name": "Novimp", "international_non_proprietary_name_inn_common_name": "goserelin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-36/1298", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "16/09/2011", "first_published_date": "06/02/2012", "last_updated_date": "06/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/novimp" }, { "category": "Human", "referral_name": "Novosis Goserelin", "international_non_proprietary_name_inn_common_name": "goserelin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Goserelin Novosis ;Gosacin", "class": "", "reference_number": "EMEA/H/A-36/1295", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "16/09/2011", "first_published_date": "06/02/2012", "last_updated_date": "06/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/novosis-goserelin" }, { "category": "Human", "referral_name": "Goserelin Cell Pharm", "international_non_proprietary_name_inn_common_name": "goserelin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Novosis Goserelin ;Goserelin Cell Pharm ;Novimp and associated names", "class": "", "reference_number": "EMEA/H/A-36/1297", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "16/09/2011", "first_published_date": "24/06/2011", "last_updated_date": "06/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/goserelin-cell-pharm" }, { "category": "Veterinary", "referral_name": "Clavudale 50mg tablet for cats and dogs", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/068", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/06/2011", "european_commission_decision_date": "24/08/2011", "first_published_date": "03/02/2012", "last_updated_date": "03/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/clavudale-50mg-tablet-cats-dogs" }, { "category": "Human", "referral_name": "Dexamethasone Alapis", "international_non_proprietary_name_inn_common_name": "dexamethasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1308", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/07/2011", "european_commission_decision_date": "24/10/2011", "first_published_date": "23/07/2011", "last_updated_date": "02/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dexamethasone-alapis" }, { "category": "Human", "referral_name": "Diflucan", "international_non_proprietary_name_inn_common_name": "fluconazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Fluconazole ;Fungustatin ;Fungata ;Triflucan", "class": "", "reference_number": "EMEA/H/A-30/1156", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "02/09/2011", "first_published_date": "24/06/2011", "last_updated_date": "02/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diflucan" }, { "category": "Veterinary", "referral_name": "Cephalosporins", "international_non_proprietary_name_inn_common_name": "ceftiofur;cefquinome", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/V/A/070", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/10/2011", "european_commission_decision_date": "13/01/2012", "first_published_date": "01/02/2012", "last_updated_date": "01/02/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cephalosporins" }, { "category": "Human", "referral_name": "Levothyroxine Alapis", "international_non_proprietary_name_inn_common_name": "levothyroxine sodium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/H/A-29/1328", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2012", "european_commission_decision_date": "14/01/2013", "first_published_date": "19/01/2012", "last_updated_date": "19/01/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/levothyroxine-alapis" }, { "category": "Human", "referral_name": "Protium", "international_non_proprietary_name_inn_common_name": "pantoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Anagastra ;Apton ;Controloc ;Eupantol ;Inipomp ;Pantec ;Pantecta ;Pantipp ;Panto-Byk-20 / 40 / IV ;Pantoc ;Pantoloc ;PantoLomberg ;Pantopan ;Pantorc ;Pantozol ;Peptazol ;Rifun ;Somac ;Ulcotenal ;Zurcal ;Zurcale ;Zurcazol", "class": "", "reference_number": "EMEA/H/A-30/1002", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/12/2009", "european_commission_decision_date": "15/04/2010", "first_published_date": "17/12/2009", "last_updated_date": "17/01/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/protium" }, { "category": "Human", "referral_name": "Dexrazoxane", "international_non_proprietary_name_inn_common_name": "dexrazoxane", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cardioxane ;Cyrdanax ;Dexrazoxane Cyathus ;Enaxozar ;Procard", "class": "", "reference_number": "EMEA/H/A-31/1275", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2011", "european_commission_decision_date": "13/09/2011", "first_published_date": "24/06/2011", "last_updated_date": "16/01/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dexrazoxane" }, { "category": "Human", "referral_name": "Cozaar", "international_non_proprietary_name_inn_common_name": "irbesartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Loortan ;Loortan Cardio Start ;Cozaar Startpakkle ;Cardopal Start ;Lorzaar ;Lorzaar start ;Lorzaar Protect ;Pinzaar ;Lorzaar Varipharmstart ;Lortaan ;Neo-Lotan ;Losaprex ;Cozaar IC ;Lortaar IC", "class": "", "reference_number": "EMEA/H/A-29 PAD/1022", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/10/2008", "european_commission_decision_date": "22/01/2009", "first_published_date": "13/01/2012", "last_updated_date": "13/01/2012", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cozaar-0" }, { "category": "Veterinary", "referral_name": "Hiprabovis Pneumos", "international_non_proprietary_name_inn_common_name": "Mannheimia haemolytica biotype A serotype A1, inactivated cell free suspension containing leukotoxoid Ph. Eur.;inactivated Histophilus somni Bailie strain", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/V/A/072", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/07/2011", "european_commission_decision_date": "03/11/2011", "first_published_date": "09/12/2011", "last_updated_date": "12/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/hiprabovis-pneumos" }, { "category": "Veterinary", "referral_name": "Combimox Lactating Cow", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid;Prednisolone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/V/A/061", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/04/2011", "european_commission_decision_date": "05/08/2011", "first_published_date": "08/12/2011", "last_updated_date": "09/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/combimox-lactating-cow" }, { "category": "Veterinary", "referral_name": "APPM Respipharm", "international_non_proprietary_name_inn_common_name": "formaldehyde-inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (serotypes 2, 9 and 11) and one strain of Pasteurella multocida (serotype A)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/839689/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/11/2009", "european_commission_decision_date": "27/01/2010", "first_published_date": "19/02/2010", "last_updated_date": "08/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/appm-respipharm" }, { "category": "Veterinary", "referral_name": "Nisamox Lactating Cow", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid;Prednisolone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/V/A/062", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/04/2011", "european_commission_decision_date": "05/08/2011", "first_published_date": "08/12/2011", "last_updated_date": "08/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/nisamox-lactating-cow" }, { "category": "Veterinary", "referral_name": "Combisyn Lactating Cow", "international_non_proprietary_name_inn_common_name": "amoxicillin;clavulanic acid;Prednisolone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/V/A/063", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "06/04/2011", "european_commission_decision_date": "05/08/2011", "first_published_date": "08/12/2011", "last_updated_date": "08/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/combisyn-lactating-cow" }, { "category": "Veterinary", "referral_name": "Unisol", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/215198/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/01/2009", "european_commission_decision_date": "05/05/2009", "first_published_date": "29/07/2009", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/unisol" }, { "category": "Veterinary", "referral_name": "Solacyl", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/209536/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/02/2008", "european_commission_decision_date": "17/04/2008", "first_published_date": "23/05/2008", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/solacyl" }, { "category": "Veterinary", "referral_name": "Shotaflor", "international_non_proprietary_name_inn_common_name": "florfenicol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/313852/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/05/2009", "european_commission_decision_date": "03/08/2009", "first_published_date": "02/10/2009", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/shotaflor" }, { "category": "Veterinary", "referral_name": "Fenflor", "international_non_proprietary_name_inn_common_name": "florfenicol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/313849/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/05/2009", "european_commission_decision_date": "03/08/2009", "first_published_date": "02/10/2009", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/fenflor" }, { "category": "Veterinary", "referral_name": "Enro-K", "international_non_proprietary_name_inn_common_name": "enrofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/214378/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/01/2009", "european_commission_decision_date": "05/05/2009", "first_published_date": "29/07/2009", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/enro-k" }, { "category": "Veterinary", "referral_name": "Enurace 50", "international_non_proprietary_name_inn_common_name": "ephedrine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/532222/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/04/2007", "european_commission_decision_date": "10/07/2007", "first_published_date": "15/11/2007", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/enurace-50" }, { "category": "Veterinary", "referral_name": "Ecomectin 18.7mg/g Oral Paste for Horses", "international_non_proprietary_name_inn_common_name": "ivermectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/495339/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "08/11/2007", "european_commission_decision_date": "17/01/2008", "first_published_date": "20/02/2008", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/ecomectin-187mg-g-oral-paste-horses" }, { "category": "Veterinary", "referral_name": "Equimectin", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/532271/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/01/2007", "european_commission_decision_date": "02/04/2007", "first_published_date": "15/11/2007", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/equimectin" }, { "category": "Veterinary", "referral_name": "Equibactin vet.", "international_non_proprietary_name_inn_common_name": "trimethoprim;sulfadiazine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/455918/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/12/2007", "european_commission_decision_date": "03/03/2008", "first_published_date": "09/10/2008", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/equibactin-vet" }, { "category": "Veterinary", "referral_name": "Doxyprex 100mg Premix", "international_non_proprietary_name_inn_common_name": "doxycycline", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/532206/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/02/2007", "european_commission_decision_date": "22/05/2007", "first_published_date": "15/11/2007", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxyprex-100mg-premix" }, { "category": "Veterinary", "referral_name": "Compagel", "international_non_proprietary_name_inn_common_name": "heparin sodium;levomenthol;hydroxyethyl salicylate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/459391/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/02/2008", "european_commission_decision_date": "02/04/2008", "first_published_date": "09/10/2008", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/compagel" }, { "category": "Veterinary", "referral_name": "Bovilis BVD", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP532090/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/04/2007", "european_commission_decision_date": "29/06/2007", "first_published_date": "15/11/2007", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/bovilis-bvd" }, { "category": "Veterinary", "referral_name": "Dolovet Rifen", "international_non_proprietary_name_inn_common_name": "ketoprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/532160/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/11/2006", "european_commission_decision_date": "17/04/2007", "first_published_date": "15/11/2007", "last_updated_date": "07/12/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/dolovet-rifen" }, { "category": "Veterinary", "referral_name": "Synulox Lactating Cow", "international_non_proprietary_name_inn_common_name": "amoxicillin trihydrate;potassium clavulanate;Prednisolone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/512798/2011", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "07/06/2011", "european_commission_decision_date": "20/10/2011", "first_published_date": "17/11/2011", "last_updated_date": "17/11/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/synulox-lactating-cow" }, { "category": "Human", "referral_name": "Bufexamac", "international_non_proprietary_name_inn_common_name": "bufexamac", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Parfenac ;Bufal ;Calmaderm ;Fansamac ;Mastu S ;Parfenoide ;Proctosan", "class": "", "reference_number": "EMEA/H/A-107/001260", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/04/2010", "european_commission_decision_date": "27/07/2010", "first_published_date": "22/04/2010", "last_updated_date": "10/11/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bufexamac" }, { "category": "Human", "referral_name": "Vascace Plus", "international_non_proprietary_name_inn_common_name": "cilazapril;hydrochlorothiazide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Co-Inhibace ;Dynorm Plus ;Inhibace Plus", "class": "", "reference_number": "EMEA/H/A-30/001153", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/10/2010", "european_commission_decision_date": "21/01/2011", "first_published_date": "22/10/2010", "last_updated_date": "09/11/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vascace-plus" }, { "category": "Human", "referral_name": "Ketoprofen topical", "international_non_proprietary_name_inn_common_name": "ketoprofen", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Fastum ;Ketum ;Orudis", "class": "", "reference_number": "EMEA/H/A-107/001259", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/07/2010", "european_commission_decision_date": "29/11/2010", "first_published_date": "22/07/2010", "last_updated_date": "28/10/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ketoprofen-topical" }, { "category": "Human", "referral_name": "Bisphosphonates", "international_non_proprietary_name_inn_common_name": "alendronic acid;clodronic acid;etidronic acid;ibandronic acid;neridronic acid;pamidronic acid;risedronic acid;tiludronic acid;zoledronic acid", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Actonel ;Aredia ;Bonefos ;Didronel ;Fosamax ;Nerixia ;Skelid", "class": "Bisphosphonates", "reference_number": "EMA/288359/2011", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/04/2011", "european_commission_decision_date": "13/07/2011", "first_published_date": "15/04/2011", "last_updated_date": "28/10/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bisphosphonates" }, { "category": "Human", "referral_name": "Atacand Plus", "international_non_proprietary_name_inn_common_name": "candesartan;hydrochlorothiazide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Atacand Zid ;Blopresid ;Blopress Comp ;Blopress Plus ;CoKenzen ;Hytacand ;Parapres Plus ;Ratacand Plus", "class": "", "reference_number": "EMEA/H/A-30/001152", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/06/2010", "european_commission_decision_date": "16/09/2010", "first_published_date": "25/06/2010", "last_updated_date": "21/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/atacand-plus" }, { "category": "Human", "referral_name": "Prevora", "international_non_proprietary_name_inn_common_name": "chlorhexidine diacetate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1258", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/09/2010", "european_commission_decision_date": "03/12/2010", "first_published_date": "24/09/2010", "last_updated_date": "20/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/prevora" }, { "category": "Human", "referral_name": "Losec", "international_non_proprietary_name_inn_common_name": "omeprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Antra ;Logastric ;Losec Forte ;Mopral ;Omeprazen ;Omeprazole ;AstraZeneca ;Zoltum", "class": "", "reference_number": "EMEA/H/A-30/1001", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/01/2010", "european_commission_decision_date": "10/06/2010", "first_published_date": "22/01/2010", "last_updated_date": "19/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/losec" }, { "category": "Human", "referral_name": "Norsed Combi D", "international_non_proprietary_name_inn_common_name": "risedronate sodium;calcium carbonate;colecalciferol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Actonel Combi D ;Optinate Plus Ca&D ;Opticalcio D3", "class": "", "reference_number": "EMEA/H/A-29/001273", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/06/2010", "european_commission_decision_date": "05/10/2010", "first_published_date": "25/06/2010", "last_updated_date": "13/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/norsed-combi-d" }, { "category": "Human", "referral_name": "Fortipan Combi D", "international_non_proprietary_name_inn_common_name": "risedronate sodium;calcium carbonate;colecalciferol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Actocalcio D3 ;Acrelcombi", "class": "", "reference_number": "EMEA/H/A-29/001272", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/06/2010", "european_commission_decision_date": "05/10/2010", "first_published_date": "25/06/2010", "last_updated_date": "13/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fortipan-combi-d" }, { "category": "Human", "referral_name": "Lescol", "international_non_proprietary_name_inn_common_name": "fluvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Canef ;Cardiol ;Cardiol XL ;Cranoc ;Digardil ;Digaril Prolib ;Fluvastatin Novartis ;Fluvastatina ;Fractal ;Leposit Prolib ;Lescol Depot ;Lescol Exel ;Lescol LP ;Lescol MR ;Lescol Prolib ;Lescol XL ;Lipaxan ;Lipaxin ;Liposit ;Locol ;Lymetel ;Primesin ;Vaditon ;Vaditon Prolib", "class": "", "reference_number": "EMEA/H/A-30/1078", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2009", "european_commission_decision_date": "15/03/2010", "first_published_date": "20/11/2009", "last_updated_date": "13/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lescol" }, { "category": "Human", "referral_name": "Kytril", "international_non_proprietary_name_inn_common_name": "granisetron", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Kevatril", "class": "", "reference_number": "EMEA/H/A-30/1155", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2011", "european_commission_decision_date": "20/07/2011", "first_published_date": "20/05/2011", "last_updated_date": "12/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/kytril" }, { "category": "Human", "referral_name": "Famvir", "international_non_proprietary_name_inn_common_name": "famciclovir", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Famciclovir-Sandoz ;Famciclovir-SB ;Famciclovir-SB Zoster ;Famvir Zoster and Oravir", "class": "", "reference_number": "EMEA/H/A-30/001005", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/04/2010", "european_commission_decision_date": "27/07/2010", "first_published_date": "23/04/2010", "last_updated_date": "09/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/famvir" }, { "category": "Human", "referral_name": "Clopidogrel Teva", "international_non_proprietary_name_inn_common_name": "clopidogrel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1246", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/02/2010", "european_commission_decision_date": "04/06/2010", "first_published_date": "19/02/2010", "last_updated_date": "08/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/clopidogrel-teva" }, { "category": "Human", "referral_name": "Clopidogrel Orion", "international_non_proprietary_name_inn_common_name": "clopidogrel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1247", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/02/2010", "european_commission_decision_date": "02/06/2010", "first_published_date": "19/02/2010", "last_updated_date": "08/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/clopidogrel-orion" }, { "category": "Human", "referral_name": "Levact", "international_non_proprietary_name_inn_common_name": "bendamustine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Ribomustin", "class": "", "reference_number": "EMEA/H/A-29/1238", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "07/07/2010", "first_published_date": "19/03/2010", "last_updated_date": "08/09/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/levact" }, { "category": "Veterinary", "referral_name": "Doxyfar 50%", "international_non_proprietary_name_inn_common_name": "doxycycline hyclate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/512470/2011", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "04/05/2011", "european_commission_decision_date": "13/07/2011", "first_published_date": "23/08/2011", "last_updated_date": "24/08/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxyfar-50" }, { "category": "Veterinary", "referral_name": "Doxycycline 50% WSP", "international_non_proprietary_name_inn_common_name": "doxycycline hyclate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/507899/2011", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "04/05/2011", "european_commission_decision_date": "13/07/2011", "first_published_date": "23/08/2011", "last_updated_date": "24/08/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxycycline-50-wsp" }, { "category": "Human", "referral_name": "Benfluorex", "international_non_proprietary_name_inn_common_name": "benfluorex", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/811097/2009 Rev. 1", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "14/06/2010", "first_published_date": "18/12/2009", "last_updated_date": "27/07/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/benfluorex" }, { "category": "Human", "referral_name": "Arimidex", "international_non_proprietary_name_inn_common_name": "anastrozole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/001263", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/03/2011", "european_commission_decision_date": "18/05/2011", "first_published_date": "18/03/2011", "last_updated_date": "27/07/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/arimidex" }, { "category": "Human", "referral_name": "Isotretinoin", "international_non_proprietary_name_inn_common_name": "isotretinoin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/001276", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/12/2010", "european_commission_decision_date": "18/05/2011", "first_published_date": "17/12/2010", "last_updated_date": "15/07/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/isotretinoin-0" }, { "category": "Veterinary", "referral_name": "Doxycycline hyclate", "international_non_proprietary_name_inn_common_name": "doxycycline hyclate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/190025/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/02/2010", "european_commission_decision_date": "14/06/2010", "first_published_date": "16/07/2010", "last_updated_date": "28/06/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/doxycycline-hyclate" }, { "category": "Human", "referral_name": "Myderison", "international_non_proprietary_name_inn_common_name": "tolperisone hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/675340/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/10/2009", "european_commission_decision_date": "06/08/2010", "first_published_date": "23/10/2009", "last_updated_date": "16/06/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/myderison" }, { "category": "Human", "referral_name": "Modified-released oral opioids", "international_non_proprietary_name_inn_common_name": "hydromorphone;morphine;oxycodone", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Opioids of the World Health Organization level III scale", "reference_number": "EMEA/H/A-31/001232", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/11/2010", "european_commission_decision_date": "20/04/2011", "first_published_date": "19/11/2010", "last_updated_date": "06/06/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/modified-released-oral-opioids" }, { "category": "Human", "referral_name": "Iodocasein- and thiamine-containing medicinal products", "international_non_proprietary_name_inn_common_name": "iodocasein;thiamine nitrate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Antiadiposo", "class": "", "reference_number": "EMEA/H/A-107", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/10/2009", "european_commission_decision_date": "", "first_published_date": "27/05/2011", "last_updated_date": "27/05/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/iodocasein-thiamine-containing-medicinal-products" }, { "category": "Human", "referral_name": "Ethirfin", "international_non_proprietary_name_inn_common_name": "morphine sulphate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/001248", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/09/2010", "european_commission_decision_date": "20/12/2010", "first_published_date": "23/07/2010", "last_updated_date": "29/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ethirfin" }, { "category": "Human", "referral_name": "Valproate", "international_non_proprietary_name_inn_common_name": "valproic acid;valproate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/1163, EMEA/H/A-6(12)/1147", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/12/2009", "european_commission_decision_date": "26/08/2010", "first_published_date": "18/12/2009", "last_updated_date": "29/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/valproate" }, { "category": "Human", "referral_name": "Sortis", "international_non_proprietary_name_inn_common_name": "atorvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Lipitor ;Zarator ;Orbeos ;Tahor ;Liprimar ;Atorvastatin ;Atorvastatina ;Edovin ;Obradon ;Xarator ;Torvast ;Totalip ;Texzor ;Cardyl ;Prevencor", "class": "", "reference_number": "EMEA/H/A-29 PAD/1255", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "01/07/2010", "first_published_date": "27/04/2011", "last_updated_date": "27/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sortis-2" }, { "category": "Human", "referral_name": "Sortis", "international_non_proprietary_name_inn_common_name": "atorvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Lipitor ;Zarator ;Orbeos ;Tahor ;Liprimar ;Atorvastatin ;Atorvastatina ;Edovin ;Obradon ;Xarator ;Torvast ;Totalip ;Texzor ;Cardyl ;Prevencor", "class": "", "reference_number": "EMEA/H/A-29 PAD/1254", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "01/07/2010", "first_published_date": "27/04/2011", "last_updated_date": "27/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sortis-0" }, { "category": "Human", "referral_name": "Sortis", "international_non_proprietary_name_inn_common_name": "atorvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Lipitor ;Zarator ;Orbeos ;Tahor ;Liprimar ;Atorvastatin ;Atorvastatina ;Edovin ;Obradon ;Xarator ;Torvast ;Totalip ;Texzor ;Cardyl ;Prevencor", "class": "", "reference_number": "EMEA/H/A-29 PAD/1253", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "01/07/2010", "first_published_date": "27/04/2011", "last_updated_date": "27/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sortis-1" }, { "category": "Human", "referral_name": "Modafinil", "international_non_proprietary_name_inn_common_name": "modafinil", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Modasomil ;Modiodal ;Provigil ;Vigil", "class": "", "reference_number": "EMEA/H/A-31/1186", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/11/2010", "european_commission_decision_date": "27/01/2011", "first_published_date": "19/11/2010", "last_updated_date": "26/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/modafinil" }, { "category": "Human", "referral_name": "Daivobet", "international_non_proprietary_name_inn_common_name": "calcipotriol;betamethasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Dovobet", "class": "", "reference_number": "EMEA/H/A-30/001266", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/07/2010", "european_commission_decision_date": "30/09/2010", "first_published_date": "23/07/2010", "last_updated_date": "26/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/daivobet" }, { "category": "Human", "referral_name": "Genotropin", "international_non_proprietary_name_inn_common_name": "somatropin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Genotonorm", "class": "", "reference_number": "EMEA/H/C/A-6(12)/001251", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/06/2010", "european_commission_decision_date": "02/09/2010", "first_published_date": "25/06/2010", "last_updated_date": "26/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/genotropin-0" }, { "category": "Human", "referral_name": "Octagam", "international_non_proprietary_name_inn_common_name": "human normal immunoglobulin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-31/001281", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/04/2011", "european_commission_decision_date": "30/05/2011", "first_published_date": "14/04/2011", "last_updated_date": "26/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/octagam" }, { "category": "Human", "referral_name": "Dextropropoxyphene", "international_non_proprietary_name_inn_common_name": "dextropropoxyphene", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/681374/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/10/2009", "european_commission_decision_date": "14/06/2010", "first_published_date": "22/10/2009", "last_updated_date": "07/04/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dextropropoxyphene" }, { "category": "Human", "referral_name": "Atacand", "international_non_proprietary_name_inn_common_name": "candesartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Amias ;Blopress ;Kenzen ;Racanda ;Ratacand ;Parapres", "class": "", "reference_number": "EMEA/H/A-30/001150", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "13/07/2010", "first_published_date": "19/03/2010", "last_updated_date": "16/03/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/atacand" }, { "category": "Human", "referral_name": "Pantoprazole Bluefish", "international_non_proprietary_name_inn_common_name": "pantoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Pantecta", "class": "", "reference_number": "EMEA/H/A-29/1216", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2009", "european_commission_decision_date": "30/03/2010", "first_published_date": "20/11/2009", "last_updated_date": "09/03/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-bluefish" }, { "category": "Human", "referral_name": "Sibutramine", "international_non_proprietary_name_inn_common_name": "sibutramine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMA/808179/2009, EMA/H/A-107/1256", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2010", "european_commission_decision_date": "06/08/2010", "first_published_date": "21/01/2010", "last_updated_date": "09/03/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sibutramine" }, { "category": "Human", "referral_name": "Pantoprazole Olinka (EMEA/H/A-29/1170)", "international_non_proprietary_name_inn_common_name": "pantoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Pantecta", "class": "", "reference_number": "EMEA/H/A-29/1170", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2009", "european_commission_decision_date": "30/03/2010", "first_published_date": "20/11/2009", "last_updated_date": "08/03/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-olinka-emea-h-29-1170" }, { "category": "Human", "referral_name": "Pantoprazole Olinka (EMEA/H/A-29/1169)", "international_non_proprietary_name_inn_common_name": "pantoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Pantecta", "class": "", "reference_number": "EMEA/H/A-29/1169", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/11/2009", "european_commission_decision_date": "30/03/2010", "first_published_date": "20/11/2009", "last_updated_date": "08/03/2011", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pantoprazole-olinka-emea-h-29-1169" }, { "category": "Veterinary", "referral_name": "Tildren", "international_non_proprietary_name_inn_common_name": "tiludronic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/193771/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/07/2010", "european_commission_decision_date": "22/07/2013", "first_published_date": "14/12/2010", "last_updated_date": "14/12/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/tildren" }, { "category": "Human", "referral_name": "Xalatan", "international_non_proprietary_name_inn_common_name": "latanoprost", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Latanoprost Pharmacia & Upjohn ;Xalatan 50 mikrogramov/ml kaplijice za oko, raztopina", "class": "", "reference_number": "EMEA/H/A-29 PAE/1270", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/07/2010", "european_commission_decision_date": "15/10/2010", "first_published_date": "08/12/2010", "last_updated_date": "08/12/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/xalatan" }, { "category": "Human", "referral_name": "Gadolinium-containing contrast agents", "international_non_proprietary_name_inn_common_name": "gadodiamide;gadopentetic acid;gadobenic acid;gadoxetic acid;gadoteridol;gadobutrol;gadoteric acid", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Omniscan ;Magnevist ;Magnegita ;Gado-MRT ratiopharm ;Primovist ;MultiHance ;Dotarem ;ProHance ;Gadovist", "class": "", "reference_number": "EMEA/H/A-31/1097", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/03/2010", "european_commission_decision_date": "01/07/2010", "first_published_date": "20/11/2009", "last_updated_date": "06/12/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gadolinium-containing-contrast-agents-0" }, { "category": "Human", "referral_name": "Seroquel XR", "international_non_proprietary_name_inn_common_name": "quetiapine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(13) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/6(13)/001188", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/04/2010", "european_commission_decision_date": "26/08/2010", "first_published_date": "23/04/2010", "last_updated_date": "19/11/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/seroquel-xr" }, { "category": "Veterinary", "referral_name": "Pregsure BVD", "international_non_proprietary_name_inn_common_name": "inactivated Bovine Viral Diarrhoea (BVD) type 1 virus, cytopathogenic strain 5960", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMA/434219/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/07/2010", "european_commission_decision_date": "07/10/2010", "first_published_date": "26/08/2010", "last_updated_date": "22/10/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/pregsure-bvd" }, { "category": "Human", "referral_name": "Fortum", "international_non_proprietary_name_inn_common_name": "ceftazidime", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Cefortam ;Glazidim ;Panzim ;Solvetan", "class": "", "reference_number": "EMEA/H/A-30/001006", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/10/2010", "european_commission_decision_date": "13/01/2011", "first_published_date": "22/10/2010", "last_updated_date": "22/10/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fortum" }, { "category": "Human", "referral_name": "Vascace", "international_non_proprietary_name_inn_common_name": "cilazapril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Dynorm ;Inhibace ;Inibace ;Justor", "class": "", "reference_number": "EMEA/H/A-30/001151", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/04/2010", "european_commission_decision_date": "07/07/2010", "first_published_date": "23/04/2010", "last_updated_date": "19/10/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vascace" }, { "category": "Veterinary", "referral_name": "Poulvac Bursa Plus", "international_non_proprietary_name_inn_common_name": "live infectious bursal disease virus, strain V877", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/698942/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/01/2010", "european_commission_decision_date": "25/01/2010", "first_published_date": "07/10/2010", "last_updated_date": "07/10/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/poulvac-bursa-plus" }, { "category": "Human", "referral_name": "Escitalopram", "international_non_proprietary_name_inn_common_name": "escitalopram", "current_status": "CHMP opinion", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1231", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/02/2010", "european_commission_decision_date": "", "first_published_date": "19/02/2010", "last_updated_date": "29/09/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/escitalopram" }, { "category": "Human", "referral_name": "Methylphenidate", "international_non_proprietary_name_inn_common_name": "methylphenidate", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/658285/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/01/2009", "european_commission_decision_date": "27/05/2009", "first_published_date": "22/01/2009", "last_updated_date": "22/09/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/methylphenidate" }, { "category": "Veterinary", "referral_name": "Porcilis M Hyo", "international_non_proprietary_name_inn_common_name": "inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMA/345914/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2010", "european_commission_decision_date": "16/08/2010", "first_published_date": "18/08/2010", "last_updated_date": "18/08/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcilis-m-hyo" }, { "category": "Veterinary", "referral_name": "Porcilis PRRS", "international_non_proprietary_name_inn_common_name": "live attenuated PRRS virus strain DV", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMA/344861/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/05/2010", "european_commission_decision_date": "16/08/2010", "first_published_date": "18/08/2010", "last_updated_date": "18/08/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/porcilis-prrs" }, { "category": "Veterinary", "referral_name": "Tiamutin", "international_non_proprietary_name_inn_common_name": "tiamulin hydrogen fumarate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "V-A-042", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/03/2010", "european_commission_decision_date": "27/07/2010", "first_published_date": "21/07/2010", "last_updated_date": "30/07/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/tiamutin" }, { "category": "Human", "referral_name": "Teicoplanin Hospira", "international_non_proprietary_name_inn_common_name": "teicoplanin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1084", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/10/2009", "european_commission_decision_date": "29/01/2010", "first_published_date": "23/10/2009", "last_updated_date": "27/07/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/teicoplanin-hospira" }, { "category": "Veterinary", "referral_name": "Quinolones", "international_non_proprietary_name_inn_common_name": "enrofloxacin;marbofloxacin;danofloxacin mesilate;danofloxacin;flumequine;amoxicillin;difloxacin hydrochloride;oxolinic acid;colistin sulfate;amoxicillin trihydrate;difloxacin;bromhexine;oxytetracycline hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/186029/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/03/2010", "european_commission_decision_date": "01/07/2010", "first_published_date": "16/07/2010", "last_updated_date": "16/07/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/quinolones" }, { "category": "Veterinary", "referral_name": "Colistin", "international_non_proprietary_name_inn_common_name": "colistin sulfate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/189829/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "10/02/2010", "european_commission_decision_date": "10/06/2010", "first_published_date": "24/06/2010", "last_updated_date": "24/06/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/colistin" }, { "category": "Human", "referral_name": "Diovan", "international_non_proprietary_name_inn_common_name": "valsartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Angiosan ;Diovane ;Tareg ;Cordinate ;Provas ;Dalzad ;Rixil ;Kalpress Cardio ;Diovan Cardio ;Miten Cardio ;Valsartan Novartis ;Kalpress ;Miten", "class": "", "reference_number": "EMEA/H/A/-29 PAD/1220", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2009", "european_commission_decision_date": "19/04/2010", "first_published_date": "31/05/2010", "last_updated_date": "31/05/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diovan" }, { "category": "Human", "referral_name": "Diovan", "international_non_proprietary_name_inn_common_name": "valsartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Angiosan ;Diovane ;Tareg ;Cordinate ;Provas ;Dalzad ;Rixil ;Kalpress Cardio ;Diovan Cardio ;Miten Cardio ;Valsartan Novartis", "class": "", "reference_number": "EMEA/H/A-29 PAD/1219", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/12/2009", "european_commission_decision_date": "19/04/2010", "first_published_date": "31/05/2010", "last_updated_date": "31/05/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diovan-1" }, { "category": "Human", "referral_name": "Arimidex", "international_non_proprietary_name_inn_common_name": "anastrozole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29 paediatrics", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/311974/2010", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "", "european_commission_decision_date": "06/11/2009", "first_published_date": "28/05/2010", "last_updated_date": "28/05/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/arimidex-0" }, { "category": "Veterinary", "referral_name": "Cevazuril", "international_non_proprietary_name_inn_common_name": "toltrazuril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMA/214243/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/12/2009", "european_commission_decision_date": "26/03/2010", "first_published_date": "05/05/2010", "last_updated_date": "05/05/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/cevazuril" }, { "category": "Veterinary", "referral_name": "Pharmasin", "international_non_proprietary_name_inn_common_name": "tylosin tartrate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "macrolide antibiotic", "reference_number": "EMA/214243/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/03/2009", "european_commission_decision_date": "08/01/2010", "first_published_date": "30/04/2010", "last_updated_date": "30/04/2010", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/pharmasin" }, { "category": "Veterinary", "referral_name": "Pulmotil AC", "international_non_proprietary_name_inn_common_name": "tilmicosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/608943/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2009", "european_commission_decision_date": "15/10/2010", "first_published_date": "22/12/2009", "last_updated_date": "22/12/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/pulmotil-ac" }, { "category": "Veterinary", "referral_name": "Pulmotil Premix", "international_non_proprietary_name_inn_common_name": "tilmicosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/608931/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2009", "european_commission_decision_date": "15/10/2009", "first_published_date": "22/12/2009", "last_updated_date": "22/12/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/pulmotil-premix" }, { "category": "Human", "referral_name": "Topamax", "international_non_proprietary_name_inn_common_name": "topiramate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/239500/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2009", "european_commission_decision_date": "01/10/2009", "first_published_date": "15/12/2009", "last_updated_date": "15/12/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/topamax" }, { "category": "Human", "referral_name": "Loratadine Sandoz 10", "international_non_proprietary_name_inn_common_name": "loratadine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1060", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "29/05/2009", "european_commission_decision_date": "06/08/2009", "first_published_date": "12/12/2009", "last_updated_date": "12/12/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/loratadine-sandoz-10" }, { "category": "Human", "referral_name": "Meronem", "international_non_proprietary_name_inn_common_name": "meropenem", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-30/1003", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/07/2009", "european_commission_decision_date": "15/10/2009", "first_published_date": "12/12/2009", "last_updated_date": "12/12/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/meronem" }, { "category": "Human", "referral_name": "Extraneal", "international_non_proprietary_name_inn_common_name": "icodextrin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/683039/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/10/2009", "european_commission_decision_date": "20/01/2010", "first_published_date": "27/10/2009", "last_updated_date": "27/10/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/extraneal" }, { "category": "Veterinary", "referral_name": "Ivermectin", "international_non_proprietary_name_inn_common_name": "ivermectin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/471056/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "05/06/2009", "european_commission_decision_date": "01/10/2009", "first_published_date": "26/10/2009", "last_updated_date": "26/10/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/ivermectin" }, { "category": "Human", "referral_name": "Rapinyl", "international_non_proprietary_name_inn_common_name": "fentanyl citrate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/336144/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "11/09/2008", "first_published_date": "25/09/2009", "last_updated_date": "25/09/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rapinyl" }, { "category": "Human", "referral_name": "Prokanazol", "international_non_proprietary_name_inn_common_name": "itraconazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/454809/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/04/2009", "european_commission_decision_date": "14/07/2009", "first_published_date": "06/08/2009", "last_updated_date": "06/08/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/prokanazol" }, { "category": "Human", "referral_name": "Octegra", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/150525/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/03/2009", "european_commission_decision_date": "02/10/2009", "first_published_date": "25/06/2009", "last_updated_date": "25/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/octegra" }, { "category": "Human", "referral_name": "Budesonide Sandoz", "international_non_proprietary_name_inn_common_name": "budesonide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1062", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/02/2009", "european_commission_decision_date": "07/05/2009", "first_published_date": "25/06/2009", "last_updated_date": "25/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/budesonide-sandoz" }, { "category": "Human", "referral_name": "Fentrix", "international_non_proprietary_name_inn_common_name": "fentanyl", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/393579/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/06/2009", "european_commission_decision_date": "06/10/2009", "first_published_date": "25/06/2009", "last_updated_date": "25/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fentrix" }, { "category": "Human", "referral_name": "Gluscan 500", "international_non_proprietary_name_inn_common_name": "fludeoxyglucose (18F)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1123", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2009", "european_commission_decision_date": "29/05/2009", "first_published_date": "23/06/2009", "last_updated_date": "23/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gluscan-500" }, { "category": "Veterinary", "referral_name": "Alpha2-adrenoreceptor agonists", "international_non_proprietary_name_inn_common_name": "xylazine;medetomidine;detomidine;romifidine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/681319/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/11/2008", "european_commission_decision_date": "30/04/2009", "first_published_date": "22/06/2009", "last_updated_date": "22/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/alpha2-adrenoreceptor-agonists" }, { "category": "Human", "referral_name": "Diovan Comp", "international_non_proprietary_name_inn_common_name": "valsartan;hydrochlorothiazide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/113861/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/03/2009", "european_commission_decision_date": "26/05/2009", "first_published_date": "11/06/2009", "last_updated_date": "11/06/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diovan-comp" }, { "category": "Human", "referral_name": "Zoloft", "international_non_proprietary_name_inn_common_name": "sertraline", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/634674/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/12/2008", "european_commission_decision_date": "27/03/2009", "first_published_date": "07/05/2009", "last_updated_date": "07/05/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zoloft" }, { "category": "Human", "referral_name": "Tritace", "international_non_proprietary_name_inn_common_name": "ramipril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/233264/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/12/2008", "european_commission_decision_date": "06/03/2009", "first_published_date": "24/04/2009", "last_updated_date": "24/04/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tritace" }, { "category": "Human", "referral_name": "Tritazide", "international_non_proprietary_name_inn_common_name": "ramipril;hydrochlorothiazide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/204584/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/12/2008", "european_commission_decision_date": "06/03/2009", "first_published_date": "14/04/2009", "last_updated_date": "14/04/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/tritazide" }, { "category": "Human", "referral_name": "Bleomycin", "international_non_proprietary_name_inn_common_name": "bleomycin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/173797/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2008", "european_commission_decision_date": "12/03/2009", "first_published_date": "31/03/2009", "last_updated_date": "31/03/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bleomycin" }, { "category": "Human", "referral_name": "Sanohex", "international_non_proprietary_name_inn_common_name": "salbutamol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/194790/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2008", "european_commission_decision_date": "12/03/2009", "first_published_date": "30/03/2009", "last_updated_date": "30/03/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sanohex" }, { "category": "Human", "referral_name": "Sabumalin", "international_non_proprietary_name_inn_common_name": "salbutamol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/194784/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2008", "european_commission_decision_date": "12/03/2009", "first_published_date": "30/03/2009", "last_updated_date": "30/03/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sabumalin" }, { "category": "Human", "referral_name": "Uman Big", "international_non_proprietary_name_inn_common_name": "human hepatitis B immunoglobulin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/173455/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/2008", "european_commission_decision_date": "06/03/2009", "first_published_date": "21/03/2009", "last_updated_date": "21/03/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/uman-big" }, { "category": "Human", "referral_name": "Diovan", "international_non_proprietary_name_inn_common_name": "valsartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/137577/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2008", "european_commission_decision_date": "16/02/2009", "first_published_date": "13/03/2009", "last_updated_date": "13/03/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/diovan-0" }, { "category": "Human", "referral_name": "Implanon", "international_non_proprietary_name_inn_common_name": "etonogestrel", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/85200/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2008", "european_commission_decision_date": "06/02/2009", "first_published_date": "27/02/2009", "last_updated_date": "27/02/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/implanon" }, { "category": "Human", "referral_name": "Trimetadizine ratiopharm", "international_non_proprietary_name_inn_common_name": "trimetazidine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/45404/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/01/2009", "european_commission_decision_date": "19/03/2009", "first_published_date": "22/01/2009", "last_updated_date": "22/01/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/trimetadizine-ratiopharm" }, { "category": "Human", "referral_name": "Mephatrim", "international_non_proprietary_name_inn_common_name": "trimetazidine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/45405/2009", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/01/2009", "european_commission_decision_date": "19/03/2009", "first_published_date": "22/01/2009", "last_updated_date": "22/01/2009", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/mephatrim" }, { "category": "Human", "referral_name": "Efexor depot", "international_non_proprietary_name_inn_common_name": "venlafaxine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/384876/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "28/11/2008", "first_published_date": "20/12/2008", "last_updated_date": "20/12/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/efexor-depot" }, { "category": "Human", "referral_name": "Lisonorm", "international_non_proprietary_name_inn_common_name": "lisinopril;amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/633842/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/07/2008", "european_commission_decision_date": "12/11/2008", "first_published_date": "18/12/2008", "last_updated_date": "18/12/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lisonorm" }, { "category": "Human", "referral_name": "Efexor", "international_non_proprietary_name_inn_common_name": "venlafaxine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/384875/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "28/11/2008", "first_published_date": "18/12/2008", "last_updated_date": "18/12/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/efexor" }, { "category": "Human", "referral_name": "Arcoxia", "international_non_proprietary_name_inn_common_name": "etoricoxib", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/438258/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "09/09/2008", "first_published_date": "21/11/2008", "last_updated_date": "21/11/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/arcoxia" }, { "category": "Human", "referral_name": "Etoricoxib", "international_non_proprietary_name_inn_common_name": "etoricoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/329177/2008, CHMP/542169/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "", "first_published_date": "21/11/2008", "last_updated_date": "21/11/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib" }, { "category": "Veterinary", "referral_name": "Sodium Salicylate", "international_non_proprietary_name_inn_common_name": "sodium salicylate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/436209/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2008", "european_commission_decision_date": "26/09/2008", "first_published_date": "19/11/2008", "last_updated_date": "19/11/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/sodium-salicylate" }, { "category": "Human", "referral_name": "Risperdal", "international_non_proprietary_name_inn_common_name": "risperidone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/384877/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "07/10/2008", "first_published_date": "13/11/2008", "last_updated_date": "13/11/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/risperdal" }, { "category": "Human", "referral_name": "Ciprofloxacin Bayer", "international_non_proprietary_name_inn_common_name": "ciprofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/384874/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "07/10/2008", "first_published_date": "23/10/2008", "last_updated_date": "23/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-bayer" }, { "category": "Human", "referral_name": "Risperdal Consta", "international_non_proprietary_name_inn_common_name": "risperidone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/384879/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "07/10/2008", "first_published_date": "22/10/2008", "last_updated_date": "22/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/risperdal-consta" }, { "category": "Human", "referral_name": "Zyrtec", "international_non_proprietary_name_inn_common_name": "cetirizine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/296484/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "30/05/2008", "european_commission_decision_date": "06/10/2008", "first_published_date": "16/10/2008", "last_updated_date": "16/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zyrtec" }, { "category": "Veterinary", "referral_name": "Suramox 15 % LA and its associated name Stabox 15 % LA", "international_non_proprietary_name_inn_common_name": "amoxicillin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/344321/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/06/2008", "european_commission_decision_date": "05/09/2008", "first_published_date": "15/10/2008", "last_updated_date": "15/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suramox-15-la-its-associated-name-stabox-15-la" }, { "category": "Human", "referral_name": "Avelox", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/524251/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2008", "european_commission_decision_date": "14/07/2008", "first_published_date": "13/10/2008", "last_updated_date": "13/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/avelox" }, { "category": "Human", "referral_name": "Octegra", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/524284/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2008", "european_commission_decision_date": "14/07/2008", "first_published_date": "13/10/2008", "last_updated_date": "13/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/octegra-0" }, { "category": "Human", "referral_name": "Actira", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/524135/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2008", "european_commission_decision_date": "14/07/2008", "first_published_date": "13/10/2008", "last_updated_date": "13/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/actira" }, { "category": "Human", "referral_name": "Remeron", "international_non_proprietary_name_inn_common_name": "mirtazapine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/336158/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "15/09/2008", "first_published_date": "13/10/2008", "last_updated_date": "13/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/remeron" }, { "category": "Veterinary", "referral_name": "Tribrissen", "international_non_proprietary_name_inn_common_name": "trimethoprim;sulfadiazine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CVMP/457286/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "12/12/2007", "european_commission_decision_date": "11/03/2008", "first_published_date": "09/10/2008", "last_updated_date": "09/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/tribrissen" }, { "category": "Veterinary", "referral_name": "Methoxasol-T", "international_non_proprietary_name_inn_common_name": "trimethoprim;sulfamethoxazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/458933/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "11/10/2007", "european_commission_decision_date": "11/01/2008", "first_published_date": "09/10/2008", "last_updated_date": "09/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/methoxasol-t" }, { "category": "Human", "referral_name": "Gemzar", "international_non_proprietary_name_inn_common_name": "gemcitabine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/512295/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "23/09/2008", "first_published_date": "06/10/2008", "last_updated_date": "06/10/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gemzar" }, { "category": "Human", "referral_name": "Activelle", "international_non_proprietary_name_inn_common_name": "estradiol;norethisterone acetate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/336151/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "11/09/2008", "first_published_date": "25/09/2008", "last_updated_date": "25/09/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/activelle" }, { "category": "Human", "referral_name": "Cozaar", "international_non_proprietary_name_inn_common_name": "losartan", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/495795/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2008", "european_commission_decision_date": "03/09/2008", "first_published_date": "25/09/2008", "last_updated_date": "25/09/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cozaar" }, { "category": "Human", "referral_name": "Cozaar Comp", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/495840/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2008", "european_commission_decision_date": "03/09/2008", "first_published_date": "25/09/2008", "last_updated_date": "25/09/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cozaar-comp" }, { "category": "Human", "referral_name": "Lamictal", "international_non_proprietary_name_inn_common_name": "lamotrigine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/212114/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2008", "european_commission_decision_date": "23/07/2008", "first_published_date": "08/09/2008", "last_updated_date": "08/09/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lamictal" }, { "category": "Human", "referral_name": "Oracea", "international_non_proprietary_name_inn_common_name": "doxycycline monohydrate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/428671/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2008", "european_commission_decision_date": "22/07/2008", "first_published_date": "21/08/2008", "last_updated_date": "21/08/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/oracea" }, { "category": "Human", "referral_name": "Singulair", "international_non_proprietary_name_inn_common_name": "montelukast", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/212107/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/04/2008", "european_commission_decision_date": "11/07/2008", "first_published_date": "05/08/2008", "last_updated_date": "05/08/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/singulair" }, { "category": "Human", "referral_name": "Alvesco", "international_non_proprietary_name_inn_common_name": "ciclesonide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/151554/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2008", "european_commission_decision_date": "11/07/2008", "first_published_date": "05/08/2008", "last_updated_date": "05/08/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/alvesco" }, { "category": "Veterinary", "referral_name": "Toltrazuril", "international_non_proprietary_name_inn_common_name": "toltrazuril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "EMEA/402698/2008", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/07/2008", "european_commission_decision_date": "26/09/2008", "first_published_date": "26/07/2008", "last_updated_date": "26/07/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/toltrazuril" }, { "category": "Human", "referral_name": "Moxifloxacin", "international_non_proprietary_name_inn_common_name": "moxifloxacin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Avalox ;Avelox", "class": "", "reference_number": "CHMP/380454/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "24/10/2008", "first_published_date": "24/07/2008", "last_updated_date": "24/07/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/moxifloxacin" }, { "category": "Human", "referral_name": "Norfloxacin", "international_non_proprietary_name_inn_common_name": "norfloxacin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/262776/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2008", "european_commission_decision_date": "19/11/2008", "first_published_date": "29/08/2006", "last_updated_date": "24/07/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/norfloxacin" }, { "category": "Human", "referral_name": "Belanette", "international_non_proprietary_name_inn_common_name": "drospirenone;ethinyl estradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 5(11) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/332403/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/12/2007", "european_commission_decision_date": "17/06/2008", "first_published_date": "03/07/2008", "last_updated_date": "03/07/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/belanette" }, { "category": "Human", "referral_name": "Yasminelle", "international_non_proprietary_name_inn_common_name": "drospirenone;ethinylestradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 5(11) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/40502/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/12/2007", "european_commission_decision_date": "17/06/2008", "first_published_date": "03/07/2008", "last_updated_date": "03/07/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/yasminelle" }, { "category": "Human", "referral_name": "Ergot-derived dopamine agonists", "international_non_proprietary_name_inn_common_name": "bromocriptine;cabergoline;dihydroergocryptine;lisuride;pergolide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/319054/08", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2008", "european_commission_decision_date": "", "first_published_date": "26/06/2008", "last_updated_date": "26/06/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ergot-derived-dopamine-agonists" }, { "category": "Human", "referral_name": "Menitorix", "international_non_proprietary_name_inn_common_name": "haemophilus type b and Meningococcal group C conjugate vaccine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/498198/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/11/2007", "european_commission_decision_date": "01/04/2008", "first_published_date": "18/04/2008", "last_updated_date": "18/04/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/menitorix" }, { "category": "Human", "referral_name": "Ciprofloxacin Nycomed", "international_non_proprietary_name_inn_common_name": "ciprofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/350278/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/11/2006", "european_commission_decision_date": "18/01/2008", "first_published_date": "18/02/2008", "last_updated_date": "18/02/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-nycomed" }, { "category": "Human", "referral_name": "Xeomin", "international_non_proprietary_name_inn_common_name": "clostridium botulinum neurotoxin type A", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/350251/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2007", "european_commission_decision_date": "24/10/2007", "first_published_date": "08/02/2008", "last_updated_date": "08/02/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/xeomin" }, { "category": "Human", "referral_name": "Bicaluplex", "international_non_proprietary_name_inn_common_name": "bicalutamide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/433691/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/09/2007", "european_commission_decision_date": "22/11/2007", "first_published_date": "07/02/2008", "last_updated_date": "07/02/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bicaluplex" }, { "category": "Human", "referral_name": "Piroxicam", "international_non_proprietary_name_inn_common_name": "piroxicam", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/380917/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/06/2007", "european_commission_decision_date": "07/09/2007", "first_published_date": "31/01/2008", "last_updated_date": "31/01/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/piroxicam" }, { "category": "Human", "referral_name": "Agreal", "international_non_proprietary_name_inn_common_name": "veralipride", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/432352/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2007", "european_commission_decision_date": "01/10/2007", "first_published_date": "07/01/2008", "last_updated_date": "07/01/2008", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/agreal" }, { "category": "Human", "referral_name": "Fentanyl-ratiopharm TTS", "international_non_proprietary_name_inn_common_name": "fentanyl", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/331678/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2007", "european_commission_decision_date": "23/10/2007", "first_published_date": "14/12/2007", "last_updated_date": "14/12/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fentanyl-ratiopharm-tts" }, { "category": "Human", "referral_name": "Lansoprazole", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/283378/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/06/2007", "european_commission_decision_date": "18/09/2007", "first_published_date": "14/12/2007", "last_updated_date": "14/12/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazole" }, { "category": "Human", "referral_name": "Fentanyl-ratiopharm Matrixpflaster", "international_non_proprietary_name_inn_common_name": "fentanyl", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/338591/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/07/2007", "european_commission_decision_date": "23/10/2007", "first_published_date": "14/12/2007", "last_updated_date": "14/12/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fentanyl-ratiopharm-matrixpflaster" }, { "category": "Human", "referral_name": "Lumiracoxib", "international_non_proprietary_name_inn_common_name": "lumiracoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Prexige", "class": "", "reference_number": "EMEA/H/A-107", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2007", "european_commission_decision_date": "", "first_published_date": "14/12/2007", "last_updated_date": "14/12/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lumiracoxib" }, { "category": "Human", "referral_name": "Aprotinin", "international_non_proprietary_name_inn_common_name": "aprotinin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Trasylol", "class": "", "reference_number": "EMEA/533599/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2007", "european_commission_decision_date": "15/02/2008", "first_published_date": "22/11/2007", "last_updated_date": "22/11/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/aprotinin" }, { "category": "Human", "referral_name": "Carisoprodol", "international_non_proprietary_name_inn_common_name": "carisoprodol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Somadril", "class": "", "reference_number": "CHMP/520140/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/11/2007", "european_commission_decision_date": "05/02/2008", "first_published_date": "16/11/2007", "last_updated_date": "16/11/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/carisoprodol" }, { "category": "Veterinary", "referral_name": "Suvaxyn Parvo/E", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/532267/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/01/2007", "european_commission_decision_date": "17/04/2007", "first_published_date": "15/11/2007", "last_updated_date": "15/11/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suvaxyn-parvo-e" }, { "category": "Veterinary", "referral_name": "Suvaxyn Ery", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CVMP/532233/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/01/2007", "european_commission_decision_date": "19/04/2007", "first_published_date": "15/11/2007", "last_updated_date": "15/11/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suvaxyn-ery" }, { "category": "Human", "referral_name": "Gadograf, Gadovist", "international_non_proprietary_name_inn_common_name": "gadobutrol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/508212/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/11/2006", "european_commission_decision_date": "13/04/2007", "first_published_date": "09/11/2007", "last_updated_date": "09/11/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/gadograf-gadovist" }, { "category": "Human", "referral_name": "Clobutinol", "international_non_proprietary_name_inn_common_name": "clobutinol", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Silomat", "class": "", "reference_number": "CHMP/471052/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/10/2007", "european_commission_decision_date": "30/11/2007", "first_published_date": "19/10/2007", "last_updated_date": "19/10/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/clobutinol" }, { "category": "Human", "referral_name": "Bicalutamide 150 mg", "international_non_proprietary_name_inn_common_name": "bicalutamide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/378451/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2007", "european_commission_decision_date": "03/09/2007", "first_published_date": "03/10/2007", "last_updated_date": "03/10/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bicalutamide-150-mg" }, { "category": "Human", "referral_name": "Xefo", "international_non_proprietary_name_inn_common_name": "lornoxicam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/144030/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/02/2007", "european_commission_decision_date": "29/05/2007", "first_published_date": "28/09/2007", "last_updated_date": "28/09/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/xefo" }, { "category": "Human", "referral_name": "Cefuroximaxetil", "international_non_proprietary_name_inn_common_name": "cefuroxime (as axetil)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/248862/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/04/2007", "european_commission_decision_date": "22/08/2007", "first_published_date": "24/09/2007", "last_updated_date": "24/09/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cefuroximaxetil" }, { "category": "Human", "referral_name": "Nimesulide", "international_non_proprietary_name_inn_common_name": "nimesulide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 107 procedures (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "Aulin ;Nimed", "class": "", "reference_number": "CHMP/430988/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/09/2007", "european_commission_decision_date": "16/10/2009", "first_published_date": "21/09/2007", "last_updated_date": "21/09/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide" }, { "category": "Human", "referral_name": "Vantas", "international_non_proprietary_name_inn_common_name": "histrelin acetate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/247760/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/05/2007", "european_commission_decision_date": "30/07/2007", "first_published_date": "06/09/2007", "last_updated_date": "06/09/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vantas" }, { "category": "Human", "referral_name": "Ciprofloxacin Hikma", "international_non_proprietary_name_inn_common_name": "ciprofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/75066/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/01/2007", "european_commission_decision_date": "11/06/2007", "first_published_date": "06/09/2007", "last_updated_date": "06/09/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-hikma" }, { "category": "Human", "referral_name": "Alendronate HEXAL", "international_non_proprietary_name_inn_common_name": "alendronic acid (as sodium alendronate trihydrate)", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/75285/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/01/2007", "european_commission_decision_date": "13/04/2007", "first_published_date": "20/08/2007", "last_updated_date": "20/08/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/alendronate-hexal" }, { "category": "Veterinary", "referral_name": "Suramox", "international_non_proprietary_name_inn_common_name": "amoxicillin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CVMP/301122/07", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "14/03/2007", "european_commission_decision_date": "13/06/2007", "first_published_date": "25/07/2007", "last_updated_date": "25/07/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/veterinary/referrals/suramox" }, { "category": "Human", "referral_name": "Seretide Evohaler", "international_non_proprietary_name_inn_common_name": "salmeterol;fluticasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(13) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/306351/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/04/2006", "european_commission_decision_date": "04/07/2006", "first_published_date": "14/07/2007", "last_updated_date": "14/07/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/seretide-evohaler" }, { "category": "Human", "referral_name": "Viani Evohaler", "international_non_proprietary_name_inn_common_name": "salmeterol;fluticasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(13) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/306455/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/04/2006", "european_commission_decision_date": "04/07/2006", "first_published_date": "14/07/2007", "last_updated_date": "14/07/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/viani-evohaler" }, { "category": "Human", "referral_name": "Seretide Diskus", "international_non_proprietary_name_inn_common_name": "salmeterol;fluticasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(13) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/306065/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/04/2006", "european_commission_decision_date": "04/07/2006", "first_published_date": "14/07/2007", "last_updated_date": "14/07/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/seretide-diskus" }, { "category": "Human", "referral_name": "Betavert N", "international_non_proprietary_name_inn_common_name": "betahistine dihydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/H/A-29/1094", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2009", "european_commission_decision_date": "02/06/2009", "first_published_date": "01/07/2007", "last_updated_date": "01/07/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/betavert-n" }, { "category": "Human", "referral_name": "Ciprofloxacin Kabi", "international_non_proprietary_name_inn_common_name": "ciprofloxacin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/515890/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/11/2006", "european_commission_decision_date": "24/01/2007", "first_published_date": "06/02/2007", "last_updated_date": "06/02/2007", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ciprofloxacin-kabi" }, { "category": "Human", "referral_name": "Agopton", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/407636/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/09/2006", "european_commission_decision_date": "13/12/2006", "first_published_date": "20/12/2006", "last_updated_date": "20/12/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/agopton" }, { "category": "Human", "referral_name": "Glucomed", "international_non_proprietary_name_inn_common_name": "glucosamine hydrochloride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/405628/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/09/2006", "european_commission_decision_date": "13/12/2006", "first_published_date": "20/12/2006", "last_updated_date": "20/12/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/glucomed" }, { "category": "Human", "referral_name": "Sortis", "international_non_proprietary_name_inn_common_name": "atorvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/477258/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/03/2006", "european_commission_decision_date": "22/05/2006", "first_published_date": "09/12/2006", "last_updated_date": "09/12/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sortis" }, { "category": "Human", "referral_name": "Doxagamma 4mg", "international_non_proprietary_name_inn_common_name": "doxazosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/423308/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2006", "european_commission_decision_date": "11/10/2006", "first_published_date": "11/10/2006", "last_updated_date": "11/10/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/doxagamma-4mg" }, { "category": "Human", "referral_name": "Doxazosin \"Winthrop\" 4mg", "international_non_proprietary_name_inn_common_name": "doxazosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/423591/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2006", "european_commission_decision_date": "11/10/2006", "first_published_date": "11/10/2006", "last_updated_date": "11/10/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/doxazosin-winthrop-4mg" }, { "category": "Human", "referral_name": "Cardoreg 4mg", "international_non_proprietary_name_inn_common_name": "doxazosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/422351/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2006", "european_commission_decision_date": "11/10/2006", "first_published_date": "11/10/2006", "last_updated_date": "11/10/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cardoreg-4mg" }, { "category": "Human", "referral_name": "Doxazosin Retard \"Arrow\" 4 mg", "international_non_proprietary_name_inn_common_name": "doxazosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/423796/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2006", "european_commission_decision_date": "11/10/2006", "first_published_date": "11/10/2006", "last_updated_date": "11/10/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/doxazosin-retard-arrow-4-mg" }, { "category": "Human", "referral_name": "Doxastad 4 mg", "international_non_proprietary_name_inn_common_name": "doxazosin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/423384/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "28/06/2006", "european_commission_decision_date": "11/10/2006", "first_published_date": "11/10/2006", "last_updated_date": "11/10/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/doxastad-4-mg" }, { "category": "Human", "referral_name": "Neurontin", "international_non_proprietary_name_inn_common_name": "gabapentin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/142335/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "01/06/2006", "european_commission_decision_date": "04/08/2006", "first_published_date": "06/09/2006", "last_updated_date": "06/09/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/neurontin" }, { "category": "Human", "referral_name": "Prozac", "international_non_proprietary_name_inn_common_name": "fluoxetine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/46089/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "01/06/2006", "european_commission_decision_date": "21/08/2006", "first_published_date": "05/09/2006", "last_updated_date": "05/09/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/prozac" }, { "category": "Human", "referral_name": "Ceftriaxone Tyrol Pharma", "international_non_proprietary_name_inn_common_name": "rabbit", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/212746/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "01/06/2006", "european_commission_decision_date": "21/08/2006", "first_published_date": "30/08/2006", "last_updated_date": "30/08/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ceftriaxone-tyrol-pharma" }, { "category": "Human", "referral_name": "Elidel", "international_non_proprietary_name_inn_common_name": "pimecrolimus", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/80270/06, CHMP/262776/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/03/2006", "european_commission_decision_date": "", "first_published_date": "29/08/2006", "last_updated_date": "29/08/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/elidel" }, { "category": "Human", "referral_name": "Viani Diskus", "international_non_proprietary_name_inn_common_name": "salmeterol;fluticasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(13) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/306421/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/04/2006", "european_commission_decision_date": "04/07/2006", "first_published_date": "14/07/2006", "last_updated_date": "14/07/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/viani-diskus" }, { "category": "Human", "referral_name": "Stamaril", "international_non_proprietary_name_inn_common_name": "live attenuated yellow fever virus", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/169383/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/04/2006", "european_commission_decision_date": "04/07/2006", "first_published_date": "14/07/2006", "last_updated_date": "14/07/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/stamaril" }, { "category": "Human", "referral_name": "Prograf", "international_non_proprietary_name_inn_common_name": "tacrolimus", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/85997/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/01/2006", "european_commission_decision_date": "10/04/2006", "first_published_date": "16/05/2006", "last_updated_date": "16/05/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/prograf" }, { "category": "Human", "referral_name": "Nifedipine Pharmamatch 30 and 60 mg", "international_non_proprietary_name_inn_common_name": "nifedipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/106563/06", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/01/2006", "european_commission_decision_date": "03/04/2006", "first_published_date": "05/05/2006", "last_updated_date": "05/05/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nifedipine-pharmamatch-30-60-mg" }, { "category": "Human", "referral_name": "Adartrel", "international_non_proprietary_name_inn_common_name": "ropinirole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/CHMP/416317/2005", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2005", "european_commission_decision_date": "03/04/2006", "first_published_date": "21/04/2006", "last_updated_date": "21/04/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/adartrel" }, { "category": "Human", "referral_name": "Lansoprazol CT-Arzneimittel 15 mg and 30 mg", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/373108/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2005", "european_commission_decision_date": "21/02/2006", "first_published_date": "25/02/2006", "last_updated_date": "25/02/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-ct-arzneimittel-15-mg-30-mg" }, { "category": "Human", "referral_name": "Lansoprazol-ratiopharm 15 mg and 30 mg", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/373061/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2005", "european_commission_decision_date": "21/02/2006", "first_published_date": "25/02/2006", "last_updated_date": "25/02/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-ratiopharm-15-mg-30-mg" }, { "category": "Human", "referral_name": "Lansoprazol AbZ-Pharma 15 mg and 30 mg", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/373083/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "15/09/2005", "european_commission_decision_date": "21/02/2006", "first_published_date": "25/02/2006", "last_updated_date": "25/02/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-abz-pharma-15-mg-30-mg" }, { "category": "Human", "referral_name": "Actilyse", "international_non_proprietary_name_inn_common_name": "alteplase", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3346/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2002", "european_commission_decision_date": "30/09/2002", "first_published_date": "25/01/2006", "last_updated_date": "25/01/2006", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/actilyse" }, { "category": "Human", "referral_name": "Coversyl", "international_non_proprietary_name_inn_common_name": "perindopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/408150/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/07/2005", "european_commission_decision_date": "07/11/2005", "first_published_date": "23/12/2005", "last_updated_date": "23/12/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/coversyl" }, { "category": "Human", "referral_name": "Celecoxib", "international_non_proprietary_name_inn_common_name": "celecoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/323166/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2005", "european_commission_decision_date": "28/11/2005", "first_published_date": "06/12/2005", "last_updated_date": "06/12/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/celecoxib" }, { "category": "Human", "referral_name": "Etoricoxib", "international_non_proprietary_name_inn_common_name": "etoricoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CHMP/324317/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2005", "european_commission_decision_date": "28/11/2005", "first_published_date": "06/12/2005", "last_updated_date": "06/12/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib-0" }, { "category": "Human", "referral_name": "Lumiracoxib", "international_non_proprietary_name_inn_common_name": "lumiracoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/324332/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2005", "european_commission_decision_date": "28/11/2005", "first_published_date": "06/12/2005", "last_updated_date": "06/12/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lumiracoxib-0" }, { "category": "Human", "referral_name": "Paroxetine", "international_non_proprietary_name_inn_common_name": "paroxetine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/187488/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "09/12/2004", "european_commission_decision_date": "29/03/2005", "first_published_date": "22/11/2005", "last_updated_date": "22/11/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/paroxetine" }, { "category": "Human", "referral_name": "Serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors", "international_non_proprietary_name_inn_common_name": "atomoxetine;citalopram;escitalopram;fluoxetine;fluvoxamine;mianserine;milnacipran;mirtazapine;paroxetine;reboxetine;sertraline;venlafaxine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Serotonin-specific reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors", "reference_number": "CHMP/287837/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2005", "european_commission_decision_date": "19/08/2005", "first_published_date": "03/11/2005", "last_updated_date": "03/11/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/serotonin-specific-reuptake-inhibitors-serotonin-noradrenaline-reuptake-inhibitors" }, { "category": "Human", "referral_name": "Lansopon 15 mg and 30 mg", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/308522/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2005", "european_commission_decision_date": "15/09/2005", "first_published_date": "13/10/2005", "last_updated_date": "13/10/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansopon-15-mg-30-mg" }, { "category": "Human", "referral_name": "Lansoprazol HEXAL 15 mg and 30 mg", "international_non_proprietary_name_inn_common_name": "lansoprazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/308176/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/06/2005", "european_commission_decision_date": "15/09/2005", "first_published_date": "15/09/2005", "last_updated_date": "15/09/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lansoprazol-hexal-15-mg-30-mg" }, { "category": "Human", "referral_name": "Crestor 5 mg", "international_non_proprietary_name_inn_common_name": "rosuvastatin calcium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/145829/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2005", "european_commission_decision_date": "09/08/2005", "first_published_date": "09/08/2005", "last_updated_date": "09/08/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/crestor-5-mg" }, { "category": "Human", "referral_name": "Calcium Sandoz", "international_non_proprietary_name_inn_common_name": "calcium lactate gluconate;calcium carbonate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/289490/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/04/2005", "european_commission_decision_date": "09/08/2005", "first_published_date": "09/08/2005", "last_updated_date": "09/08/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcium-sandoz" }, { "category": "Human", "referral_name": "Rigevidon", "international_non_proprietary_name_inn_common_name": "levonorgestrel;ethinylestradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/94618/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2005", "european_commission_decision_date": "10/05/2005", "first_published_date": "08/06/2005", "last_updated_date": "08/06/2005", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rigevidon" }, { "category": "Human", "referral_name": "Lopid", "international_non_proprietary_name_inn_common_name": "gemfibrozil", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CHMP/289490/05", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/03/2004", "european_commission_decision_date": "29/07/2004", "first_published_date": "18/08/2004", "last_updated_date": "18/08/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lopid" }, { "category": "Human", "referral_name": "Zestril", "international_non_proprietary_name_inn_common_name": "lisinopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/423/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/09/2003", "european_commission_decision_date": "16/01/2004", "first_published_date": "09/08/2004", "last_updated_date": "09/08/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zestril" }, { "category": "Human", "referral_name": "Loratadine and pseudoephedrine", "international_non_proprietary_name_inn_common_name": "loratadine;pseudoephedrine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4060/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2003", "european_commission_decision_date": "28/04/2004", "first_published_date": "14/07/2004", "last_updated_date": "14/07/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/loratadine-pseudoephedrine" }, { "category": "Human", "referral_name": "Loratadine", "international_non_proprietary_name_inn_common_name": "loratadine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1333/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2003", "european_commission_decision_date": "28/04/2004", "first_published_date": "14/07/2004", "last_updated_date": "14/07/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/loratadine" }, { "category": "Human", "referral_name": "Amlodipin Woerwag", "international_non_proprietary_name_inn_common_name": "amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/538/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2004", "european_commission_decision_date": "27/04/2004", "first_published_date": "30/06/2004", "last_updated_date": "30/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/amlodipin-woerwag" }, { "category": "Human", "referral_name": "Talam", "international_non_proprietary_name_inn_common_name": "amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/540/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2004", "european_commission_decision_date": "27/04/2004", "first_published_date": "30/06/2004", "last_updated_date": "30/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/talam" }, { "category": "Human", "referral_name": "Zocord", "international_non_proprietary_name_inn_common_name": "simvastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/459/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/01/2004", "european_commission_decision_date": "28/04/2004", "first_published_date": "09/06/2004", "last_updated_date": "09/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zocord" }, { "category": "Human", "referral_name": "Etoricoxib", "international_non_proprietary_name_inn_common_name": "etoricoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1748/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/02/2004", "european_commission_decision_date": "28/04/2004", "first_published_date": "09/06/2004", "last_updated_date": "09/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/etoricoxib-1" }, { "category": "Human", "referral_name": "Rofecoxib", "international_non_proprietary_name_inn_common_name": "rofecoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1749/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2003", "european_commission_decision_date": "28/04/2004", "first_published_date": "09/06/2004", "last_updated_date": "09/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/rofecoxib" }, { "category": "Human", "referral_name": "Celecoxib", "international_non_proprietary_name_inn_common_name": "celecoxib", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1747/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2003", "european_commission_decision_date": "29/04/2004", "first_published_date": "09/06/2004", "last_updated_date": "09/06/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/celecoxib-0" }, { "category": "Human", "referral_name": "Nimesulide", "international_non_proprietary_name_inn_common_name": "nimesulide", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1724/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/12/2003", "european_commission_decision_date": "26/04/2004", "first_published_date": "13/05/2004", "last_updated_date": "13/05/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/nimesulide-0" }, { "category": "Human", "referral_name": "Pravachol", "international_non_proprietary_name_inn_common_name": "pravastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/6214/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/11/2003", "european_commission_decision_date": "02/03/2004", "first_published_date": "13/05/2004", "last_updated_date": "13/05/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pravachol" }, { "category": "Human", "referral_name": "Pidolma", "international_non_proprietary_name_inn_common_name": "amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3122/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2004", "european_commission_decision_date": "27/04/2004", "first_published_date": "27/04/2004", "last_updated_date": "27/04/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/pidolma" }, { "category": "Human", "referral_name": "Amlovita", "international_non_proprietary_name_inn_common_name": "amlodipine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "EMEA/CPMP/539/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/01/2004", "european_commission_decision_date": "26/04/2004", "first_published_date": "26/04/2004", "last_updated_date": "26/04/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/amlovita" }, { "category": "Human", "referral_name": "Calcitonins", "international_non_proprietary_name_inn_common_name": "calcitonin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/867/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/11/2002", "european_commission_decision_date": "12/06/2003", "first_published_date": "02/03/2004", "last_updated_date": "02/03/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcitonins" }, { "category": "Human", "referral_name": "Laurina", "international_non_proprietary_name_inn_common_name": "desogestrel;ethinyl estradiol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1390/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/09/2003", "european_commission_decision_date": "05/02/2004", "first_published_date": "01/03/2004", "last_updated_date": "01/03/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/laurina" }, { "category": "Human", "referral_name": "Fluconazol Tiefenbacher 50mg, 100mg, 150mg, 200mg capsules, hard", "international_non_proprietary_name_inn_common_name": "fluconazole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/6236/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2003", "european_commission_decision_date": "01/12/2003", "first_published_date": "11/02/2004", "last_updated_date": "11/02/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fluconazol-tiefenbacher-50mg-100mg-150mg-200mg-capsules-hard" }, { "category": "Human", "referral_name": "Calcichew D3 mite", "international_non_proprietary_name_inn_common_name": "calcium;colecalciferol", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3258/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2003", "european_commission_decision_date": "01/12/2003", "first_published_date": "21/01/2004", "last_updated_date": "21/01/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcichew-d3-mite" }, { "category": "Human", "referral_name": "Calcichew D3", "international_non_proprietary_name_inn_common_name": "colecalciferol;calcium", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3257/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2003", "european_commission_decision_date": "01/12/2003", "first_published_date": "21/01/2004", "last_updated_date": "21/01/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcichew-d3" }, { "category": "Human", "referral_name": "Calcitugg", "international_non_proprietary_name_inn_common_name": "calcium carbonate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3256/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/06/2003", "european_commission_decision_date": "01/12/2003", "first_published_date": "21/01/2004", "last_updated_date": "21/01/2004", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/calcitugg" }, { "category": "Human", "referral_name": "Coversyl", "international_non_proprietary_name_inn_common_name": "perindopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CPMP/32703/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2003", "european_commission_decision_date": "04/12/2003", "first_published_date": "23/12/2003", "last_updated_date": "23/12/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/coversyl-0" }, { "category": "Human", "referral_name": "Renitec", "international_non_proprietary_name_inn_common_name": "enalapril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CPMP/3175/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/09/2002", "european_commission_decision_date": "21/05/2003", "first_published_date": "02/12/2003", "last_updated_date": "02/12/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/renitec" }, { "category": "Human", "referral_name": "Roaccutane", "international_non_proprietary_name_inn_common_name": "isotretinoin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2846/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2003", "european_commission_decision_date": "17/10/2003", "first_published_date": "02/12/2003", "last_updated_date": "02/12/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/roaccutane" }, { "category": "Human", "referral_name": "Isotretinoin", "international_non_proprietary_name_inn_common_name": "isotretinoin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2811/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2003", "european_commission_decision_date": "17/10/2003", "first_published_date": "02/12/2003", "last_updated_date": "02/12/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/isotretinoin" }, { "category": "Human", "referral_name": "Botox", "international_non_proprietary_name_inn_common_name": "Clostridium botulinum type A neurotoxin complex", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4260/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/02/2003", "european_commission_decision_date": "25/06/2003", "first_published_date": "16/10/2003", "last_updated_date": "16/10/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/botox" }, { "category": "Human", "referral_name": "Lisinopril Biochemie", "international_non_proprietary_name_inn_common_name": "lisinopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/886/04/Final", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2003", "european_commission_decision_date": "23/02/2004", "first_published_date": "01/09/2003", "last_updated_date": "01/09/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lisinopril-biochemie" }, { "category": "Human", "referral_name": "Norditropin", "international_non_proprietary_name_inn_common_name": "somatropin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3478/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2003", "european_commission_decision_date": "", "first_published_date": "29/08/2003", "last_updated_date": "29/08/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/norditropin" }, { "category": "Human", "referral_name": "Genotropin", "international_non_proprietary_name_inn_common_name": "somatropin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3477/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2003", "european_commission_decision_date": "26/06/2003", "first_published_date": "29/08/2003", "last_updated_date": "29/08/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/genotropin" }, { "category": "Human", "referral_name": "Lederfoline", "international_non_proprietary_name_inn_common_name": "calcium folinate", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3736/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/03/2003", "european_commission_decision_date": "30/06/2003", "first_published_date": "14/08/2003", "last_updated_date": "14/08/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/lederfoline" }, { "category": "Human", "referral_name": "Salmeterol and Fluticasone Propionate", "international_non_proprietary_name_inn_common_name": "salmeterol;fluticasone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "Salmeterol and fluticasone", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/01/2003", "european_commission_decision_date": "21/05/2003", "first_published_date": "31/07/2003", "last_updated_date": "31/07/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/salmeterol-fluticasone-propionate" }, { "category": "Human", "referral_name": "Prozac", "international_non_proprietary_name_inn_common_name": "fluoxetine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3263/03", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/09/2002", "european_commission_decision_date": "", "first_published_date": "18/06/2003", "last_updated_date": "18/06/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/prozac-0" }, { "category": "Human", "referral_name": "Cardiostad", "international_non_proprietary_name_inn_common_name": "lisinopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/869/04", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "24/07/2003", "european_commission_decision_date": "23/02/2004", "first_published_date": "01/03/2003", "last_updated_date": "01/03/2003", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cardiostad" }, { "category": "Human", "referral_name": "Cerivastatin", "international_non_proprietary_name_inn_common_name": "cerivastatin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/3962/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "21/03/2002", "european_commission_decision_date": "22/08/2002", "first_published_date": "20/12/2002", "last_updated_date": "20/12/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cerivastatin" }, { "category": "Human", "referral_name": "Sibutramine", "international_non_proprietary_name_inn_common_name": "", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4514/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2002", "european_commission_decision_date": "26/03/2001", "first_published_date": "13/12/2002", "last_updated_date": "13/12/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sibutramine-0" }, { "category": "Human", "referral_name": "Bupropion hydrochloride", "international_non_proprietary_name_inn_common_name": "bupropion", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2852/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/07/2002", "european_commission_decision_date": "25/10/2002", "first_published_date": "06/12/2002", "last_updated_date": "06/12/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bupropion-hydrochloride" }, { "category": "Human", "referral_name": "Leponex", "international_non_proprietary_name_inn_common_name": "clozapine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/6034/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "02/08/2002", "european_commission_decision_date": "12/11/2002", "first_published_date": "27/11/2002", "last_updated_date": "27/11/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/leponex" }, { "category": "Human", "referral_name": "Cisapride", "international_non_proprietary_name_inn_common_name": "cisapride", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/24844/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/12/2001", "european_commission_decision_date": "30/05/2002", "first_published_date": "29/10/2002", "last_updated_date": "29/10/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cisapride" }, { "category": "Human", "referral_name": "Motilium", "international_non_proprietary_name_inn_common_name": "domperidone", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4786/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/06/2002", "european_commission_decision_date": "17/10/2002", "first_published_date": "17/10/2002", "last_updated_date": "17/10/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/motilium" }, { "category": "Human", "referral_name": "Ecazide", "international_non_proprietary_name_inn_common_name": "captopril;hydrochlorothiazide", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CPMP/4717/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2002", "european_commission_decision_date": "22/08/2002", "first_published_date": "19/09/2002", "last_updated_date": "19/09/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ecazide" }, { "category": "Human", "referral_name": "Sertindole", "international_non_proprietary_name_inn_common_name": "sertindole", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 36 referrals (prior to July 2012)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2852/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/10/2000", "european_commission_decision_date": "20/01/2000", "first_published_date": "19/09/2002", "last_updated_date": "19/09/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/sertindole" }, { "category": "Human", "referral_name": "Dacarbazine Faulding", "international_non_proprietary_name_inn_common_name": "dacarbazine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2020/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/04/2002", "european_commission_decision_date": "21/08/2002", "first_published_date": "19/09/2002", "last_updated_date": "19/09/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/dacarbazine-faulding" }, { "category": "Human", "referral_name": "Hypnovel", "international_non_proprietary_name_inn_common_name": "midazolam", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4620/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "22/02/2002", "european_commission_decision_date": "26/06/2002", "first_published_date": "16/09/2002", "last_updated_date": "16/09/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/hypnovel" }, { "category": "Human", "referral_name": "Floxyfral", "international_non_proprietary_name_inn_common_name": "fluvoxamine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "-", "reference_number": "CPMP/600/02", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/01/2002", "european_commission_decision_date": "30/05/2002", "first_published_date": "25/07/2002", "last_updated_date": "25/07/2002", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/floxyfral" }, { "category": "Human", "referral_name": "Glucophage/Glucophage Forte/Risidon/Dianben", "international_non_proprietary_name_inn_common_name": "metformin", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4082/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/10/2000", "european_commission_decision_date": "06/02/2001", "first_published_date": "07/02/2001", "last_updated_date": "07/02/2001", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/glucophage-glucophage-forte-risidon-dianben" }, { "category": "Human", "referral_name": "Ketoprofene Ethypharm LP", "international_non_proprietary_name_inn_common_name": "ketoprofen", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1988/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "29/06/2000", "european_commission_decision_date": "27/12/2000", "first_published_date": "28/12/2000", "last_updated_date": "28/12/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/ketoprofene-ethypharm-lp" }, { "category": "Human", "referral_name": "MultiHance", "international_non_proprietary_name_inn_common_name": "gadobenic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1361/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/05/2000", "european_commission_decision_date": "15/09/2000", "first_published_date": "15/12/2000", "last_updated_date": "15/12/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/multihance" }, { "category": "Human", "referral_name": "Zofenil, Zopranol, Bifril", "international_non_proprietary_name_inn_common_name": "zofenopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/2011/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/07/2000", "european_commission_decision_date": "29/11/2000", "first_published_date": "29/11/2000", "last_updated_date": "29/11/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zofenil-zopranol-bifril" }, { "category": "Human", "referral_name": "Bifril, Teoula, Zofepril, Zopranol", "international_non_proprietary_name_inn_common_name": "zofenopril", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 6(12) referrals (prior to January 2010)", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/4362/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "27/07/2000", "european_commission_decision_date": "29/11/2000", "first_published_date": "29/11/2000", "last_updated_date": "29/11/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/bifril-teoula-zofepril-zopranol" }, { "category": "Human", "referral_name": "Engerix B", "international_non_proprietary_name_inn_common_name": "hepatitis B recombinant vaccine, adsorbed", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 30 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1493/01", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "13/04/2000", "european_commission_decision_date": "28/08/2000", "first_published_date": "28/08/2000", "last_updated_date": "28/08/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/engerix-b" }, { "category": "Human", "referral_name": "Cyklo-f", "international_non_proprietary_name_inn_common_name": "tranexamic acid", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/902/00", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "25/05/2000", "european_commission_decision_date": "12/09/2000", "first_published_date": "27/07/2000", "last_updated_date": "27/07/2000", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/cyklo-f" }, { "category": "Human", "referral_name": "Aggrastat", "international_non_proprietary_name_inn_common_name": "tirofiban", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/990/99", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "26/03/1999", "european_commission_decision_date": "18/06/1999", "first_published_date": "18/06/1999", "last_updated_date": "18/06/1999", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/aggrastat" }, { "category": "Human", "referral_name": "Vigabatrin", "international_non_proprietary_name_inn_common_name": "vigabatrin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1357/99", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/05/1999", "european_commission_decision_date": "05/10/1999", "first_published_date": "12/10/1998", "last_updated_date": "12/10/1998", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/vigabatrin" }, { "category": "Human", "referral_name": "Amaryl", "international_non_proprietary_name_inn_common_name": "glimepiride", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1416/98", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "17/04/1996", "european_commission_decision_date": "29/08/1996", "first_published_date": "03/08/1998", "last_updated_date": "03/08/1998", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/amaryl" }, { "category": "Human", "referral_name": "Mizollen", "international_non_proprietary_name_inn_common_name": "mizalostine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1500/98", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/1996", "european_commission_decision_date": "01/04/1997", "first_published_date": "03/08/1998", "last_updated_date": "03/08/1998", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/mizollen" }, { "category": "Human", "referral_name": "Fluoxetin NM", "international_non_proprietary_name_inn_common_name": "fluoxetine", "current_status": "European Commission final decision", "safety_referral": "No", "referral_type": "Article 29(4) referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/1154/98", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "18/12/1997", "european_commission_decision_date": "09/06/1998", "first_published_date": "19/06/1998", "last_updated_date": "19/06/1998", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/fluoxetin-nm" }, { "category": "Human", "referral_name": "Terfenadine", "international_non_proprietary_name_inn_common_name": "terfenadine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/34168/98", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "20/11/1997", "european_commission_decision_date": "22/09/1998", "first_published_date": "22/01/1998", "last_updated_date": "22/01/1998", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/terfenadine" }, { "category": "Human", "referral_name": "Chlormezanone", "international_non_proprietary_name_inn_common_name": "chlormezanone", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/375/97", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "23/01/1997", "european_commission_decision_date": "27/08/1997", "first_published_date": "22/09/1997", "last_updated_date": "22/09/1997", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/chlormezanone" }, { "category": "Human", "referral_name": "Anorectics", "international_non_proprietary_name_inn_common_name": "phentermine;amfepramome;clobenzorex;dexfenfluramine;fenbutrazate;fenfluramine;fenproporex;mazindol;mefenorex;norpseudoephedrine;phenmetrazine;phendimetrazine;propylhexedrine", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "Anorectics", "reference_number": "CPMP/101-109/96, CPMP/111-112/96, CPMP/113-114/96", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "16/02/1996", "european_commission_decision_date": "09/12/1996", "first_published_date": "10/12/1996", "last_updated_date": "10/12/1996", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/anorectics" }, { "category": "Human", "referral_name": "Naftidrofuryl", "international_non_proprietary_name_inn_common_name": "naftidrofuryl", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/578/95", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/10/1995", "european_commission_decision_date": "26/06/1996", "first_published_date": "26/06/1996", "last_updated_date": "26/06/1996", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/naftidrofuryl" }, { "category": "Human", "referral_name": "Zagam", "international_non_proprietary_name_inn_common_name": "sparfloxacin", "current_status": "European Commission final decision", "safety_referral": "Yes", "referral_type": "Article 31 referrals", "associated_names_centrally_authorised_medicines": "", "associated_names_non_centrally_authorised_medicines": "", "class": "", "reference_number": "CPMP/931/95", "non_prac_decision_making_model": "", "prac_decision_making_model": "", "authorisation_model": "", "prac_recommendation": "", "procedure_start_date": "", "prac_recommendation_date": "", "cmdh_position_date": "", "chmp_cvmp_opinion_date": "19/12/1995", "european_commission_decision_date": "", "first_published_date": "06/05/1996", "last_updated_date": "06/05/1996", "referral_url": "https://www.ema.europa.eu/en/medicines/human/referrals/zagam" } ] }